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Aims: To comprehensively investigate the incidence, nature and risk factors of adverse drug reactions
(ADRs) in a hospital-based population of children, with rigorous assessment of causality, severity and
avoidability, and to assess the consequent impact on children and families. We aimed to improve the
assessment of ADRs by development of new tools to assess causality and avoidability, and to minimise the
impact on families by developing better strategies for communication.
Review methods: Two prospective observational studies, each over 1 year, were conducted to assess
ADRs in children associated with admission to hospital, and those occurring in children who were in
hospital for longer than 48 hours. We conducted a comprehensive systematic review of ADRs in children.
We used the ﬁndings from these studies to develop and validate tools to assess causality and avoidability
of ADRs, and conducted interviews with parents and children who had experienced ADRs, using these
ﬁndings to develop a leaﬂet for parents to inform a communication strategy about ADRs.
Results: The estimated incidence of ADRs detected in children on admission to hospital was 2.9%
[95% conﬁdence interval (CI) 2.5% to 3.3%]. Of the reactions, 22.1% (95% CI 17% to 28%) were either
deﬁnitely or possibly avoidable. Prescriptions originating in the community accounted for 44 out of 249
(17.7%) of ADRs, the remainder originating from hospital. A total of 120 out of 249 (48.2%) reactions
resulted from treatment for malignancies. Off-label and/or unlicensed (OLUL) medicines were more likely to
be implicated in an ADR than authorised medicines [relative risk (RR) 1.67, 95% CI 1.38 to 2.02;vii
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ABSTRACT
viiip < 0.001]. When medicines used for the treatment of oncology patients were excluded, OLUL medicines
were not more likely to be implicated in an ADR than authorised medicines (RR 1.03, 95% CI 0.72 to
1.48; p = 0.830). For children who had been in hospital for > 48 hours, the overall incidence of deﬁnite
and probable ADRs based on all admissions was 15.9% (95% CI 15.0 to 16.8). Opiate analgesic drugs
and drugs used in general anaesthesia (GA) accounted for > 50% of all drugs implicated in ADRs.
The odds ratio of an OLUL drug being implicated in an ADR compared with an authorised drug was 2.25
(95% CI 1.95 to 2.59; p < 0.001). Risk factors identiﬁed were exposure to a GA, age, oncology treatment
and number of medicines. The systematic review estimated that the incidence rates for ADRs causing
hospital admission ranged from 0.4% to 10.3% of all children [pooled estimate of 2.9% (95% CI 2.6% to
3.1%)] and from 0.6% to 16.8% of all children exposed to a drug during hospital stay. New tools to
assess causality and avoidability of ADRs have been developed and validated. Many parents described
being dissatisﬁed with clinician communication about ADRs, whereas parents of children with cancer
emphasised conﬁdence in clinician management of ADRs and the way clinicians communicated about
medicines. The accounts of children and young people largely reﬂected parents’ accounts. Clinicians
described using all of the features of communication that parents wanted to see, but made active
decisions about when and what to communicate to families about suspected ADRs, which meant that
communication may not always match families’ needs and expectations. We developed a leaﬂet to assist
clinicians in communicating ADRs to parents.
Conclusion: The Adverse Drug Reactions In Children (ADRIC) programme has provided the most
comprehensive assessment, to date, of the size and nature of ADRs in children presenting to, and cared
for in, hospital, and the outputs that have resulted will improve the management and understanding of
ADRs in children and adults within the NHS. Recommendations for future research: assess the values that
parents and children place on the use of different medicines and the risks that they will ﬁnd acceptable
within these contexts; focusing on high-risk drugs identiﬁed in ADRIC, determine the optimum drug dose
for children through the development of a gold standard practice for the extrapolation of adult drug
doses, alongside targeted pharmacokinetic/pharmacodynamic studies; assess the research and clinical
applications of the Liverpool Causality Assessment Tool and the Liverpool Avoidability Assessment Tool;
evaluate, in more detail, morbidities associated with anaesthesia and surgery in children, including
follow-up in the community and in the home setting and an assessment of the most appropriate treatment
regimens to prevent pain, vomiting and other postoperative complications; further evaluate strategies for
communication with families, children and young people about ADRs; and quantify ADRs in other settings,
for example critical care and neonatology.
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any common medicines have not been tested on children either properly or at all. We wanted toMimprove the safety of medicines used in children by investigating their side effects [adverse drug
reactions (ADRs)].
We showed that three out of every 100 children admitted to hospital experienced an ADR due to a
medicine taken at home. One out of ﬁve times this might have been avoidable. Nearly half of all ADRs
were due to anticancer medicines.
We found that one in six children experienced an ADR while in hospital. More than half were due to
medicines used in general anaesthesia and to treat pain after an operation. We used the results of these
studies to develop tools to assess the likelihood of symptoms resulting from an ADR (causality) and
whether an ADR was avoidable (avoidability).
We reviewed the literature on previous studies of ADRs in children and found that most studies had ﬂaws
in design and reporting, and lacked essential information, such as the name of the drugs causing ADRs
and whether they were avoidable.
We interviewed children, parents and clinicians about ADRs. Many children and parents thought that
communication about medicines could be improved, whereas parents of children with cancer were
generally happy about the way clinicians communicated. Clinicians often made decisions about when and
what to tell families but this did not always match what parents needed or expected. To address this, we
developed information leaﬂets for parents and children to support communication between clinicians and
families about ADRs.xxi
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Background
Drug safety is an important issue in all medical disciplines but in paediatrics this is compounded by the fact
that medicines are often not tested in children, and therefore at the time of licensing there is no indication
for use in children. This leads to off-label and/or unlicensed (OLUL) prescribing, estimated to occur in 25%
of paediatric inpatient prescriptions. It is clear that extrapolation of efﬁcacy, dosing regimens and adverse
drug reactions (ADRs) from adult data to children is inappropriate owing to size differences, developmental
changes in physiology and drug handling. Taken together with the fact that the pattern of diseases in
children is different from that in adults, this puts them at high risk of serious and unpredictable ADRs.
Much of the work to identify and address these problems was led from Liverpool, and this programme of
research was conceived to address important gaps in the evidence.
Most studies to date have focused on individual aspects of ADRs, for example ADRs causing hospital
admission, ADRs occurring within small, specialised units, etc. However, no previous programme of work
has looked at the whole spectrum from when and where ADRs are occurring to developing solutions to
reduce the burden of ADRs. Our research planned to focus on this spectrum and the clinical studies were
conducted in the largest children’s hospital in Europe, with between 12,000 and 13,000 admissions per
annum. During the course of the programme, we found that none of the commonly used tools to assess
causality and avoidability of ADRs was sufﬁciently reliable to be used in these studies. This led us to
develop and validate new assessment tools (see objectives 4 and 5, below). We also wished to assess the
impact of ADRs on families to identify any unmet communication needs. Because of the scale of the
communication problems that we identiﬁed, the ﬁnal objective of the programme was to develop
strategies to improve communication between clinicians and families about ADRs.
Objectives
1. To determine the incidence of ADRs that were associated with admission to hospital in children;
describe their causality, severity, avoidability and nature; and identify which children were particularly at
risk of this complication.
2. To determine the incidence of ADRs that occurred in children in hospital; characterise them in terms of
type, drug aetiology, causality and severity; and identify risk factors for the occurrence of ADRs in
hospitalised children.
3. To conduct a systematic review of observational studies of ADRs in children in three settings: causing
admission to hospital; occurring during hospital stay; and occurring in the community. We were
particularly interested in understanding how these ADRs might be better detected, assessed
and avoided.
4. To develop and validate a new ADR causality assessment tool (CAT) that would be easy to use
and reliable.
5. To develop and validate a new ADR avoidability assessment tool (AAT) that would be generalisable and
applicable to a variety of settings.
6. To identify any unmet information and communication needs described by families following a
suspected ADR in a child.
7. To develop a strategy to support communication between families and clinicians by identifying any
barriers to effective communication with families from the perspective of clinicians following a
suspected ADR, and to develop information leaﬂets about ADRs for parents, children and young people
to support their communication with clinicians.
xxiii
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xxivMethods
All clinical studies were conducted in Alder Hey Children’s NHS Foundation Trust (Alder Hey), a large
children’s hospital, with an accident and emergency department, providing local and specialist regional
and national paediatric care in the north-west of England. Participants were aged between 0 and 16 years
11 months. Study 1 was a prospective observational study of all acute paediatric admissions, over a 1-year
period, of all children who had taken any form of medication during the previous 2 weeks. The outcome
measure was a suspected ADR. Study 2 was a prospective cohort study of children admitted over
48 hours; patients were not observed while admitted to the paediatric intensive care unit (PICU), the
transitional care unit (TCU), theatre, recovery or the department of radiology. A nested case–control study
within the cohort examined the impact of OLUL drug use on ADR risk.
The systematic review was conducted by searching 19 electronic databases using a comprehensive search
strategy. The primary outcome was any clinical event described as an ADR to one or more drugs.
Additional information relating to the ADR was collected: associated drug classiﬁcation; clinical
presentation; associated risk factors; methods used for assessing causality, severity and avoidability.
A new ADR CAT, the Liverpool Causality Assessment Tool (LCAT), and a new AAT were developed by the
‘Adverse Drug Reactions In Children’ (ADRIC) programme group to address the limitations of the widely
used Naranjo CAT and the Hallas scale, respectively. The LCAT was compared with the Naranjo CAT in
80 cases from a prospective observational study and 37 published ADR case reports (819 causality
assessments in total). The AAT development occurred in two phases: ﬁrst deﬁning the tool, modifying the
tool and reﬁning the tool, by a multidisciplinary team, and, second, the independent assessment of
50 ADR cases from study 2 by six different reviewers and a comparison of the results. Following the
completion of phase 2, it was decided that further testing was needed and that perhaps the best way to
assess avoidability is in a group setting. Agreement in phase 2 ranged from poor to good; possible reasons
for this may be attributable to lack of experience in certain specialty areas or a possible training effect. The
next step in the development process will be to carry out group assessments of additional cases and look
for an improvement in the results. For both CAT and AAT, we assessed utilisation of categories, measure
of disagreements and inter-rater reliability (IRR).We conducted semistructured qualitative interviews with 20 children and young people, and the parents
of 44 children and young people who had experienced a suspected ADR. Interviews were conducted face
to face or by telephone; most were audio-recorded and transcribed. To develop a communication strategy
about ADRs between clinicians and families, we conducted semistructured qualitative interviews with
42 clinicians about their experiences of ADRs in children. Face-to-face interviews were audio-recorded and
transcribed. The parental leaﬂet on ADRs was developed based on feedback from a range of stakeholders,
including parents and clinicians. The usefulness of the leaﬂet was further examined by conducting
structured interviews with 17 clinicians after they had used the leaﬂet during routine parent–clinician
discussions about suspected ADRs. Analysis of these parts of the programme was informed by the
principles of the constant comparative method.
Findings
In study 1, 240 out of 8345 admissions in 178 out of 6821 patients admitted acutely to a paediatric
hospital were thought to be related to an ADR, giving an estimated incidence of 2.9% [95% conﬁdence
interval (CI) 2.5% to 3.3%], with the reaction directly causing, or contributing to the cause of, admission in
97.1% of cases. No deaths were attributable to an ADR. Of the reactions, 22.1% (95% CI 17% to 28%)
were either deﬁnitely or possibly avoidable. Prescriptions originating in the community accounted for 44 out
of 249 (17.7%) ADRs, the remainder originating from hospital. Of 16,551 prescription medicine courses,
11,511 (69.5%) were authorised, 4080 (24.7%) were off-label and 960 (5.8%) were unlicensed. Treatment
for malignancies resulted in 120 out of 249 (48.2%) reactions. The drugs most commonly implicated in
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vaccines and immunosuppressant drugs. OLUL medicines were more likely to be implicated in an ADR than
authorised medicines [relative risk (RR) 1.67, 95% CI 1.38 to 2.02; p < 0.001]. When medicines used to
treat oncology patients were excluded, OLUL medicines were not more likely to be implicated in an ADR
than authorised medicines (RR 1.03, 95% CI 0.72 to 1.48; p = 0.830). The most common reactions were
neutropenia, immunosuppression and thrombocytopenia.
In study 2, over the 1-year period, 5118 children were admitted to hospital for > 48 hours. Of all children,
17.7% experienced at least one ADR. Opiate analgesic drugs and drugs used in general anaesthesia (GA)
accounted for > 50% of all drugs implicated in ADRs. A total of 0.9% of ADRs caused permanent harm or
required admission to a higher level of care. The hazard of an ADR for children after GA is more than
six times that in children who had not received a GA [hazard ratio (HR) 6.38, 95% CI 5.30 to 7.68]. Other
factors increasing the risk of an ADR were increasing age (HR 1.06 for each year, 95% CI 1.04 to 1.07),
increasing number of drugs (HR 1.25 for each additional drug, 95% CI 1.22 to 1.28) and oncological
treatment (HR 1.89, 95% CI 1.36 to 2.63). Our nested case–control study included 1388 patients. The
odds ratio of an OLUL drug being implicated in an ADR compared with an authorised drug was 2.25
(95% CI 1.95 to 2.59; p < 0.001). Risk factors identiﬁed were exposure to a GA, age, oncology treatment
and number of medicines.
One hundred and two studies were included in the systematic review. Seventy-one per cent (72/102) of
studies assessed causality and 33% (34/102) performed a severity assessment. Only 19 studies (19%)
assessed avoidability. Incidence rates for ADRs causing hospital admission ranged from 0.4% to 10.3% of
all children [pooled estimate of 2.9% (95% CI 2.6% to 3.1%)] and from 0.6% to 16.8% of all children
exposed to a drug during hospital stay. Anti-infective drugs and antiepileptic drugs were the most
frequently reported therapeutic class associated with ADRs in children admitted to hospital (17 studies
and 12 studies, respectively) and children in hospital (24 studies and 14 studies, respectively), whereas
anti-infective drugs and NSAIDs were frequently reported as associated with ADRs in outpatient children
(13 studies and 6 studies, respectively). Fourteen studies reported rates ranging from 7% to 98% of ADRs
being either deﬁnitely or possibly avoidable.
The LCAT, using 40 cases from an observational study, showed causality categories of 1 unlikely,
62 possible, 92 probable and 125 deﬁnite (1, 62, 92, 125) and ‘moderate’ IRR [kappa (κ) = 0.48] compared
with Naranjo (0, 100, 172, 8) with ‘moderate’ IRR (κ = 0.45). In a further 40 cases, the LCAT (0, 66, 81, 133)
showed ‘good’ IRR (κ = 0.6), whereas Naranjo (1, 90, 185, 4) remained ‘moderate’.
In the qualitative study to assess the impact on families of their children experiencing an ADR, many
parents described being dissatisﬁed with clinicians’ communication about ADRs. In contrast, the accounts
of parents of children with cancer emphasised conﬁdence in clinicians’ management of ADRs and the way
clinicians communicated about medicines. The accounts of children and young people largely reﬂected
parents’ accounts. Families were positive about the Yellow Card Scheme and felt recording and reporting
ADRs was important. Parents, children and young people linked symptoms to medicines using a similar
reasoning as clinicians use to evaluate the possibility of an ADR.
Clinicians reported all of the features of communication about ADRs that parents wanted to see. However,
clinicians made active decisions about when and what to communicate to families about suspected ADRs.
These decisions mean that communication may not always match families’ needs and expectations.
Clinicians describe a number of complexities with effective communication, some of which are unique to
paediatric settings. The complexities perceived by clinicians may explain, at least in part, the discordance
between clinician and family perspectives. Clinicians found the leaﬂet useful in supporting discussions with
parents about a suspected ADR in their child.
xxv
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Smyth et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
SCIENTIFIC SUMMARY
xxviConclusions1. ADRs in children are an important public health problem. Most of those serious enough to require
hospital admission are due to hospital-based prescribing, of which just over one-ﬁfth may be avoidable.
2. ADRs are as common in hospitalised children as in hospitalised adults. A concerning aspect of our
ﬁndings was that GA agents and opiate analgesic drugs were the most important causes. OLUL
drugs are more likely to be implicated in an ADR than authorised drugs. It is important to develop
strategies to reduce the burden of ADRs occurring in hospitalised children and these areas merit
particular attention.
3. Our systematic review found that although there is extensive literature that investigates ADRs in
children, studies are heterogeneous and generally not well reported. Further work is needed to address
how ADRs in children may be prevented.
4. The LCAT assigns the full range of causality categories and shows good IRR. Further assessment by
different investigators in different settings is needed to fully assess the utility of this tool.
5. The Liverpool ADR AAT showed mixed IRR in the individual assessment phase therefore further testing
in a group setting is required to develop and validate the tool.
6. Most parents felt clinicians’ communication about ADRs was poor, suggesting that improvements are
needed. The accounts of parents of children with cancer indicate that prospective explanation about
ADRs can be effective. Convergence between parents and clinicians in their reasoning for linking
children’s symptoms to medicines could be a starting point for improved communication.
7. The parent leaﬂet was useful in supporting discussions between parents and clinicians about suspected
ADRs. Further strategies to improve communication between families and clinicians should focus on
aligning clinicians’ decision-making about what and when to communicate with the priorities of
families following a suspected ADR.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research.
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Drug safety is an important issue in all disciplines. The World Health Organization’s (WHO) stateddeﬁnition of an adverse drug reaction (ADR) is ‘A response to a drug which is noxious, and
unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of
disease, or for the modiﬁcation of physiological function’.1
The problem of drug safety in paediatrics is compounded by the fact that medicines are often not tested in
children, and therefore at the time of licensing there is no indication for use in children. For example, in
2006 around 75% of all 317 centrally licensed medicines were relevant for children but only half (34%)
had a paediatric indication.2 This leads to off-label and/or unlicensed (OLUL) prescribing: this has been
estimated to occur in 25%3 of paediatric inpatient prescriptions and 65% of neonatal prescriptions.4
It is clear that extrapolation of efﬁcacy, dosing regimens and ADRs from adult data are inappropriate
owing to developmental changes in physiology and drug handling.5 Taken together with the fact that the
pattern of diseases in children is different from that in adults, this puts them at high risk of serious and
unpredictable ADRs from the use of medicines. As with any population, distinguishing between an ADR
and non-drug-induced pathology is difﬁcult but is further compounded in this age group. Important
examples of ADRs in children include deaths associated with propofol used for paediatric intensive care
unit (PICU) sedation,6 acute adrenal crisis associated with inhaled corticosteroids,7 grey baby syndrome in
neonates associated with chloramphenicol,8 the threefold increase in Stevens–Johnson syndrome with
lamotrigine9 and colonic strictures in cystic ﬁbrosis owing to high-strength pancreatic enzymes.10 The last
of these examples was ﬁrst reported at Alder Hey Children’s NHS Foundation Trust (Alder Hey) in
Liverpool; the primary author led the study conﬁrming the association with pancreatic enzyme therapy and
because of this, and subsequent regulatory measures, this problem is no longer reported in the UK. A
trend towards more ADRs when OLUL medicines are prescribed in children and young people was ﬁrst
reported from this research group.11 However, the recognition of serious new ADRs generally depends on
a cluster of individuals presenting with a similar pattern of unexplained clinical features and there is no
systematic, pre-emptive approach to this problem in children, largely because of the dearth of good-quality
scientiﬁc evidence on this topic. The burden of ADRs in children has not been systematically assessed and
the knowledge base of the impact of ADRs in children on morbidity, overall health economy and societal
consequences is poorly understood. In addition, methods to detect and assess causality and avoidability of
suspected ADRs have not been validated in children. Evidence suggests that patients are generally poorly
informed about medicines and the systems to ensure drug safety.12 There is a need to consider
communication about ADRs as an integral component of medicine adherence as well as an important
transaction in its own right. Particular concerns surround children’s medicines; although health-care
professionals have access to mechanisms to report and manage suspected ADRs, little is known about the
understanding and experiences of families who experience a suspected ADR. Given the lack of robust
evidence in the broad spectrum of ADR burden and characterisation in the population of children and
young people, and the lack of knowledge and understanding of the interactions between health-care
professionals and families whose child experiences a suspected ADR, Adverse Drug Reactions In Children
(ADRIC) was designed to address this knowledge gap.The regulatory and policy perspective of pharmacovigilance in
children and young peopleThe Department of Health recognised the importance of the development of medicines and drug safety
science in children by establishing the National Institute for Health Research (NIHR) Medicines for Children
Research Network (MCRN) in 2006. Assessment of the harms of medicines is as important as assessment
of their beneﬁts and is integral to the proposals within the European regulation on medicines for children13
and the guidance on pharmacovigilance in children. In July 2012, new pharmacovigilance legislation came
into effect across the European Union (EU),14 including centralised reporting by industry of ADRs to the1
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2EudraVigilance database at the European Medicines Agency (EMA) and the inclusion of reports from
patients as valid, reportable ADRs. The Children and Young People’s Outcomes Strategy (commissioned by
the Secretary of State for Health) identiﬁed the need to optimise the safe use of medicines.15 In 2008,
there were 33,000 safety incidents in children reported to the National Reporting and Learning
System by health-care professionals, and of these 19% were for a medication problem. This led to a
recommendation report that ‘the Medicines and Healthcare Products Regulatory Agency (MHRA), with
immediate effect, prioritises pharmacovigilance of children’s medicines, including medication errors and
off-label use, in line with the new EU legislation effective in July 2012’.16
The MHRA is responsible for monitoring the safety of medicines in the UK.17 The collection and analysis of
reports of ADRs is critical to the MHRA’s responsibility to monitor the safety of medicines in practice: this is
achieved through the submission of spontaneous reports of suspected ADRs by health-care professionals
and the public through the Yellow Card Scheme.18 The Yellow Card Scheme is designed to detect signals
that may indicate a potential hazard with a medicine, leading to further investigations that may result in
withdrawal of the medicine or changes in prescribing recommendations and restrictions in its use. Signal
detection from spontaneous reports of ADRs and subsequent guidance in risk–beneﬁt decisions is highly
dependent on the availability of reliable instruments to assess ADR causality, which presents difﬁculties in
paediatric pharmacovigilance. There is considerable variation in reporting of ADRs by practitioners and the
potential for under-reporting and, partly in response to these concerns, the Yellow Card Scheme was
extended to patients and families in 2005. The detail of individual ADR reports from patients is generally
superior to those of health-care professionals, contributing to the EU pharmacovigilance legislation.16 There
is a clear statement through legislation, regulation and policy recommendations that the framework for
pharmacovigilance in children is suboptimal and that a broader understanding of the assessment and
improvement in the systems and quality of reporting of ADRs in this age group is urgently needed.Burden of adverse drug reactions in children and young peopleGiven the stated importance of medicines for children by the Department of Health and the EMA, as well
as other international authorities, it is important that we perform robust studies to ﬁll knowledge gaps in
the burden of ADRs in children and young people. Drugs are the mainstay of treatment in paediatric
practice, yet a high proportion of drugs have not been tested in children. This leads to OLUL prescribing,
the use of inappropriate doses, the use of age-inappropriate formulations, which may result in
underdosing or overdosing, and drug development without due regard for the processes that are vital for
normal development of a child into an adult. There are data showing that the current practice of drug
development and drug use in paediatrics leads to avoidable adverse effects, which lead to morbidity and
mortality. There is a need to identify the burden of ADRs in children; this has been emphasised by recent
documents from the EMA and the US Food and Drug Administration (FDA), and is one of the important
aims of the MCRN.
A number of studies have been performed in children to determine the incidence of ADRs; however, there
are deﬁciencies in the evidence available at present. There is a lack of reliable and contemporary data
estimating how frequently ADRs are causing admissions, how frequently they occur in general paediatric
wards, how frequently they are life-threatening or cause death, and how often they could have been
avoidable by better prescribing, better information in summary of product characteristics (SmPC) or better
monitoring. Additionally, we do not have the tools to prevent these reactions. A number of studies have
attempted to estimate the incidence of ADRs in children and have reported data on ADR rates causing
admission to hospital, within inpatients and in the outpatient setting. The summary data conﬁrmed that
ADRs in children are a considerable burden. However, studies to date have varied considerably in their
methodological rigour,19 including the deﬁnition of an ADR used, the age range of the study population
and the clinical settings for data collection. Similarly, systematic reviews and meta-analyses of studies of
ADRs in children also demonstrate methodological limitations, including the source bibliographical
databases, deﬁnitions of ADRs to include adverse events (AEs) and exclusion of paediatric data fromNIHR Journals Library www.journalslibrary.nihr.ac.uk
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there was substantial heterogeneity in the incidence estimates in the different studies reﬂecting differing,
and often inadequate, methodologies that were used. Often the severity of the ADR was not reported,
and patient age, diagnosis and drug prescription patterns were often not reported, and thus could not be
considered in determining factors associated with ADRs in children. The need to conduct rigorous,
prospective studies of ADRs in children, both which cause hospital admission20,21 and within the inpatient
setting,22 was clearly needed. In addition, a methodologically rigorous systematic review incorporating the
ﬁndings of these novel prospective studies was required.19Assessment of causality and avoidability of adverse drug
reactions in children and young peopleIn addition to the overall burden of ADRs, the characterisation of individual ADRs provides essential
information in the context of drug safety science: two important factors are assessment of causality and
avoidability. Causality assessment estimates the strength of the relationship between drug exposure and
the occurrence of an ADR. Assessment of ADR avoidability, or preventability, does not have a universally
accepted deﬁnition, but there are two conventionally recognised principles: whether in the absence of
error an event is preventable, and, if so, whether the event can be prevented. The concepts of causality
and avoidability are relevant to health-care professionals, regulators, the pharmaceutical sector and the
academic community, although the context may vary among these constituencies. Regardless of the
reason or motivation to undertake causality or avoidability assessments, the availability of reliable and valid
instruments to generate meaningful data is essential. Given the difﬁculties in distinguishing between ADRs
and non-drug-induced pathology in children, these aspects are of particular importance in this population.
The Naranjo ADR probability scale23 is most widely used and reported causality assessment tool (CAT). This
instrument contains 10 weighted items that generate a construct to produce a total score resulting in
categorisation of the event as either unlikely, possible, probable or deﬁnite. Each item is based on
concepts including temporal relationships, biological plausibility and rechallenge/previous exposure. The
instrument was developed by adult physicians and psychiatrists using published case reports to validate
instrument reliability. The validity and reliability of the Naranjo tool has been subject to challenge and, in
addition, the use of the instrument to assess causality of ADRs in children is questionable given that
individual items were developed and validated using adult case reports.24
There is currently no standardised method for determining ADR avoidability and many of the established
tools are not suitable for use in paediatric practice. A number of instruments have been developed for
assessment of ADR avoidability and a systematic review found that several deﬁnitions exist for the
preventability of drug-related harm as a consequence of the variability in methodological approaches to
assessment of avoidability, and none ﬁts all circumstances.25 The authors of the systematic review
proposed an approach to preventability, based on analysis of the mechanisms of ADRs and their clinical
manifestations. Some authors have proposed a methodological framework for future studies of ADR
avoidability and the development of valid instruments.26 This includes reliability and validity testing,
standardisation of the measurement processes, description of assessor training and experience in assessing
preventability, details of independent or consensus assessments and rationalisation of assessor
disagreement. These authors recommend that there is a need to modify existing instruments or develop
novel instruments for use in different settings and populations.
The available instruments for assessment of causality and avoidability of ADRs vary in reliability and
validity.19 In particular, the assessment of avoidability is compromised by a lack of consensus on the
deﬁnition of avoidability and associated heterogeneity in underpinning methodology for instrument
development. No instruments are available speciﬁcally for characterisation of ADRs in children and young
people, and there is a requirement to develop such instruments.3
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4Communication about drug safety in children and
young peoplePrevious literature on communication concerning medicines highlights the beneﬁts of open discussion
between health-care professionals and patients, at the time of prescribing, on their potential risks
and the importance of supplementary written information in conveying key messages about drug
safety.12,27 Despite the movement towards patient reporting of ADRs and changes in EU legislation on
pharmacovigilance in children,16 patients and their families are generally poorly informed about ADRs
and pharmacovigilance systems to optimise safety of medicines. Other than in the context of
understanding parental beliefs and attitudes to childhood vaccination, very little is known about the
experiences of parents whose child has experienced a suspected ADR.28 As a consequence, health-care
professionals have no approriate evidence base from which to inform either generic or individualised
communication strategies with the family when a child experiences a suspected ADR. In addition, there is
little knowledge and documentary evidence of the experience of health-care professionals in the same
circumstances. The perspectives of health-care professionals regarding what information parents require
during episodes of suspected ADRs, have not been described and the mechanisms for decision analysis
and motivations which underpin the timing, content and narrative of communication by clinicians has not
been explored. In addition, there has been no attempt to identify if there are barriers to effective
communication with families from the perspective of clinicians following a suspected ADR. More
fundamentally, we did not know if the nature of the communication by health-care professionals about
ADRs meets the needs and expectations of parents. Despite the beneﬁcial impact of written supplementary
information on the understanding of drug safety at the point of prescribing, this paradigm has not
extended into circumstances when there is a suspected ADR in children. There are no customised written
materials, generated with the involvement of relevant stakeholders, which provide a framework within
which communication between health-care professionals and parents can be guided, and, in particular,
documentation intended for parents, which allows enquiry and dialogue to be initiated and led from their
perspective. Beyond this, it is important that further materials to guide communication pay adequate
attention to key principles of transaction and process, including what and when to communicate to
families, as opposed to developing and modifying the communication skills of clinicians.29The Adverse Drug Reactions In Children programmeMost studies of pharmacovigilance in children and young people to date have focused on individual
aspects of ADRs, for example ADRs causing hospital admission and ADRs occurring within small specialised
units. However, no programme of work has investigated a broad spectrum incorporating when and where
ADRs occur, characterising the nature of ADRs in this age group, developing instruments customised for
assessment of casuality and avoidability of ADRs in paediatric practice, and understanding the narratives
and communications between families and health-care professionals during episodes of suspected ADRs.
ADRIC was designed to undertake a comprehensive and coherent suite of studies aiming to add
signiﬁcantly to the existing evidence base and to generate outputs that can be adopted into both clinical
practice and further research to improve methodologies for our understanding and management of
pharmacovigilance in this vulnerable age group.
The ADRIC research strategy comprised the following component parts, which logically follow on from
each other:
l Quantification To estimate the incidence of ADRs in children, causing admission to hospital,
and to estimate the burden to the health-care economy; to estimate the incidence of ADRs in
hospitalised children.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3l Evaluation To identify risk factors for ADRs in causing admission to hospital and for causing ADRs in
hospitalised children, and to characterise these ADRs in terms of type, drug aetiology, causality,
avoidability and severity. To identify the unmet communication needs of parents whose child has
experienced a suspected ADR.
l Instrument development To develop and validate instruments to improve the assessment of causality
and avoidability of ADRs in children.
l Intervention To develop written materials that will guide the communication between parents and
health-care professionals following an episode of a suspected ADR(s).
The methodologies used to undertake the above aims included two large and comprehensive
single-centre prospective observational studies; a systematic review; reliability and validity testing of novel
ADR assessment instruments; qualitative enquiry; structured interviews and evaluation of
intervention implementation.
The ADRIC team was assembled with the necessary expertise to achieve the aims set out above. The
Senior Investigator Team comprised paediatricians and neonatologists, a clinical pharmacologist with
extensive experience in leadership and design of studies of assessment of ADRs in the adult population,
experienced secondary researchers, a senior paediatric pharmacist, a senior academic psychologist with
experience in qualitative methodologies for understanding the experience of children and families, and a
NIHR Paediatric Clinical Research Network Director. Members of the team also hold executive positions
within the NIHR MCRN and membership of expert committees, including the EMA and the UK
Commission on Human Medicines.
The ADRIC study was supported by a steering group to provide an independent strategic overview of the
programme. The steering group was overseen by an independent chairperson (Professor Sir Alisdair
Breckenridge, Chairman, MHRA) and included senior representation from the MHRA (Director of Vigilance
and Risk Management), US FDA, international academic paediatric pharmacovigilance expertise, and the
chairperson of the NIHR Research Methods programme. A management group, comprising ADRIC senior
investigators and members of the research team, was responsible for the design, implementation, analysis
and reporting of each study within the overall of the programme.
A multidisciplinary research team comprised paediatric research nurses, research pharmacists, paediatric
medical research fellows and research associates in qualitative methodologies. The setting for the ADRIC
study was Alder Hey, widely recognised as the largest specialist children’s health-care provider in Western
Europe, serving a population of children and young people in excess of two million and acting as a tertiary
referral centre for much of the north-west of England and north Wales. Alder Hey provides general and all
specialist paediatric services at local, regional and national levels. Community child health services are
provided alongside Child and Adolescent Mental Health Services (CAMHS) over a large geographical
footprint. The full range of paediatric services is provided at a single site with 325 beds and typically there
are annually 120,000 outpatient episodes, 26,000 inpatient admissions including day case episodes,
70,000 accident and emergency (A&E) attendances, 1000 critical care admissions and 13,000 CAMHS
episodes at Alder Hey (with 14,400 CAMHS outpatient episodes in community teams). ADRIC was
conducted over a 5-year period, between May 2008 and April 2013.5
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admission to a paediatric hospital
This chapter contains information reproduced from Gallagher RM, Mason JR, Bird KA, Kirkham JJ, PeakM, Williamson PR, et al. Adverse drug reactions causing admission to a paediatric hospital. PLOS ONE
2012;7:e50127,21 © 2012 Gallagher et al. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits
unrestricted use, distribution and reproduction in any medium, provided that the original author and
source are credited; and information reproduced with permission from Bellis JR, Kirkham JJ, Nunn AJ,
Pirmohamed M. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective
cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol 2013;77:545–53,30 with
permission from the British Pharmacological Society and Blackwell Publishing; and information reproduced
with permission from Bellis JR. Adverse Drug Reactions in Children – The Contribution of Off-label and
Unlicenced Prescribing. PhD thesis. Liverpool: University of Liverpool, 2013.31Abstract
Objective(s)
To determine the incidence of ADRs, which were associated with admission to hospital in children,
describe their causality, severity, avoidability and nature, and identify which children were particularly at
risk of this complication. To identify potential areas where intervention may reduce the burden of ill health.Design
Prospective observational study.Setting
A large children’s hospital providing general and specialty care in the UK.Participants
All acute paediatric admissions over a 1-year period.Main exposure
Any medication taken in the 2 weeks prior to admission.Outcome measures
Occurrence of ADR.Results
In total, 240 out of 8345 admissions in 178 out of 6821 patients who were admitted acutely to a paediatric
hospital were thought to be related to an ADR, giving an estimated incidence of 2.9% [95% conﬁdence
interval (CI) 2.5% to 3.3%], with the reaction directly causing, or contributing to the cause of, admission in
97.1% of cases. No deaths were attributable to an ADR. Overall, 22.1% (95% CI 17% to 28%) of the
reactions were either deﬁnitely or possibly avoidable. Prescriptions originating in the community accounted
for 44 out of 249 (17.7%) of ADRs, the remainder originating from hospital. Of 16,551 prescription
medicine courses, 11,511 (69.5%) were authorised, 4080 (24.7%) were off-label and 960 (5.8%) were
unlicensed. A total of 120 out of 249 (48.2%) reactions resulted from treatment for malignancies. The
drugs most commonly implicated in causing admissions were cytotoxic agents, corticosteroids, non-steroidal
anti-inﬂammatory drugs (NSAIDs), vaccines and immunosuppressants. OLUL medicines were more likely to
be implicated in an ADR than an authorised medicines [relative risk (RR) 1.67, 95% CI 1.38 to 2.02;
p < 0.001]. When medicines used for the treatment of malignancies were excluded, OLUL medicines were7
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8not more likely to be implicated in an ADR than authorised medicines (RR 1.03, 95% CI 0.72 to 1.48;
p = 0.830). The most common reactions were neutropenia, immunosuppression and thrombocytopenia.Conclusions
Adverse drug reactions in children are an important public health problem. Most of those serious enough
to require hospital admission are due to hospital-based prescribing, of which just over one-ﬁfth may be
avoidable. Strategies are needed to reduce the burden of ill health from ADRs causing admission.IntroductionChildren are vulnerable to ADRs.32–37 A recent retrospective study by Hawcutt et al.38 identiﬁed 31,726 of
222,755 (14.2%) ADR reports received by the UK MHRA through the Yellow Card Scheme, from 2000 to
2009, concerned children of < 17 years of age.38 However, it is well recognised that spontaneous reporting
systems, such as the Yellow Card Scheme in the UK,39 are subject to under-reporting of ADRs, even those
that are severe.40 Thus, it is likely that the number of paediatric ADR reports received each year by the
MHRA is a considerable underestimate of the magnitude of the problem in the UK.
Hospital-based ADRs can be identiﬁed by retrospective studies using case note review; such studies,
however, are likely to be less reliable than prospective studies in estimating the frequency with which
ADRs occur owing to the inadequacy of recorded information. To obtain reliable information about the
incidence of ADRs, prospective studies are needed.
A systematic review of observational studies of ADRs causing paediatric hospital admissions, between
1976 and 1996, estimated the overall rate of paediatric hospital admissions due to ADRs in children to be
2.1% (95% CI 1.0% to 3.8%).34 This review included ﬁve prospective observational studies investigating
ADRs causing admission in children.32,33,41–43 Three of the studies were large, including > 1000 admissions
each.32,33,41 Three of the studies used published measures to assess causality of ADRs,41–43 whereas the
two largest studies in the review used self-derived deﬁnitions for assessing causality.32,33 Only one of the
studies,41 with a low comparative reported ADR incidence of 10 out of 1682 admissions (0.6%), reported
on avoidability of the cases using an adapted version of a published method44 but did not detail which
ADRs were deemed avoidable or the reasons for assessing ADRs as being avoidable. The other studies did
not report avoidability of the admissions associated with ADRs.
A further systematic review of prospective studies published between 2001 and 2007 included four
studies37,45–47 but did not identify any large signiﬁcant studies detailing the incidence and nature of ADRs
causing admission of children to hospital.35 Three studies37,45,46 included < 1000 admissions and the
remaining study47 included a study population of 39,625 admissions but resulted in an ADR admission rate
of only 0.16%. All four studies37,45–47 assessed causality using a published algorithm. However, only one
study reported the avoidability of the ADR cases.46 This study46 did not give detail of the method used for
assessing avoidability, nor did the investigators detail the reasons for assigning cases as avoidable.
There have been no large paediatric studies that have looked at ADRs leading to hospital admission and
then gone on to consider the inﬂuence of OLUL medicine use. There is one small pilot study48 that
included ADRs to medicines administered before admission and recorded whether or not the medicines
implicated were off-label. Of the 41 ADRs detected in 41 out of 1619 patients, 12 were attributed to
medicines administered before admission and 29 were attributed to medicines administered in the
hospital. In 16 out of the 41 patients experiencing an ADR, an off-label medicine was implicated; ﬁve of
these were patients who experienced an ADR due to medicines administered before admission.
The aim of this study was to prospectively identify ADRs in children causing admission to hospital during a
1-year period in order to quantify and characterise the burden of ADRs. One important aspect of the study
was to determine the avoidability of the ADRs identiﬁed and detail the reasons for categorising theNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3reactions as ‘possibly’ or ‘deﬁnitely’ avoidable. In addition, the impact of OLUL medicine use on ADR risk in
this context was examined.MethodsThe study hospital had an induction programme that was delivered to new members of staff to educate
them about the hospital and some aspects of speciﬁc practice within the setting. This provided training to
clinicians regarding medication prescribing and drug safety for children but did not speciﬁcally address
ADRs, their diagnosis or how to report them. Therefore, before the start of this observational study, a
comprehensive educational programme was undertaken within the hospital among clinicians of all grades.
The study team attended hospital induction for new clinicians (and continued to do so through the entirety
of the study period) to give formal presentations about the study and ADRs in children. The study team
gave a formal presentation to an audience at the main weekly educational hospital meeting (for clinicians
and staff from all specialties), as well as presenting at individual specialty team meetings occurring within
the hospital.
The goal of this educational programme was to raise awareness about the aims of the study and to
increase clinicians’ understanding of their role in information recording. First, clinicians were made aware
of the primary aim of the study, which was to identify prospectively ADRs causing admission to the
hospital. Clinicians were reminded of the importance of good record-keeping with regard to descriptions
of symptoms and signs to allow for more accurate assessment of causality by the study team. Second, the
study team aimed to raise awareness of taking detailed medication histories in relation to identifying ADRs
accurately and assigning causality. A structured medication history was added to acute general paediatric
medical admission documentation with the aim of ensuring all families were asked for details about
medication taken in the preceding 2 weeks. A 2-week medication history was chosen as the time when
reactions causing admission were most likely to have occurred following exposure to a drug. A 2-week
pilot study to develop and reﬁne the methodology for this larger study was conducted prior to the
commencement of this study.20
The study team prospectively screened all unplanned admissions to a large paediatric centre (which
provides local and specialist regional and national services) for ADRs over a 1-year period, including
weekends and public holidays, from 1 July 2008 to 30 June 2009. Weekends were included in routine
daily data collection to eliminate any bias that may occur in trends of possible ADR admissions. Admissions
were excluded if they were planned or occurred as a result of accidental or intentional overdose. The
deﬁnition of ADR used was that of Edwards and Aronson,49 which is ‘an appreciably harmful or
unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which
predicts hazard from future administration and warrants prevention or speciﬁc treatment, or alteration of
the dosage regimen, or withdrawal of the product’.
Hospital information systems at the study hospital routinely recorded demographic data about admitted
patients. These data, with assistance from the hospital information technology department, were
automatically downloaded each morning at 06.00, for the patients coded as having an emergency
admission, from the hospital computer system to a password-protected Microsoft Access 2007 database
(Microsoft Corporation, Redmond, WA, USA) stored on a secure hospital hard drive. Only the study team
had access to the database and the patient information recorded within.
Members of the study team, consisting of a paediatric registrar (RMG), a research pharmacist (JRB) and a
research nurse (KAB) collected the following information from the case notes of each patient: presenting
complaint, summary of clinical history and diagnosis (if available at the time of admission). The details of
any medication taken at any time during the 2 weeks before admission were recorded, speciﬁcally drug
name, route, dose, frequency, duration, indication (if this required clariﬁcation) and whether it was a
prescription or non-prescription medicine. The data on prescription medicine use were scrutinised in order9
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10to deﬁne each medicine course as either authorised, off-label, unlicensed or unknown. Authorised use was
deﬁned as the use of a medicine with a UK marketing authorisation (MA), within the terms of that MA.
The terms of the MA were found in the SmPC available online from the Electronic Medicines Compendium
(EMC).50 If no SmPC was available, the British National Formulary for Children (BNF-C)51 was consulted for
details of the product MA. If neither reference source provided adequate clarity of information, the
manufacturer of the medicine was contacted. Off-label use was deﬁned as the use of a medicine with a
UK MA, outside the terms of that MA. According to the deﬁnitions described by Turner et al.,52 unlicensed
medicines were deﬁned as those without a UK MA, and an ‘unknown’ category was reserved for medicine
courses for which inadequate detail was available to decide whether use was authorised or OLUL. If any
information was unclear, study team members interviewed the family, patient or carers as appropriate to
clarify the history (i.e. medication history), symptoms and timing of events.
The study team cross-referenced the presenting symptoms/signs against medication history for each
patient using the ADR proﬁle for relevant drugs from the SmPC50 in the EMC or, if not available, the
BNF-C.51 Possible ADRs were identiﬁed using this information combined with the clinical history and
temporal relationships of the medication(s) taken. All possible ADRs were reported by the study team to
the responsible clinicians during the study. All possible ADRs were reported to the MHRA using the
electronic Yellow Card Scheme at the end of the study period. Reporting to the MHRA occurred after
internal causality assessment of the possible ADR cases. The origin of prescription, for drugs thought to be
associated with ADRs, was classiﬁed using the following criteria:
1. Community Drugs where prescriptions originated in community settings, for example general practice,
or where administration took place prior to hospital admission (e.g. paramedic administered).
2. Hospital Drugs where the prescription originated, or administration took place, in hospital and then
may or may not have been continued, for example by repeat prescription, in community or
outpatient settings.
3. Oncology All drugs administered, or prescribed, from the oncology ward. These drugs may or may not
be cytotoxic in nature.
We performed assessment of causality for all cases using the Liverpool Causality Assessment Tool (LCAT).53
Three investigators (RMG, JRB, KAB) independently assessed causality for all possible ADR cases.
Agreement on causality category between all three investigators was taken as accepted consensus. In
cases when the three investigators did not achieve consensus, a fourth investigator assessed cases to
decide on causality (MPir).
Avoidability of the ADR cases was assessed by consensus meeting between the investigators, using the
deﬁnitions developed by Hallas et al.54 Cases were assessed as deﬁnitely avoidable, possibly avoidable or
unavoidable. In addition, the type of ADR for each case identiﬁed was determined according to the
classiﬁcation of Rawlins and Thompson55 as either Type A (predictable from the known pharmacology) or
Type B (not predictable). Severity was determined using an adapted Hartwig scale.56 This adapted scale is
shown in Table 1. Grades 3 and 4 are adapted from the original schema, as not all ADR admissions
necessitate cessation of the causative drug(s).
We chose these assessment tools to describe the nature of the ADRs in our study as they have been
used previously in ADR studies by other investigators and can be completed quickly. Three investigators
independently assessed 217 out of 4514 (4.8%) reports of admissions exposed to medication, but deemed
not to have had an ADR, to assess for occurrence of possible ADR cases wrongly classiﬁed by the study
team (AJN, MPir, MAT).Statistical analysis
Analyses of the rates of ADRs were based on the number of admissions with the rate expressed as ADR
per 100 admissions, together with 95% CIs. Other results are presented either as medians and
interquartile ranges (IQRs) or percentage frequencies and 95% CI, as appropriate. The formal statisticalNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 1 Adapted Hartwig severity scale
Severity score Description
6 Directly or indirectly resulted in patient death
5 Caused permanent harm or signiﬁcant haemodynamic instability
4 Resulted in patient transfer to higher level of care
3 Required treatment (admission) or drug discontinued
2 Drug dosing or frequency changed, without treatment
1 No change in treatment with suspected drug
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3analysis was based on the data obtained at the ﬁrst admission for patients exposed to a medication.
Univariate statistical analyses were performed using the Mann–Whitney U-test except for frequency data,
which were analysed using a chi-squared test. Multivariate logistic regression analysis was undertaken to
calculate odds ratios (ORs) for possible risk factors for ADR. The RR (with 95% CI) for OLUL medicines
being implicated in an ADR was calculated for prescription medicines. A p-value of < 0.05 was regarded as
being signiﬁcant.Ethics
This study used routinely collected clinical data in an anonymised format. The chairperson of Liverpool
Paediatric Local Research Ethics Committee informed us that this study did not require individual patient
consent or review by an ethics committee.ResultsOver the study period, there were 6821 patients admitted acutely to the study hospital, accounting
for 8345 unplanned admissions. Boys accounted for 3961 out of 6821 (58.1%) patients and 4793 out of
8345 (57.4%) admissions. The median number of admissions per patient was one, with 932 patients
having more than one acute admission, up to a maximum of 15. A total of 178 patients experienced
240 admissions with an ADR. This gives an incidence of 2.9 ADRs per 100 admissions (95% CI 2.5 to 3.3);
233 of the 240 (97.1%) admissions were deemed to have been directly caused, or contributed to, by at
least one ADR. There were 249 ADRs in 240 admissions, with nine admissions having two separate ADRs;
35 out of 178 (19.7%) patients had more than one admission with an ADR, up to a maximum of seven.
There were 4656 patients exposed to a medication in the 2 weeks prior to acute admission to the hospital.
Of these patients, 142 (3%) had a suspected ADR on their ﬁrst hospital admission within the study period.
There was no signiﬁcant difference between the proportion of boys (76/2677, 2.8%) and girls (66/1979,
3.3%) experiencing an ADR on their ﬁrst admission, for the group as a whole or oncology patients studied
separately (Table 2). For non-oncology patients, there was a slightly higher proportion of girls admitted
with an ADR [boys 48/2627 (1.8%), girls 53/1955 (2.7%); p = 0.044], although overall more boys than
girls were admitted to the hospital.
The median age of the 4656 patients who had been exposed to a drug on their ﬁrst admission was
3 years 1 month (IQR 9 months to 9 years). Patients with an ADR (6 years, IQR 2 years 4 months to
11 years) were signiﬁcantly older (p < 0.001) than those without (3 years, IQR 9 months to 9 years)
(Table 3). There was no age difference between the 41 oncology patients admitted with an ADR (6 years,
IQR 3–10 years) and the 33 oncology patients admitted without an ADR (6 years, IQR 3 years 6 months to
13 years). There was a signiﬁcant age difference (p < 0.001) between 101 non-oncology patients admitted
with ADR (6 years, IQR 1 year 7 months to 11 years) and 4481 admitted without ADR (2 years 11 months,
IQR 9 months to 9 years).11
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TABLE 2 Univariate analyses of ADRs by gender
Gender All No ADR ADR Chi-squared test p-value
All boys 2677 2601 (97.2%) 76 (2.8%) 0.947 0.331
All girls 1979 1913 (96.7%) 66 (3.3%)
Oncology Boys 50 22 (44.0%) 28 (56.0%) 0.022 0.882
Girls 24 11 (45.8%) 13 (54.2%)
Non-oncology Boys 2627 2579 (98.2%) 48 (1.8%) 4.062 0.044
Girls 1955 1902 (97.3%) 53 (2.7%)
TABLE 3 Univariate analyses of ADRs by patient age
Age (years, months);
median: quartile 1,
quartile 3 All No ADR ADR
Mann–Whitney
U-test p-value
All 3 years 1 month;
9 months, 9 years
(n = 4656)
3 years 0 months;
9 months, 9 years
(n = 4514)
6 years 0 months;
2 years 4 months,
11 years (n = 142)
244,161 < 0.001
Oncology 6 years; 3 years
6 months,
12 years (n = 74)
6 years; 3 years
6 months,
13 years (n = 33)
6 years; 3 years
0 months,
10 years (n = 41)
580.5 0.296
Non-oncology 3 years;
9 months, 9 years
(n = 4582)
2 years
11 months;
9 months, 9 years
(n = 4481)
6 years; 1 year
7 months,
11 years (n = 101)
178,319.5 < 0.001
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12Patients admitted with an ADR had taken a greater number of drugs than those admitted for other
reasons (Table 4). For patients admitted with an ADR (n = 142), the number of medicines taken was higher
(6, IQR 3–9; p < 0.001) than those for other reasons (n = 4514) (2, IQR 1–3). The number of medicines
taken by oncology patients admitted with an ADR (8, IQR 5–10) was higher than those admitted without
an ADR (4, IQR 3–7) and this difference was also found for non-oncology patients (with ADR 5, IQR 3–9;
without ADR 2, IQR 1–3).
Logistic regression analysis showed a trend towards boys being less likely to experience an ADR than girls,
with an OR of 0.77 (95% CI 0.52 to 1.12; p = 0.17) (Table 5). There was an increased likelihood of ADRs
with increasing age (OR 1.04, 95% CI 1.003 to 1.08; p = 0.03). No children were admitted with an ADR in
the ﬁrst month of life. Oncology patients were much more likely to have an ADR causing admission
(OR 29.71, 95% CI 17.35 to 50.88; p < 0.001). The likelihood of a child being admitted with an ADR
increased with the number of medicines taken (OR 1.24, 95% CI 1.19 to 1.29; p < 0.001). Therefore, for
each additional medicine taken by a patient the risk of an ADR occurring increases by almost 25%.TABLE 4 Univariate analyses of ADRs by number of medicines taken
Drug count All (median; IQR) No ADR ADR Mann–Whitney U-test p-value
All 2 (1–3) (n = 4656) 2 (1–3) (n = 4514) 6 (3–9) (n = 142) 115,391.5 < 0.001
Oncology 6 (4–9) (n = 74) 4 (3–7) (n = 33) 8 (5–10) (n = 41) 380.5 0.001
Non-oncology 2 (1–3) (n = 4582) 2 (1–3) (n = 4481) 5 (3–9) (n = 101) 100,371.5 < 0.001
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 5 Multivariate logistic regression analysis
Parametera OR 95% CI for OR p-value
Gender (male) 0.77 0.52 to 1.12 0.17
Age 1.04 1 to 1.08 0.03
Oncology 29.71 17.35 to 50.88 < 0.01
No. of medicines 1.24 1.19 to 1.29 < 0.01
a Variable(s) entered on step 1: gender (male), age, oncology, no. of medicines.
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3A further univariate analysis was carried out which included only patients on their ﬁrst admission who had
received at least one prescription medicine in the 2 weeks prior to admission (n = 3869). This analysis
compared each continuous variable in the group of patients who had experienced at least one ADR with
those who had not in three subpopulations: all patients, patients who had been exposed to at least
one OLUL medicine and patients who had received only authorised medicines. There was no signiﬁcant
difference in the proportion of each gender in any of the subpopulations. The median age and median
number of medicines was greater in patients who had experienced at least one ADR; however, within the
population of patients exposed to authorised medicines only there was no difference. The median number
of medicines was signiﬁcantly greater in children who experienced an ADR for all subpopulations.
Oncology patients and patients exposed to OLUL medicines were signiﬁcantly more likely to experience
an ADR (Table 6). Multivariate analysis indicated oncology patients were more likely to have experienced
an ADR: OR 25.70 (95% CI 14.56 to 45.38; p < 0.001). The number of authorised medicines courses
administered in the 2 weeks before admission was a signiﬁcant ADR risk factor (OR 1.25, 95% CI 1.16 to
1.35; p < 0.001) but so was the number of OLUL medicines administered (OR 1.23, 95% CI 1.10 to 1.36;
p < 0.001). In addition, increasing age was associated with an increased risk of ADR; OR 1.04 (95% CI
1.00 to 1.08; p = 0.045). There was a trend towards females being more likely to experience an ADR: OR
0.74 (95% CI 0.51 to 1.09; p = 0.130) (Table 7).13
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TABLE 6 Univariate analyses of ADRs for all ﬁrst admissions who received at least one prescription medicine in the
2 weeks before admission by gender, age and number of medicines taken (n = 3869)
Variable All No ADR ADR p-value
Gender
All boys 2247 2172
(96.7%)
75 (3.3%) 0.271a
All girls 1622 1557
(96.0%)
65 (4.0%)
OLUL exposed Boys 869 812 (93.4%) 57 (6.6%) 0.982a
Girls 627 585 (93.3%) 42 (6.7%)
Authorised only Boys 1321 1303
(98.6%)
18 (1.4%) 0.063a
Girls 953 930 (97.6%) 23 (2.4%)
Age (years, months): median; quartile 1, quartile 3
All 3 years
1 month;
8 months,
9 years
(n = 3869)
3 years;
8 months,
9 years
(n = 3729)
6 years;
2 years
4 months,
11 years
(n = 140)
< 0.001b
OLUL exposed 2 years
5 months;
3 months,
8 years
(n = 1595)
2 years
1 month;
3 months,
7 years
(n = 1496)
7 years;
3 years
7 months,
12 years
(n = 99)
< 0.001b
Authorised only exposed 3 years
8 months;
1 year,
10 years
(n = 2274)
3 years
8 months;
1 year,
10 years
(n = 2233)
3 years
9 months;
8 months;
8 years
6 months
(n = 41)
0.968b
No. of medicines: median; quartile 1, quartile 3
All 2; 1, 4
(n = 3869)
2; 1, 4
(n = 3729)
6; 3, 9
(n = 140)
< 0.001b
OLUL exposed 3; 2, 6
(n = 1565)
3; 2, 5
(n = 1496)
8; 5, 10
(n = 99)
< 0.001b
Authorised only exposed 2; 1, 3
(n = 2274)
2; 1, 3
(n = 2233)
3; 2, 6
(n = 41)
0.003b
Specialty
Oncology 73 32 (43.8%) 41 (56.2%) < 0.001a
Non-oncology 3796 3697
(97.4%)
99 (2.6%)
OLUL exposure
OLUL exposed 1595 1496
(93.8%)
99 (6.2%) < 0.001a
Authorised only exposed 2274 2233
(98.2%)
41 (1.8%)
a Chi-squared test.
b Mann–Whitney U-test.
Reproduced from Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label
and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital.
Br J Clin Pharmacol 2013;77:545–5330 with permissions from John Wiley and Sons. This article is protected by copyright.
All rights reserved. © 2013 The British Pharmacological Society.
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TABLE 7 Multivariate logistic regression analysis for all ﬁrst admissions who received at least one prescription
medicine in the 2 weeks before admission (n = 3869)
Variable OR (95% CI) p-value
Gender (male) 0.74 (0.51 to 1.09) 0.130
Specialty (oncology) 25.70 (14.56 to 45.38) < 0.001
No. of authorised medicines 1.25 (1.16 to 1.35) < 0.001
No. of OLUL medicines 1.23 (1.10 to 1.36) < 0.001
No. of unknown medicines 0.84 (0.59 to 1.18) 0.303
Age in years 1.04 (1.00 to 1.08) 0.045
Reproduced from Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and unlicensed
medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol
2013;77:545–5330 with permissions from John Wiley and Sons. This article is protected by copyright. All rights reserved.
© 2013 The British Pharmacological Society.
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The main class of drugs contributing to ADR-related admissions (n = 110; 44.2%) was cytotoxic drugs
(Table 8). Corticosteroids (n = 102, 41%), NSAIDs (n = 31, 12.4%), vaccines (n = 22, 8.8%) and
immunosuppressant drugs (n = 18, 7.2%) were the next most commonly implicated drug classes causing
ADR-related hospital admissions.
A total of 551 courses of medicines contributed to the 249 ADRs causing 240 admissions. The median
number of drugs causing an ADR admission was two (n = 79), with a maximum of six (three admissions).
Seven admissions were caused by ﬁve drugs, 25 by four drugs and 57 by three drugs. A total of
69 admissions were caused by one drug only. None of the ADRs, caused by more than one drug, occurred
as a result of a pharmacokinetic drug–drug interaction. All of the ADRs caused by more than one drug
were a result of pharmacodynamic interactions.
There were 17,758 prescription medicine courses given to 3869 patients in the 2 weeks prior to admission.
Of these, 1207 (6.8%) could not be categorised, 11,511 (64.8%) were authorised, 4080 (23.0%) were
off-label and 960 (5.4%) were unlicensed. OLUL medicines were more likely to be implicated in an ADR
than authorised medicines [RR 1.67 (95% CI 1.38 to 2.02)]. In total, 14,923 out of 16,106 medicine courses
administered to non-oncology patients could be categorised. Of these, 71% were authorised, 24% off-label
and 5% unlicensed and OLUL medicines were not more likely to be implicated in an ADR than authorised
medicines [RR 1.03 (95% CI 0.72 to 1.48)]. In comparison, among the 1652 medicine courses administered
to oncology patients, 1628 could be classiﬁed and 57% were approved, 34% were off-label and 9% were
unlicensed, and OLUL medicines were more likely to be implicated in an ADR than authorised medicines
[RR 1.39 (95% CI 1.12 to 1.71)].Nature of the adverse drug reactions
The most common ADRs were oncology related, including neutropenia (n = 89), thrombocytopenia (n = 55)
and anaemia (n = 38). The next most common ADR was immunosuppression (n = 74), occurring in both
oncology and non-oncology patients. Overall, 84 cases of neutropenia, thrombocytopenia, anaemia and/or
immunosuppression among oncology patients involved at least one OLUL medicine, and 12 cases of
immunosuppression among non-oncology patients involved at least one OLUL medicine. Postoperative
bleeding, linked to perioperative corticosteroid administration and/or NSAIDs, caused 28 admissions
(26 post tonsillectomy), and 21 of the post-tonsillectomy bleeds were attributed to at least one OLUL
medicine. Vomiting (n = 15), diarrhoea (n = 14), rash (n = 11) and constipation (n = 9) were all common
ADRs causing admission. Hypoglycaemia in diabetic patients treated with regular insulin caused nine
admissions and none of the insulin prescriptions were off-label. Respiratory depression following treatment15
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TABLE 8 Classiﬁcation of drugs associated with ADR admissions
Drug class (no. of cases) No. of drugs Drugs ADRs
Cytotoxics (110) 275 Vincristine, 51; doxorubicin, 38;
methotrexate, 35; etoposide, 30;
mercaptopurine, 27;
cytarabine, 24; ifosfamide, 18;
cyclophosphamide, 15;
carboplatin, 7; vinblastine, 5; peg
asparaginase, 5; dactinomycin, 5;
daunorubicin, 4; cisplatin, 3;
irinotecan, 3; temozolomide, 2;
ﬂudarabine, 1; amsacrine, 1;
imatinib, 1
Neutropenia, 89;
thrombocytopenia, 55;
anaemia, 38; vomiting, 8;
mucositis, 8; deranged liver
function tests, 7;
immunosuppression, 7; diarrhoea,
5; nausea, 4; constipation, 3;
headache, 2; abdominal pain, 1;
back pain, 1; haematuria, 1;
leucoencephalopathy, 1; deranged
renal function, 1
Corticosteroids (102) 107 Dexamethasone, 68;
prednisolone, 33;
hydrocortisone, 2;
betamethasone, 1;
mometasone, 1;
methylprednisolone, 1;
ﬂuticasone, 1
Immunosuppression, 71;
postoperative bleeding, 23;
hyperglycaemia, 3; hypertension, 1;
gastritis, 1; increased appetite, 1;
impaired healing, 1; adrenal
suppression, 1
NSAIDs (31) 43 Ibuprofen, 28; diclofenac, 15 Postoperative bleeding, 27;
haematemesis, 2; constipation, 1;
abdominal pain, 1
Vaccines (22) 37 Diphtheria, tetanus, pertussis,
inactivated polio Haemophilus
influenzae vaccine, 11;
pneumococcal conjugate, 9;
meningococcal C, 8; measles;
mumps and rubella (MMR), 7;
Haemophilus influenzae type b, 1;
inﬂuenza, 1
Fever, 8; rash 5; irritability, 4;
seizure, 4; vomiting, 3; pallor, 1;
apnoea, 1; limb swelling, 1;
lethargy, 1; thrombocytopenia, 1;
diarrhoea, 1; abdominal pain, 1;
respiratory distress, 1; Kawasaki
disease, 1
Drugs affecting the
immune response (18)
26 Tacrolimus, 15; mycophenolate,
7; azathioprine, 2; methotrexate,
1; inﬂiximab, 1
Immunosuppression, 18
Antibacterial drugs (16) 17 Co-amoxiclav, 4; penicillin v, 3;
amoxicillin, 3; ﬂucloxacillin, 2;
cefaclor, 1; cefalexin, 1;
cefotaxime, 1; teicoplanin, 1;
erythromycin, 1
Diarrhoea, 7; rash, 4; vomiting, 4;
lip swelling, 1; deranged LFTs, 1;
thrush, 1
Drugs used in diabetes (9) 13 Insulin detemir, 4; insulin aspart, 3;
isophane insulin, 2; biphasic
isophane, 2; human insulin, 2
Hypoglycaemia, 9
Drugs used in status
epilepticus (8)
12 Lorazepam, 5; diazepam, 5;
midazolam, 2
Respiratory depression, 8
Opioid analgesia (6) 7 Dihydrocodeine, 3; codeine
phosphate, 3; fentanyl, 1
Constipation, 4; ileus, 1; decreased
conscious level, 1
Drugs used in nausea (4) 4 Ondansetron, 4 Constipation, 4
Antiepileptic drugs (2) 2 Carbamazepine, 1; nitrazepam, 1 Constipation, 1; respiratory
depression, 1
Drugs that suppress
rheumatic disease (2)
2 Methotrexate, 1; anakinra, 1 Immunosuppression, 2
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TABLE 8 Classiﬁcation of drugs associated with ADR admissions (continued )
Drug class (no. of cases) No. of drugs Drugs ADRs
Other (16) 4 Calcium carbonate and
amlodipine, 1; oxybutynin, 1;
baclofen, 1
Constipation, 3
2 Dimethicone, 1; carbocysteine, 1 Rash, 2
2 Desmopressin acetate, 1;
alimemazine, 1
Seizure, 2
10 Glucose and dextrose, 1;
propanolol, 1; acetazolomide, 1;
spironolactone, 1; loperamide, 1;
macrogols, 1; captopril, 1;
alfacalcidol, 1; ethinylestradiol, 1
Hyperglycaemia, 1;
wheeze/difﬁculty in breathing, 1;
headache, 1; hyperkalaemia, 1;
intestinal obstruction, 1;
diarrhoea, 1; renal dysfunction, 1;
hypercalcaemia, 1;
intermenstrual bleed, 1
LFT, liver function test.
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3for status epilepticus caused eight admissions to the hospital’s PICU: unlicensed buccal midazolam liquid
was implicated in two of these.Origin of adverse drug reaction drug prescriptions
Prescriptions originating from community settings accounted for 44 out of 249 (17.7%) of the ADRs,
and 85 out of 249 (34.1%) ADRs arose from prescriptions originating in hospital for the treatment of
conditions other than oncology. Prescriptions originating from oncology accounted for 120 out of
249 (48.2%) of ADRs. Of the patients with one ADR (n = 140) in the study period, 39 (27.9%) occurred
with community-originated prescriptions, 71 (50.7%) with hospital-originated prescriptions and
30 (21.4%) with oncology-originated prescriptions. Of patients with two ADRs (n = 22) in the study period,
two (9.1%) occurred with community prescriptions, six (27.3%) with hospital prescriptions and 14 (63.6%)
with oncology prescriptions. Prescriptions originating from oncology accounted for 15 out of 16 patients
with three or more ADRs. One patient, with three ADRs in the study period, had two ADRs to
hospital-originated prescriptions and one ADR to a community prescription.Adverse drug reaction assessments (reaction type, causality, severity,
avoidability)
A total of 238 out of 249 (95.6%) ADRs were classiﬁed as type A (predictable from the known
pharmacology), with 11 out of 249 (4.4%) being type B (not predictable). Assessment of causality using
the LCAT showed the highest proportion of cases (94/249, 37.8%) to be in the ‘deﬁnite’ category.
Oncology cases accounted for 80 of these 94 deﬁnite causality cases (Table 9). In total, 41 out of 55
(74.5%) of possibly or deﬁnitely avoidable cases were classiﬁed as ‘deﬁnite’ or ‘probable’, 92 out of 238
(39.1%) type A reactions were assessed to be of deﬁnite causality, and 8 out of 11 (72.7%) type B
reactions were assessed to be ‘possible’. The majority (16/17, 94.1%) of the more severe reactions
(adapted Hartwig severity score of grade 4 or more) were assessed to have deﬁnite or probable causality.
A total of 223 out of 249 (89.6%) of the ADRs were classiﬁed as grade 3 (‘required treatment or drug
administration discontinued’) according to the Hartwig severity scale, as we deﬁned anyone requiring
admission to hospital as ‘needing treatment’. Fourteen (5.6%) were classiﬁed as grade 4 (‘resulted in
patient transfer to higher level of care’), including respiratory depression (n = 8), immunosuppression
(n = 4), neutropenia (n = 1), fever/seizure (n = 1) and leukoencephalopathy (n = 1). Three ADRs were
classiﬁed as grade 5 (‘caused permanent harm or signiﬁcant haemodynamic instability’). Two of these most
severe ADRs occurred in oncology patients with febrile neutropenia and septicaemia, and the remaining
case was a child who required bowel resection for ileus, with impacted faecal matter, following treatment17
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DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3with loperamide. No ADRs contributed to death. Two ADRs were classiﬁed as grade 2 (‘drug dosing or
frequency changed, without treatment’) and seven were classiﬁed as grade 1 with (‘no change in
treatment with the suspected drug’).
Of the ADRs, 194 out of 249 (78%) were assessed as ‘unavoidable’, whereas 45 (18%) were classiﬁed
as ‘possibly avoidable’ and 10 (4%) as ‘deﬁnitely avoidable’. Five of the cases deemed to be deﬁnitely
avoidable were associated with hospital-prescribed drugs and ﬁve with community-prescribed drugs;
31 possibly avoidable cases were associated with hospital-prescribed drugs and 14 with community-
prescribed drugs. A total of 114 (47.5%) of the ADR admissions occurred in oncology patients, accounting
for 120 ADRs. Of the ADRs due to oncology drugs, 112 out of 120 (93.3%) were unavoidable, with a
further six being possibly avoidable and two deﬁnitely avoidable. These ‘deﬁnitely avoidable’ cases were
oncology patients with constipation following treatment with vincristine and ondansetron (with one also
having dihydrocodeine) without laxative prophylaxis.
Of the ADR admissions not associated with oncology patients (n = 126 admissions and 129 ADRs), 82 out
of 129 ADRs (63.6%) were classiﬁed as unavoidable, 39 (30.2%) as possibly avoidable and eight (7.6%) as
deﬁnitely avoidable. The eight ‘deﬁnitely avoidable’ cases comprised four patients who were prescribed
antibiotics, for whom the antibiotic choice or indication was deemed to be inconsistent with good
practice: one patient with intestinal obstruction being treated with loperamide, who had not passed stool
for 2 days prior to admission; one patient who had a seizure after alimemazine, having had two previous
occurrences of seizure after the antihistamine; one patient with deranged renal function, which improved
after cessation of captopril, for whom the ADR may have been avoided through improved renal function
monitoring; and one patient who presented with adrenal suppression following 2 years of continuous
treatment with intranasal corticosteroids. The possibly and deﬁnitely avoidable cases and the reasons for
their allocation are summarised in Table 10.TABLE 10 Possibly and deﬁnitely avoidable cases and explanation of assessment result
Avoidable? Frequency ADR(s) Drug classes
Reason for potential
avoidability
Deﬁnitely 3 Diarrhoea and/or
vomiting
Antibacterial drugs Inappropriate indication,
signs/symptoms of viral illness
2 Constipation Cytotoxic drugs, drugs used in
nausea, opioid analgesia
Appropriate prophylaxis
not used
1 Lip swelling, rash Antibacterial drugs Same ADR previously to same
medication
1 Seizure Antihistamine Same ADR previously to
similar medication
1 Adrenal
suppression
Corticosteroids Avoidable with more rational
prescribing (prolonged use of
drugs) and improved
monitoring
1 Intestinal
obstruction
Antimotility drugs Could be prevented by
improved parent/patient
education
1 Deranged renal
function
Drugs affecting the
renin–angiotensin system
Avoidable with improved
monitoring
continued
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TABLE 10 Possibly and deﬁnitely avoidable cases and explanation of assessment result (continued )
Avoidable? Frequency ADR(s) Drug classes
Reason for potential
avoidability
Possibly 9 Hypoglycaemia Drugs used in diabetes Avoidable with improved
patient education (e.g. insulin
use when unwell) and more
rational prescribing
8 Respiratory
depression
Drugs used in status
epilepticus, hypnotic drugs
Alternative medicine available,
multiple doses given;
avoidable with more rational
prescribing
6 Diarrhoea/vomiting Antibacterial Inappropriate indication,
symptoms suggested viral
infection
5 Constipation Antiepileptic drugs, opioid
analgesia, drugs used in
nausea, NSAIDs, cytotoxic
drugs, calcium channel
blockers, calcium supplements
Prophylaxis not used
4 Immunosuppression Drugs affecting the immune
response, corticosteroids
Possibly avoidable with
improved monitoring of drug
levels; avoidable with more
rational prescribing
2 Haematemesis NSAIDs Avoidable with improved
patient education/more
rational prescribing (less
NSAID use)
1 Neutropenia Cytotoxic drugs Same ADR previously at same
dose of medication
1 Neutropenia,
thrombocytopenia,
anaemia
Cytotoxic drugs Superﬁcial infection after
recent admission with febrile
neutropenia; possibly
avoidable by prolonging
antibiotic use or commencing
granulocyte colony-stimulating
factor
1 Hyperglycaemia Corticosteroids Avoidable with more rational
prescribing (prolonged course
steroids used)
1 Hyperglycaemia Parenteral preparations Avoidable with more rational
prescribing (more judicial use)
or improved monitoring
1 Seizure Posterior pituitary hormones Possibly inappropriate
medication used for a patient
with seizures
1 Diarrhoea Laxatives Avoidable with improved
patient education
1 Ileus Opioid analgesia Avoidable with more rational
prescribing (possibly use
alternative analgesia)
1 CNS depression Opioid analgesia Avoidable with improved
patient education
1 Vomiting Cytotoxic drugs Possibly avoidable with more
appropriate antiemetic
prophylaxis
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TABLE 10 Possibly and deﬁnitely avoidable cases and explanation of assessment result (continued )
Avoidable? Frequency ADR(s) Drug classes
Reason for potential
avoidability
1 Gastritis Corticosteroids Previous gastritis; possibly
avoidable with improved
prophylaxis
1 Hypercalcaemia Vitamins Avoidable with improved
monitoring
CNS, central nervous system.
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3Drug exposure prior to acute admission
Of 8345 admissions, 6020 (72.1%) were exposed to medication in the 2 weeks prior to admission;
3417 (56.8%) of these were male and 2603 were female (43.2%). The median number of drugs taken
was 2 (IQR 1–4), with one child exposed to 34 courses of medication owing to an admission for
cardiothoracic surgery in the 2 weeks prior to readmission. Figure 1 shows the distribution of drugs
per admission.
Children of < 1 year of age accounted for the most number of admissions: 1737 out of 2539 (68.4%) of
< 1-year-olds had been exposed to medication prior to admission (Figure 2). Of the other children
admitted, the age group most frequently exposed to medication was the 16-year-old group (95/99
admissions, 96%). Children aged 7 years were the least exposed to medication (163/245, 66.5%)
prior to admission.
Of 6020 children exposed to at least one medicine prior to admission, those aged 16 years were exposed
to the greatest number of drugs per admission, with a mean of 5.93 (95% CI 4.92 to 6.93) drugs.
Children aged < 1 year were exposed to fewer medicines on average, with a mean of 2.82 (95% CI 2.71
to 2.93) drugs per admission (Figures 3 and 4).2000
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24Cost of adverse drug reactions and length of stay
The mean cost of 238 out of 240 ADR admissions to the study hospital, using information provided by the
ﬁnance department, was calculated to be £4753 per admission (95% CI £3439 to £6066). Cost data were
missing for two ADR admissions: one oncology admission and one non-oncology patient admission. The
mean cost of 113 oncology ADR admissions to the study hospital was £5428.91 (95% CI £4041.24 to
£6816.58). The mean cost of 125 non-oncology admissions was £4141.40 (95% CI £1963.84 to
£6318.95). The mean length of stay (LOS) of all 240 ADR admissions was 5.67 (95% CI 3.28 to 8.06)
days. The mean LOS for the oncology admissions was 5.45 (95% CI 4.35 to 6.55) days, and
5.87 (95% CI 1.4 to 10.34) days for the non-oncology admissions.
Data from the Health and Social Care Information Centre57 showed that in 1 year, between 2009 and
2010, the total number of paediatric emergency admissions in England was approximately 597,800
(includes paediatrics and paediatric surgery, cardiology and neurology). We estimate the annual mean cost
of paediatric ADR admissions to the NHS in England to be £82.4M using the mean cost of all ADR
admissions to the study hospital. Using the upper and lower CIs for both our estimate of ADR incidence
and study hospital costs we estimate the cost to the NHS in England of paediatric ADR admissions to be
between £51.4M and £119M.DiscussionThis prospective observational study is the largest of its kind in children and the only one to
comprehensively assess causality, type of reaction (predictable or not), severity, origin of drug prescription
and avoidability. This is the ﬁrst large study in children to investigate risk factors for the occurrence of an
ADR-related admission inclusive of the use of OLUL medicines. The majority of admissions associated with
ADRs in children occurred as a result of prescriptions originating in hospital. Potential preventative
strategies for ADRs causing admission in children should therefore be targeted at hospital prescribing.
Analysis of the ‘deﬁnitely avoidable’ ADRs in this study suggests that more careful attention to practical
aspects of care – such as improved monitoring, following prescribing guidelines, improved patient
education and heightened suspicion about potential adverse reactions – could lead to a reduction in the
frequency of ADRs causing admission.
The incidence of ADRs causing admission in this study (2.9%, 95% CI 2.5% to 3.3%) was similar to the
incidence in two systematic reviews: 2.09% (95% CI 1.02% to 3.77%) and 1.8% (95% CI 0.4% to 3.2%)
but was signiﬁcantly less than that of a large US study published in 1988.33 In that study, the top three
drugs causing ADRs were phenobarbital, aspirin and phenytoin, all of which are used in children much less
now than in 1988. As these medicines were hardly used in our population, it is possible that the
discrepancy in incidence rates relates in part to the reduction in use of these medicines.
This prospective observational study is the ﬁrst to attempt the identiﬁcation of possible risk factors for
ADRs causing hospital admission in children. Older children, those exposed to more medicines in the
2 weeks prior to admission and oncology patients were shown to have an increased risk of ADR in this
study. Girls showed a trend towards being more likely to experience an ADR than boys but this result was
not statistically signiﬁcant. An increased risk of ADRs occurring in the female gender has been described in
studies in adult populations.58,59 The number of authorised medicines and the number of OLUL medicines
administered in the 2 weeks before admission were both signiﬁcant predictors of ADR risk in this study,
which supports the ﬁnding that the administration of multiple medicines increases ADR risk.
Causality was determined, of the ADR cases, using a novel CAT, the LCAT. The largest proportion of ADR
causality classiﬁcations were ‘deﬁnite’ and most of these occurred in oncology patients. In order for a case
report to achieve a score of ‘deﬁnite’ it would have to include a positive rechallenge or a previous history
of the ADR to the same medication, a condition which these oncology-related ADRs satisﬁed. Type A
reactions were more likely to be assigned a deﬁnite or possible causality, and type B reactions were moreNIHR Journals Library www.journalslibrary.nihr.ac.uk
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are unpredictable and less frequent. The more severe reactions in our study were more often assessed to
have deﬁnite or probable causality. This may reﬂect a conﬁdence in assessing severe ADRs, which are more
likely to be described in the drug safety literature.
The majority of the ADRs seen during the study were oncology related. These were mainly children with a
febrile illness who developed neutropenia 1–2 weeks after intravenous chemotherapy. Clearly, patients
with malignancy are often exposed to medications that cause ADRs,60 such as neutropenia (with fever),
nausea, vomiting, diarrhoea, anaemia and bleeding secondary to thrombocytopenia, all of which may
require hospital admission. ADRs to cytotoxic chemotherapy drugs are expected and, for the most part,
may be unavoidable given the nature of the underlying illness and the treatment options currently
available. Although several studies have evaluated a potential preventative strategy for neutropenia,61 no
deﬁnitive evidence exists regarding the routine prophylactic use of granulocyte colony-stimulating factors
to prevent ADRs due to myelosuppression.62
Steroids, along with other immunosuppressant drugs, increase the risk of infection.63 Immunosuppressant
drugs featured frequently in our study as causative agents for ADRs. The nature of ADRs associated with
immunosuppressive therapy included proven bacterial infections and viral infections (e.g. shingles).
Although we recognise that infections may also occur in healthy children, the role of immunosuppressive
therapy in predisposing patients to infections is well recognised.64–66
Another frequently recorded ADR in our study was postoperative bleeding, in particular secondary
haemorrhage following elective tonsillectomy. The majority (23 out of 28 admissions) of these occurred in
patients exposed to intravenous dexamethasone (as prophylaxis for postoperative nausea and vomiting)
and NSAIDs, with ibuprofen being used commonly in the postoperative period. A few patients received
either dexamethasone or NSAIDs. Dexamethasone has been linked to post-tonsillectomy bleeding67 but its
role, and the role of NSAIDs, in causing secondary haemorrhage in these children needs further study.68,69
However, intraoperative steroid has played a major role in improving outcomes for postoperative nausea
and vomiting (PONV) in children undergoing operations68,70 and has enabled day-case surgery for many
conditions, thereby reducing the LOS in hospital.
Respiratory depression following treatment of seizures with benzodiazepines – a well-recognised and
potentially serious event71 – was the cause of eight admissions to PICU for ventilation until recovery. Some
of these cases were transfers from other regional district general hospitals to the study hospital tertiary
PICU. Some, in fact, occurred as a result of rectal diazepam being used by paramedics in out-of-hospital
care of seizures. Drugs used to treat status epilepticus have been widely studied and their efﬁcacy and
adverse reactions compared.72,73 There may be drugs, other than diazepam, which have an improved
beneﬁt–risk ratio when used to treat seizures in children.74 Further research is therefore warranted to
optimise strategies for treating seizures, for both in-hospital and out-of-hospital care.
In terms of OLUL medicine use, the results described here cannot be compared easily with those of other
studies, as this is the ﬁrst large admissions study of this type. Previous inpatient studies report 27–45%
of prescriptions being OLUL,3,75,76 and two previous community-based studies report 7% and 43% of
prescriptions being off-label;77,78 compare this to 28% of prescriptions in this study. With the exception
of Neubert et al.75 these studies all found an increased ADR risk associated with OLUL medicine use. In this
study, OLUL medicines were more likely to be implicated in an ADR than medicines used within the terms
of their MA; however, it is important to highlight that 87.2% of ADRs that involved at least one OLUL also
involved at least one other medicine; in some cases the OLUL medicine may not have caused the ADR in
the absence of an approved medicine. Previous studies have examined exposure to OLUL medicines as
an explanatory variable in their multivariate analysis.3,75,76 Unlike our analysis, this approach to analysis
does not take into account the relative contribution of authorised medicines. We have been able to
demonstrate that, although the number of OLUL medicines contributes to ADR risk, it does so to a similar
extent as the number of authorised medicines. Different OLUL medicines have different propensities to25
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26cause ADRs, it is not appropriate to consider them to be a homogeneous group. There are various types of
OLUL medicines used, some of which may carry a greater risk of being implicated in an ADR than others.
A key consideration is whether these medicines would be any less likely to be implicated in an ADR if
they were used within the terms of their MA or if licensed preparations were used. A more detailed
examination of the characteristics of the OLUL medicines that are implicated in ADRs may improve our
understanding of why these medicines increase ADR risk and inform potential interventions to reduce
that risk.
The design of the cohort study had limitations. The detection of suspected ADRs by the study team
relied on two things: (1) signs and symptoms associated with the ADR being recorded by the clinical
team looking after the patient and (2) the study team suspecting a link between signs and symptoms
recorded and the medicines administered before admission. When signs and symptoms were not recorded
or the study team missed the link, the ADR will not have been highlighted or evaluated. Although this
was a single-centre study, it was carried out in a large centre providing a comprehensive range of
paediatric services to a diverse population. The ADRs reported in this study highlight some of the adverse
consequences of drugs in children. A limitation of this study is that we have not taken into account
the beneﬁts of these medications. Furthermore, we cannot be certain of the aetiological fraction
(the risk of an event occurring in the presence of a risk factor) for some of the drugs in our study
(e.g. immunosuppressant drugs) in their contribution to the stated reactions. For these drugs, more
research is needed to accurately assess their contribution to ADRs and the ill health of children, to allow
for more detailed risk–beneﬁt evaluation. In this study, we have not considered ADRs caused by
medications during inpatient stay in hospital. This aspect of drug reactions is likely to add greatly to the
burden of ill health to children, and requires investigation of paediatric inpatient ADRs using a similar
prospective study design to accurately identify the epidemiology of the problem.
The cost of ADRs to the NHS in England was calculated using knowledge of the cost of admissions to the
study hospital, our estimate of the incidence of ADRs causing admission and an estimate of total paediatric
admissions annually to hospitals in England. Information regarding total annual admissions does not
include emergency paediatric admissions from other specialties, thereby underestimating the total number
of emergency paediatric admissions to hospitals in England. Although the ADR admission incidence from
this study includes oncology cases, which is not included in the total annual admissions number used for
our cost calculation, our estimate of costs of paediatric ADR admissions may be an underestimation.
The results of this study will be used to inform paediatric pharmacovigilance practice. We have
demonstrated that ADRs cause admissions to a paediatric hospital and some of these are serious and
potentially avoidable. Strategies to reduce the burden of ill health from these ADRs are needed. Prevention
will depend on whether an ADR is avoidable or not, ADRs that are avoidable by applying existing
knowledge require efforts to implement good prescribing practice. The vast majority of ADRs identiﬁed
were type A (predictable or dose related). We have shown that OLUL prescribing is a risk factor for ADRs
and identiﬁed some drugs/classes for which further work is needed. This ﬁnding must be put in context of
the fact that the number of medicines per se, irrespective of the licensing status, is also a risk factor for
ADRs. Better dosing schedules for medicines, particularly those with a narrow therapeutic index, are likely
to be key in reducing the burden of ADRs in children. Other ADRs that are currently unavoidable may be
ameliorated by comedication, for example concomitant use of laxatives to prevent constipation. As many
ADRs are unavoidable in the light of current knowledge, there is likely to be a continuing burden of ADRs
in paediatric hospitals and further research is needed. Consideration should also be given to how
suspected ADRs are handled in hospitals to improve identiﬁcation of, and communication about, ADRs.
Clinicians prescribing for children should be vigilant for the occurrence of ADRs, and should prescribe the
minimum number of drugs at the lowest possible dose and shortest duration of time, with continual
monitoring to stop drugs when relevant and to ensure that ADRs are detected as early as possible.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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This chapter contains information reproduced from Thiesen S, Conroy EJ, Bellis JR, Bracken LE,Mannix HL, Bird KA, et al. Incidence, characteristics and risk factors of Adverse Drug Reactions (ADRs)
in hospitalised children: a prospective observational cohort study of 6601 admissions. BMC Med
2013;11:237,22 © 2013 Thiesen et al.; licensee BioMed Central Ltd, an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution
and reproduction in any medium, provided that the original work is properly cited; from Bellis J, Kirkham J,
Thiesen S, Conroy E, Bracken L, Mannix H, et al. Adverse drug reactions and off-label and unlicensed
medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med
2013;11:238,79 © 2013 Bellis et al., licensee BioMed Central Ltd, an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and
reproduction in any medium, provided that the original work is properly cited; and reproduced with
permission from Bellis JR. Adverse Drug Reactions in Children – The Contribution of Off-label and
Unlicenced Prescribing. PhD thesis. Liverpool: University of Liverpool; 2013.31Abstract
Background
Adverse drug reactions are an important cause of iatrogenic harm in children. We aimed to determine the
incidence of ADRs, identify risk factors for ADRs in hospitalised children, and characterise these ADRs in
terms of type, drug aetiology, causality and severity.Methods
We undertook a prospective observational cohort study in admissions to a single UK paediatric hospital.
A nested case–control study within the cohort examined the impact of OLUL drug use on ADR risk.
Participants were aged between 0 and 16 years 11 months, who were admitted for > 48 hours between
1 October 2009 and 30 September 2010.Results
In total, 5118 children participated and 17.7% of all children experienced at least one ADR. Opiate
analgesic drugs and drugs used in general anaesthesia (GA) accounted for > 50% of all drugs implicated in
ADRs. Our nested case–control study included 1388 patients. The OR of an OLUL drug being implicated in
an ADR compared with an authorised drug was 2.25 (95% CI 1.95 to 2.59; p < 0.001). Risk factors
identiﬁed were exposure to a GA, age, oncology treatment and number of medicines.Conclusions
The incidence of ADRs is higher in hospitalised children than in hospitalised adults, with GA agents and
opiate analgesic drugs being the chief causes. OLUL drugs are more likely to be implicated in an ADR than
approved drugs. It is important to develop strategies to reduce the burden of ADRs occurring in
hospitalised children.IntroductionAdverse drug reactions are an important cause of iatrogenic morbidity and mortality in patients of all
ages.59,80–83 ADRs in children may differ from those in adults owing to age-dependent physiological
characteristics that affect the pharmacokinetics and pharmacodynamics of drugs.80,81,84,8527
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28Off-label and/or unlicensed drug use has been identiﬁed in previous studies as an ADR risk factor.
However, this has not been demonstrated consistently by all studies, many of which were small, used
different methodologies and used inexact and varying deﬁnitions.86 Off-label drug use is the use of a drug
outside of the terms of its MA, and unlicensed drugs are those without a MA in the country in which they
are prescribed. The reported incidences of OLUL use of medicines in children ranges from 36% to 100%.87
OLUL prescribing has been prevalent in paediatric practice because of the lack of assessment of the use of
drugs in children during the drug development process.88 Although the recently introduced paediatric
regulation in Europe13 and the updated regulation89 in the USA are likely to improve the situation, it is
going to take time.
The aim of this study was to determine the incidence of ADRs in paediatric medical and surgical inpatients;
characterise those ADRs identiﬁed in terms of type, drugs implicated, involvement of OLUL drugs, causality
and severity; and also identify factors that increase the risk of ADRs. Reducing the impact of paediatric
ADRs needs precise estimates of the incidence and nature of ADRs. Given the discordances in the extant
literature, we designed a study that was large enough and of robust design to overcome the problems
identiﬁed in the previous literature.Methods
Study design and setting
The study was a prospective observational cohort study conducted over 1 year in a single paediatric referral
centre providing a local and also specialist regional and national services in the north-west of England
(Alder Hey).
The study population comprised children aged between 0 and 16 years and 11 months, who were
inpatients between 1 October 2009 and 30 September 2010. Extensive pilot work was conducted prior to
the beginning of the study. This pilot work established that the study team did not have the resources to
carry out a detailed review of every inpatient every day. Three alternative inclusion criteria were
considered: all inpatients, children admitted for > 24 hours and children admitted for > 48 hours. ‘Patients
admitted for > 48 hours’ was the inclusion criterion selected, as this allowed study procedures to be
optimised for the full observational study (frequency of follow-up visits, amount of prescription and clinical
data to be recorded, source data to be considered, use of electronic database). Admissions included
elective and emergency admissions to all paediatric medical and paediatric surgical specialties.
Observations were carried out on 17 wards, including oncology wards and the high-dependency unit
(HDU). Patients were not observed while admitted to PICU, transitional care unit (TCU), theatre, recovery
or the department of radiology. Patients who spent their entire admission on PICU were excluded. The
study methodology did not cover all aspects of the clinical complexity and the study team did not have the
tools or expertise required to identify and assess ADRs in an intensive care environment. Patients who
spent their entire admission on TCU were excluded. These patients have complex medical and nursing
needs but are clinically stable. In general, they are awaiting transfer home or to a placement in the
community. If they became acutely unwell during the study, they would have been admitted to the
hospital and become eligible for inclusion. Children meeting the inclusion criteria were identiﬁed twice
daily by means of an automated computer download. Each child was followed up every 48 hours or
72 hours on weekdays and weekends, respectively, by one member of a multidisciplinary team (MDT) of
researchers comprising two research pharmacists, one research nurse and a paediatrician (LEB, JRB, KB,
HM, ST). For each child, details were recorded of all drugs administered on the wards, occurrence of new
symptoms or those that had worsened, and abnormal results that may indicate the occurrence of an ADR,
taking into account the case history, the ADR proﬁles of medication and the temporal relationship
between drug exposure and reaction. We aimed to include all potential reactions to any medication
administered in hospital (including those started prior to admission) and present after admission to a ward;
each suspected reaction was followed up with a detailed assessment by one research team member.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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study in sufﬁcient detail; therefore, a subset study of nested case–control design was undertaken to assess
the involvement of OLUL drugs that were implicated in observed ADRs. Cases were those who had
experienced at least one probable or deﬁnite ADR on their ﬁrst admission and were matched 1 : 1 to
control subjects who had not experienced any probable or deﬁnite ADRs. Matching was based on the
closest date and time of admission.Adverse drug reaction definition
In our study we used the ADR deﬁnition of Edwards and Aronson:49 ‘an appreciably harmful or unpleasant
reaction, resulting from an intervention related to the use of a drug product, which predicts hazard from
future administration and warrants prevention or speciﬁc treatment, or alteration of the dose regimen, or
withdrawal of the product’. Prescribing errors, administration errors and accidental overdoses were thus
not considered ADRs in this study. ADR cases were deﬁned as suspected reactions to any systemic or
topical drug product administered in hospital and presenting after admission to the ward or in A&E prior
to admission to the ward. This included reactions to drug products administered in PICU, theatre, recovery,
the department of radiology or TCU, providing that the reaction became apparent after transfer to a ward.
Reactions to a drug product started prior to admission were included if it was continued in hospital and
the reaction was not apparent on admission. Suspected reactions to certain drug products (including some
blood products, total parenteral nutrition and intravenous hydration ﬂuids) were excluded from this study.
For details of included/excluded drug products see Table 11.TABLE 11 Off-label and unlicensed categories
Category Deﬁnition
Off-label drugs Drugs licensed for
use in children
1 Authorised – drug used within the terms of its marketing
authorisation
2 Contraindication exists
3 Dose greater than recommended
4 Dose greater than recommended and contraindication exists
5 Not licensed in child of this age (or child below minimum
weight stated)
6 Not licensed in child of this age and contraindication exists
7 Not licensed by this route
8 Not licensed by this route and contraindication exists
9 Not licensed by this route or in a child of this age
10 Not licensed by this route or in a child of this age and
contraindication exists
11 Not licensed for this indication
12 Not licensed for this indication and contraindication exists
13 Not licensed for this indication or at this dose
14 Not licensed for this indication or at this dose and
contraindication exists
15 Not licensed for this indication or at this age
16 Not licensed for this indication or at this age and a
contraindication exists
17 Not licensed for this indication or by this route
continued
29
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TABLE 11 Off-label and unlicensed categories (continued )
Category Deﬁnition
18 Not licensed for this indication or by this route and a
contraindication exists
19 Not licensed for this indication or by this route or at this age
20 Not licensed for this indication or by this route or at this age
and a contraindication exists
Drugs not licensed
for use in children
21 Not licensed for use in children
22 Not licensed for use in children and a contraindication exists
23 Not licensed for use in children or in adults by this route
24 Not licensed for use in children or in adults by this route and
a contraindication exists
25 Not licensed for use in children or in adults for this indication
26 Not licensed for use in children or in adults for this indication
and a contraindication exists
27 Not licensed for use in children or in adults for this indication
or in adults by this route
28 Not licensed for use in children or in adults for this indication
or in adults by this route and a contraindication exists
Medicines
excluded from
analysis
29 Category cannot be assigned
30 Theatre drug
Unlicensed drugs 31 Prepared extemporaneously
32 Manufactured under a specials manufacturing licence
33 Chemical
34 Import
35 Awaiting a MA (e.g. previous trial drug)
ADVERSE DRUG REACTIONS IN HOSPITALISED CHILDREN
30Drug categories
For each patient in the nested case–control study, the record of drugs administered was updated to
include a detailed OLUL category for every drug. There were 30 off-label drug categories and ﬁve
unlicensed drug categories (see Table 11). Off-label categories were deﬁned according to the reason(s)
why their use was deemed off-label when compared with the terms of the MA. The terms of the MA were
found in the SmPC available online from the EMC.50 With regard to age, if the SmPC mentioned children,
the deﬁnition of this was assumed to be 28 days to 18 years. If no speciﬁc information pertaining to use in
neonates was provided, the use of that drug in neonates was considered to be off-label. Although it was
certainly not the case, it was assumed that all neonates were born at term because gestational age was
not recorded in this study. Owing to the complex nature of the regimens used to treat malignant disease,
the classiﬁcation of cytotoxic drugs was simpliﬁed by consulting the BNF-C90 for cytotoxic drugs with a UK
MA. If the BNF-C monograph stated the relevant indication, it was assumed that the use was authorised.
If the BNF-C monograph stated ‘not licensed in children’ then the use was considered to be off-label.
The implications of dosage from manipulation by parents or nursing staff, such as the crushing of tablets
or the addition of licensed drugs to food or drinks for ease of administration, was considered to be outside
the scope of this study.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Each suspected ADR was followed up with a detailed assessment by one research team member.
The ADR case report was then assessed independently by a research nurse, a research pharmacist and a
paediatrician using the LCAT53 as unlikely, possible, probable or deﬁnite. Outcome reporting was based on
consensus agreement between the three assessors; if agreement could not be achieved the case was
referred to a panel of two senior investigators (MAT, RLS, AJN and MPir); each panel reached consensus
about causality. For ADRs with a high or uncertain probability that the reaction is due to an underlying
disease, the causality outcome is ‘possible’ unless objective evidence of the causal ADR mechanism is
available.53 Our estimate for the overall incidence was based on the sum of probable and deﬁnite ADRs
only, as these ADRs are deemed to have a low probability of the underlying disease being responsible for
the reaction. Severity of ADRs was assessed by the researcher compiling the case report using the Hartwig
scale.56 In addition, all ADRs that occurred prior to a patient’s admission to PICU or HDU were also
assessed by a paediatrician and, if required, reviewed by a panel of two senior investigators in order to
evaluate their contribution to the patient being transferred to a higher level of care (Hartwig scale level 4).
Reactions classiﬁed as level 4 and above were considered severe.Incidence
Incidence was calculated in two ways: (1) the number of admissions in which at least one ADR occurred
divided by the total number of admissions regardless of drug exposure and (2) the number of children with
at least one ADR divided by the total number of children regardless of drug exposure.Odds ratios
For analysis of the nested case–control study, the OR with 95% CI of a drug being implicated in a
probable or deﬁnite ADR was calculated for each category of OLUL drugs administered compared with a
baseline risk for authorised drugs.Risk factor analysis
Time from admission to ﬁrst ADR was calculated in days. For patients admitted to PICU, this was time to
ﬁrst ADR prior to PICU admission. If no ADR occurred prior to PICU admission, time from admission to ﬁrst
ADR was censored at the time of admission to PICU. ADRs occurring after PICU were included in the
overall incidence calculation. For the analysis of risk factors, data collected for each patient during only
their ﬁrst admission were included.
Within the main study, we assessed age, gender, number of drugs, receipt of a GA and oncology patient
status as risk factors. Oncology patients were those requiring ongoing medical treatment for a malignancy
of solid organ or haematopoietic system. The number of drugs refers to the daily number of drugs
administered to the patient on the ward. This risk factor was treated as a continuous, time-varying
covariate in the multivariate model.
The factor ‘received a GA’ was considered to be present from the ﬁrst day the patient received a GA until
discharge from hospital. This risk factor was treated, as a binary, time-varying variable in the multivariate
model that takes the value ‘0’ on days up to the GA and ‘1’ thereafter for the remaining days of a
patient’s admission.
The same risk factors were assessed in our nested case–control study. However, to avoid issues caused by
including dependent variables, we replaced the ‘daily number of drugs’ variable in the model with the
two variables ‘daily number of OLUL drugs’ and ‘daily number of authorised drugs’. These were treated as
continuous, time-varying covariates in the model.Statistical methods
Time to ﬁrst ADR was compared between groups using a log-rank test (extending to a log-rank test for
trend when appropriate) and Kaplan–Meier curves estimated.31
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32A Cox proportional hazards regression model for an ADR was ﬁtted to the data. Results are given in terms
of the hazard ratio (HR) and associated 95% CI. Owing to their clinical importance, all of the risk factor
variables were included in the multivariate models ﬁt in both the main analysis and the subset analysis.
The assumptions of the model were assessed as follows. The proportional hazards assumption for each
covariate was investigated using log-cumulative hazard plots and Schoenfeld residual plots. The
assumption was also tested by including a time-dependent covariate effect. Deviance residuals were
plotted against the linear predictor to look for mismodelling of the data and empirical validation for the
model was carried out using a data-splitting technique to assess model accuracy. Patients with missing
prescription details for the entire duration of the admission were excluded from the analysis. The inclusion
of patients with partially missing prescription details (e.g. prescription details for day of discharge) was
assessed on a case-by-case basis.
All statistical analysis was carried out using the statistical software package R version 2.13.2
(The R Foundation for Statistical Computing, Vienna, Austria) using a two-sided signiﬁcance level of
0.05 (5%) throughout.Reporting
This study was reported according to Strengthening The Reporting of OBservational studies in
Epidemiology (STROBE) guidelines.91Ethics
This study used routinely collected clinical data in an anonymised format. The chairperson of Liverpool
Paediatric Local Research Ethics Committee informed us that this study did not require individual patient
consent or review by an ethics committee.Results
Participants and descriptive data
Prospective cohort study – 6825 eligible admissions were identiﬁed. A total of 181 (2.7%) admissions
could not be included owing to missing data. Forty-three patients spent their entire admission on PICU and
were thus excluded. The median length of follow-up time across admission was 5 days (IQR 3–8 days,
range 2–280 days). The median age on admission was 3.4 years (IQR 0.6–10.7). Overall, 2297 (44.8%)
were female, 4284 (83.7%) of children had one admission, 834 children had more than one admission,
2856 children (55.8%) underwent at least one GA during 3265 admissions, and 114 children (2.2%) were
oncology patients.
In total, 2934 suspected ADRs were assessed. After causality assessment, 213 (7.3%) of suspected
ADRs were deemed deﬁnite, 1233 (42.0%) probable, 896 (30.5%) possible and 592 (20.2%) unlikely.
Consensus was reached by independent agreement in 1805 cases (61.5%) and by panel decision in
1128 cases (38.5%). All deﬁnite and probable ADRs were included in the further analysis (total number
1446; Figure 5).NIHR Journals Library www.journalslibrary.nihr.ac.uk
1446 ADRs
6601 admissions/5118 patients
118 patients had a total > 1 ADRs during first admission
145 ADRs = ’multievent’ during first admission
356 admissions; 43 ADRs
117 ADRs
Patients on PICU from day 1 were censored from day 1
Patients on PICU after day 1 were censored from time of
PICU admission
151 admissions without drug exposure
318 ADRs ’multiadmissions’
769 patients with > 1 admission
1157 ADRs
6094 admissions/4724 patients
694 ADRs
694 patients with at least one ADR
4030 patients without ADR 
129 ADRs with identical start date
(> 1 ADR/day during same admission = 1 ADR event)
FIGURE 5 Flow chart outlining number of first admissions included in the cohort study univariate and
multivariate analysis.
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to 16.8%) and 17.7% per patient (95% CI 16.7% to 18.8%). The ADR incidence for patients with only
one admission was 14.8% (95% CI 13.8% to 15.9%). For patients with more than one admission, the
incidence per admission was 18.0% (95% CI 13.8% to 15.9%) and 32.7% per patient (95% CI 29.6%
to 35.9%). Of the ADRs 0.9% were severe and required patient transfer to a higher level of care. One
patient sustained permanent harm (peripheral neuropathy due to vincristine). No ADR resulted in patient
death (see Table 12). Details of all severe reactions by reaction type and associated drugs are listed
(Tables 12 and 13).33
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TABLE 13 Severe reactions (Hartwig severity scale level of ≥ 4) by reaction type and drug implicated
Severity
level ADR type (count) Medication implicated (count)
Admission to PICU/HDU
(if more than once)
4 Cardiac failure (1) Bisoprolol (1), carvedilol (1) HDU
Sedation withdrawal (1) Fentanyl (1), midazolam (1),
promethazine (1), chloral hydrate (1)
PICU
Raised international normalised
ratio and haemorrhage (1)
Warfarin (1) HDU
Pulmonary oedema (1) Diazoxide (1) HDU
Respiratory depression (5) Fentanyl (4), ketamine (2),
midazolam (1)
PICU (3a), HDU (2)
Respiratory arrest (2) Fentanyl (2), sevoﬂurane (1),
isoﬂurane (1), ketamine (1)
PICU, HDU
5 Peripheral neuropathy (1) Vincristine (1) N/A
N/A, not applicable.
a Adverse drug reaction was not the only factor leading to PICU admission; other, clinical factors may also
have contributed.
TABLE 12 Hartwig severity scale
Severity level Description
No. of ADRs at each severity levela
n %
1 Required no change in treatment 322 22.3
2 Drug dosing or frequency changed 66 4.6
3 Required treatment, or drug administration
discontinued
1046 72.3
4 Result in patient transfer to higher level of care 12 0.8
5 Caused permanent harm to patient or signiﬁcant
haemodynamic instability
1 0.1
6 Directly or indirectly resulted in patient death 0 0
a Denominator was the total number of probable or deﬁnite ADRs.
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A total of 1388 patients were analysed throughout their ﬁrst admission: 694 (50%) were cases; 634
(45.6%) were female; 294 (21.2%) were < 1 year old; 341 (24.6%) were aged 1–4 years; 384 (27.7%)
were 5–11 years and 369 (26.6%) were teenagers (> 12 years). The median age was 5.9 years
(IQR 1.4–12.4 years). A total of 10,699 drug courses were administered in this study.
Within this nested cohort, there were 785 suspected ADRs deemed deﬁnite or probable in 694 patients
during the ﬁrst admission. Of the suspected ADRs, 62 (7.9%) were deemed deﬁnite and 723 (92.1%)
probable. Of these, 505 (64.3%) involved one drug course, 172 (21.9%) involved two drug courses,
77 (9.8%) three and 31 (3.9%) four or more. Of the total drug courses, 10,145 (94.8%) could be
categorised using Table 11. The remaining 554 (5.2%) courses could not be categorised, as the
prescription record did not provide the required information, for example, missing dose information or
insufﬁcient detail about the exact preparation used. Of the 785 deﬁnite and probable ADRs, 301 (38%)
involved only OLUL medicines, 290 (37%) involved only authorised medicines, 160 (20.4%) involved a
combination of OLUL and authorised medicines, and the remaining 4.3% involved at least one medicine
that could not be categorised.Reaction types, drug classes and ‘off-label and/or unlicensed’ categories
implicated in adverse drug reactions
Prospective cohort study
The 10 most common reaction types were vomiting and/or nausea, pruritus, constipation, diarrhoea,
somnolence without cardiorespiratory symptoms, respiratory depression or arrest, candidiasis, urinary
retention, rash and hypokalaemia, which, together, accounted for 76.6% of all ADRs. Pruritus, respiratory
depression and urinary retention occurred almost exclusively in the post-anaesthetic setting. In over
two-thirds of patients with nausea/vomiting, constipation or somnolence, drugs given during the
anaesthetic and/or used in postoperative pain management were implicated (Table 14).
Drugs implicated in ADRs and associated reactions are listed in Table 15. Opioid analgesic drugs and
anaesthetic agents were the most commonly implicated drug groups and accounted for 54% of all drugs
associated with ADRs. Cytotoxic drugs accounted for 13% and antibiotics for 11% of medication
implicated. Drugs used in postoperative pain management accounted for 6%. Each other drug group
accounted for ≤ 2%.
Nested case–control study – of the 10,145 categorised drug courses, 6980 (68.8%) were authorised,
2407 (23.7%) off-label and 758 (7.5%) unlicensed; 435 (6.2%) of authorised, 298 (12.4%) of off-label,
and 113 (14.9%) of unlicensed drug courses were implicated in at least one probable or deﬁnite ADR.
The OR of an OLUL drug being implicated in an ADR when compared with an authorised drug course was
2.25 (95% CI 1.95 to 2.59; p < 0.001). In total, 19 (54.3%) of the OLUL categories (see Table 11) were
utilised. Table 16 shows the number of drug courses in each of these categories. Category 11 (‘drug
licensed for children but given for a different indication’) is the most common category of off-label
drug use (n = 764; 31.7%). Categories 3, 5 and 11 together represented 2050 (85.2%) of off-label drug
courses. Category 32 (‘manufactured under a specials manufacturing licence’) is the most common
category of unlicensed drug use (n = 577; 76%). Table 16 shows the proportion of drug courses from
each category implicated in at least one probable or deﬁnite ADR in comparison with the proportion of
authorised drug courses implicated (n = 6980; 6.2%). Further analysis was undertaken on six of these
categories, which contained > 100 drug courses. Results showed that category 3 (‘drugs licensed for use in
children but given at a dose greater than recommended’) had a lower risk of being implicated in an ADR
than category 1 – authorised drugs (OR 0.42, 95% CI 0.26 to 0.67). Category 5 (‘drugs licensed in
children but given to a child below the minimum age or weight’) had the greatest risk of being implicated
in an ADR (OR 3.54, 95% CI 2.82 to 4.44).35
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TABLE 14 Common ADR types observed
Reaction type
All reactions Following GAa
n
% of all
reactionsb n
% of reaction type where
reaction followed GA
Nausea and/or vomiting 400 27.5 295 73.8
Pruritus 243 16.7 232 95.5
Constipation 155 10.6 107 69.0
Diarrhoea (nine with vomiting) 88 6.0 0 0.0
Somnolence (without cardiorespiratory symptoms) 50 3.4 34 68.0
Respiratory depression/arrest (41/3) 44 3.0 43 97.7
Candidiasis 41 2.8 0 0.0
Urinary retention 40 2.7 37 92.5
Rash 31 2.1 3 9.7
Hypokalaemia 25 1.7 0 0.0
Hypotension 22 1.5 9 40.9
Hepatotoxicity (12 transaminases
increased only)
18 1.2 1 5.6
Stomatitis 16 1.1 0 0.0
Myoclonus 15 1.0 14 93.3
Pancytopenia 13 < 1 0 0.0
Hyperglycaemia 12 < 1 0 0.0
Hypertension 11 < 1 2 18.2
Allergic reactions 10 < 1 3 30.0
Pain (four with pain in jaw, two with back pain) 10 < 1 0 0.0
Other reactions (occurred < 10 times) 213 14.6 65 30.5
Total 1457 845 58.0
a Reaction occurred post theatre and drugs given in theatre and/or used in postoperative pain management
were implicated.
b If the same patient experienced two types of reactions to the same medication(s) at the same time this would have been
reported as one ADR case but will be listed here as two reaction types, for example a patient with respiratory depression
and bradycardia = one ADR case, but listed as two reactions.
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TABLE 15 Drug groups implicated in ADRs by frequency with associated reaction types
Drug group
(n of ADR cases)
Total no. of drugs
(% of total) Drugs (n) ADR typea (n)
Opioid analgesic drugs (688) 844 (27.9) Morphine (426),
fentanyl (267), codeine (144),
dihydrocodeine (4),
diamorphine (2), tramadol (1)
Pruritus (198), nausea or
vomiting (186), constipation
(143), respiratory arrest/
depression (3/37),
somnolence without
cardiorespiratory
symptoms (37), urinary
retention (28),
myoclonus (13),
hallucination (8), rash (4),
bradycardia (3), dizziness (3),
drug withdrawal
syndrome (3), ileus (3),
agitation (2), delayed recovery
from anaesthesia (2),
ﬂushing (2), visual
disturbance (2), otherb (11)
Drugs used in GA (excluding
opiate analgesic drugs other
than remifentanil) (322)
779 (25.8) Sevoﬂurane (253),
propofol (200), nitrous
oxide (131), remifentanil (83),
desﬂurane (54),
isoﬂurane (38), ketamine (6),
atracurium (4), rocuronium (4),
thiopental (4), atropine (1),
vecuronium (1)
Nausea or vomiting (266),
urinary retention (21),
respiratory arrest or
depression (2/6), delayed
recovery from anaesthesia (5),
ﬂushing (4), bradycardia (3),
allergic reaction (3),
hypotension (3), pruritus (2),
otherb (7)
Cytotoxic drugs and drugs
used for cytotoxic-induced
side effects (179)
405 (13.4) Vincristine (70),
etoposide (56),
cyclophosphamide (46),
cytarabine (41), methotrexate
(31), doxorubicin (22),
ifosfamide (21), mesna (15),
daunorubicin (13),
carboplatin (12),
cisplatin (12), melphalan (11),
busulfan (7), asparaginase (6),
ﬂudarabine (6),
clofarabine (5), actinomycin
d (5), allopurinol (4),
mitoxantrone (4),
rasburicase (4), idarubicin (3),
thiotepa (3), amsacrine (2),
temozolomide (2),
cladribine (1), gemcitabine (1),
irinotecan (1), tretinoin (1)
Nausea or vomiting (81),
stomatitis (16),
pancytopenia (13), diarrhoea
and vomiting (9), diarrhoea
without vomiting (9),
hepatotoxicity (11;
8 increased transaminases
only), febrile neutropenia (6),
rash (6), pain in jaw (3),
constipation (3), pain other
than jaw (2), headache (2),
hyperglycaemia (3), oral
candidiasis (3), otherb (14)
Antibiotic drugs (162) 319 (10.6) Cefotaxime (56),
metronidazole (29),
gentamicin (29), piperacillin
and tazobactam (28),
cefuroxime (18), teicoplanin
(19), cefalexin (17),
ciproﬂoxacin (16),
ﬂucloxacillin (15),
co-amoxiclav (16), ceftazidime
(13), rifampicin (10),
amoxicillin (8), clarithromycin
(7), vancomycin (7), penicillin
V (5), benzylpenicillin (4),
meropenem (4), amikacin (3),
Diarrhoea (66), candidiasis
(38), rash (16), nausea or
vomiting (8), Clostridium
difficile colitis (7), colonisation
with candida (4),
transaminases increased (4),
anaphylactic reaction (2),
angioedema (2), ﬂushing (2),
hepatotoxicity (3),
pruritus (2), otherb (8)
continued
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TABLE 15 Drug groups implicated in ADRs by frequency with associated reaction types (continued )
Drug group
(n of ADR cases)
Total no. of drugs
(% of total) Drugs (n) ADR typea (n)
co-trimoxazole (3),
tobramycin (3),
trimethoprim (3),
clindamycin (2), cefradine (1),
ceftriaxone (1)
Drugs used in epidurals,
regional anaesthetics and
intravenous drugs used in
postoperative pain
management other than
opioid drugs (188)
195 (6.4) Fentanyl and levobupivacaine
(116), ketamine (36),
clonidine and levobupivacaine
(25), levobupivacaine (11),
clonidine (7)
Pruritus (52), nausea and/or
vomiting (35), constipation
(24), urinary retention (15),
somnolence without
cardiorespiratory
symptoms (11), respiratory
depression/arrest (8/1),
hypotension (7),
paraesthesia (6),
bradycardia (4),
myoclonus (3),
hypoaesthesia (2), visual
disturbance (2),
hallucination (2),
hypertension (2), urinary
incontinence (2), otherb (12)
Corticosteroids (51) 62 (2.05) Dexamethasone (24),
methylprednisolone (14),
prednisolone (14),
hydrocortisone (8),
beclomethasone (1),
ﬂudrocortisone (1)
Hyperglycaemia (13),
hypertension (8), candidiasis
(9), ﬂuid retention (2),
gastritis (2), otherb (17)
Bronchodilators (31) 58 (1.92) Salbutamol (35),
aminophylline (21),
ipratropium (2)
Hypokalaemia (15), nausea
and/or vomiting (7),
tremor (4), tachycardia (2),
otherb (3)
Antiemetic drugs (50) 55 (1.82) Ondansetron (51),
levomepromazine (3),
cyclizine (1)
Constipation (45),
disorientation (2), otherb (4)
Antiepileptic drugs (45) 49 (1.62) Midazolam (35), pregabalin (4),
carbamazepine (3),
diazepam (3), gabapentin (2),
lorazepam (1), valproate (1)
Nausea and/or vomiting (24),
somnolence without
cardiorespiratory symptoms
(6), abnormal behaviour (2),
constipation (2), delayed
recovery from anaesthesia (2),
respiratory depression (2),
otherb (7)
Diuretic drugs (28) 41 (1.36) Furosemide (30),
spironolactone (8),
metolazone (2),
chlorothiazide (1)
Hyponatraemia (9),
hypokalaemia (8),
hypotension (3),
hypomagnesaemia (4),
otherb (5)
Drugs affecting the immune
responses (suppression and
modulation) + cytokine
modulators (31)
34 (1.12) Alemtuzumab (11),
ciclosporin (7), aldesleukin (5),
rabbit antihuman thymocyte
immunoglobulin (3),
tacrolimus (3), rituximab (2),
azathioprine (1),
mycophenolate (1),
tocilizumab (1)
Pyrexia (4), candidiasis (4),
infusion associated reaction
(3), stomatitis (3), oedema (2),
pruritus (2), vomiting (2),
otherb (11)
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TABLE 15 Drug groups implicated in ADRs by frequency with associated reaction types (continued )
Drug group
(n of ADR cases)
Total no. of drugs
(% of total) Drugs (n) ADR typea (n)
Drugs affecting the
cardiovascular system (23)
27 (0.89) Captopril (10), lisinopril (4),
amlodipine (4), milrinone (3),
bisoprolol (1),
dinoprostone (1), enalapril (1),
hydralazine (1),
isoprenaline (1), carvedilol (1)
Hypotension (11),
hyperglycaemia and
glycosuria (3), otherb (9)
NSAIDS (+ aspirin) (24) 24 (0.79) Diclofenac (15), ibuprofen (5),
naproxen (2), aspirin (2)
Nausea and/or vomiting (11),
haematemesis (3), other
gastrointestinal bleed (2),
constipation (2), otherb (5)
Laxatives (20) 22 (0.73) Lactulose (12), macrogol (6),
docusate (3), sennoside (1)
Diarrhoea (17), abdominal
pain (2), vomiting (1)
Antifungal and antiviral
drugs (20)
21 (0.69) Amphotericin (7), aciclovir (5),
ﬂuconazole (4),
voriconazole (2),
itraconazole (1),
miconazole (1), ribivarin (1)
Diarrhoea (8), hepatotoxicity
(3), hypokalaemia (3),
otherb (5)
Drugs used in diabetes and
hypoglycaemia (13)
16 (0.53) Insulin (4), insulin aspart (4),
insulin detemir (4),
diazoxide (3), glucagon (1)
Hypoglycaemia (7),
ﬂuid overload (2),
hypokalaemia (2), otherb (2)
Other (69) 73 (2.41) – –
a If the same patient experienced two types of reactions to the same medication at the same time then this would have
been reported as one ADR case but will be listed here as two ADR types, for example patient with respiratory depression
and bradycardia = one ADR case but listed as two types.
b Reactions that occurred once are listed as other.
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ABLE 16 Number of drug courses in each authorised, OLUL category and number implicated in at least
ne possible and deﬁnite ADR (n = 10,145)
Categorya
No. of drug
courses
% of courses
implicated in
at least one
possible and
deﬁnite ADR
OR of ADR vs.
authorised 95% CI
Off-label
drugs
Drugs licensed for
use in children
1 6980 6.2 1.00 –
2 1 0 – –
3 698 2.7 0.42 0.26 to 0.67
5 588 19.0 3.54 2.82 to 4.44
6 1 0 – –
7 61 9.8 1.64 0.70 to 3.83
11 764 14.3 2.50 2.00 to 3.13
13 8 0 – –
15 35 25.7 5.21 2.43 to 11.18
17 21 0 – –
19 2 0 – –
Drugs not
licensed for use
in children
21 215 18.6 3.44 2.41 to 4.91
22 1 100.0 – –
23 1 0 – –
25 11 18.2 3.34 0.72 to 15.52
Unlicensed drugs 31 143 14.7 2.59 1.61 to 4.16
32 577 14.9 2.64 2.05 to 3.38
33 1 0 – –
34 37 16.2 2.91 1.21 to 7.02
a See Table 11 for category deﬁnitions.
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oTable 17 shows the proportion of drug courses implicated in a probable or deﬁnite ADR speciﬁcally for
drugs, with > 100 courses administered, and the proportion of courses that were categorised as OLUL.
Fentanyl via any route excluding epidural had the greatest proportion of courses implicated in an ADR,
48.0% of courses were implicated with 99.3% of courses categorised as off-label. Fentanyl via the
epidural route had 44.3% of courses implicated with 100% of courses categorised as unlicensed.
Morphine via any route had 35.0% of courses implicated, of which 39.6% were OLUL. Table 18 shows the
four most frequently implicated drugs by OLUL category. The majority of fentanyl courses were category
11 – given for a different indication; 91.7% of implicated fentanyl courses fell into this category. A total of
60.4% of morphine courses were authorised and 49.1% of implicated morphine courses fell into this
category. Over one-third of morphine courses were category 5 (‘not licensed in child of this age or child
below minimum weight stated’) and 50.3% of implicated morphine courses fell into this category.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 17 Drugs course frequency administered, implicated and off-label, unlicensed or unknown (only drugs with
> 100 courses shown, n = 7007)
Category of drug use Drug (no. of courses)
% of courses
off-label or
unlicenseda
% of courses
implicated in
at least one ADR
No. of
courses
unknown
Drugs with only authorised
courses
Cefuroxime (245) 0 4.5 1
Cefotaxime (388) 0 9.0 0
Drugs with off-label courses Chlorphenamine (339) 0.3 0.3 1
Diazepam (107) 1.9 1.9 0
Ibuprofen (545) 4.8 0.7 0
Lactulose (272) 4.8 2.2 0
Cefalexin (148) 6.1 7.4 0
Metronidazole (257) 8.2 7.8 0
Furosemide (123) 11.8 9.8 0
Paracetamol (1786) 33.4 0.1 2
Ondansetron (550) 52.7 5.8 48
Salbutamol (146) 56.8 8.9 0
Ranitidine (109) 59.6 0.9 0
Dexamethasone (166) 64.5 6.6 7
Fentanyl (150) 99.3 48.0 0
Drugs with unlicensed courses Fentanyl and levobupivicaine
epidural (106)
100 44.3 0
Drugs with off-label and
unlicensed courses
Codeine phosphate (752) 1.6 13.2 257
Morphine (500) 39.6 35.0 0
Diclofenac (331) 45.0 1.5 159
a Drugs within each category listed in ascending order.
TABLE 18 Off-label and/or unlicensed category proportions for drugs with > 10% of courses implicated
Categorya
Fentanyl
(implicated)
Fentanyl + levobupivicaine
epidural (implicated)
Morphine
(implicated)
Codeine
(implicated)
1 1 (0) – 302 (86) 483 (67)
3 – – 2 (0) –
5 1 (0) – 189 (88) 9 (0)
11 136 (66) – 6 (1) –
15 12 (6) – – –
29 – – – 257 (32)
32 – 106 (47) 1 (0) 3 (0)
Total 150 (72) 106 (47) 500 (175) 752 (99)
a See Table 11 for category deﬁnitions.
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Prospective cohort study
In the univariate analysis, age was a signiﬁcant predictor of ADR risk and oncology patients were more
likely to experience an ADR than non-oncology patients (Table 19 and Figure 6). Multivariate risk factor
analysis of ﬁrst admissions (n = 4724, see Figure 5) showed that at any time, the hazard of an ADR in a
child following a GA was six times greater than the hazard of an ADR in a child who had not had a GA;
the hazard of an ADR increased by 25% with each additional drug given (median daily number of drugs
administered 3, IQR 1–5); the hazard of an ADR in oncology patients is nearly twice that of non-oncology
patients; and the hazard of an ADR in children increased by 6% for each year of age.Nested case–control study
Multivariate risk factor analysis of the nested cohort showed that age on admission and receipt of a GA
both had a signiﬁcant effect on ADR risk. Gender and oncology patient status did not have a signiﬁcant
effect on the hazard of an ADR. The hazard of an ADR increased by 30% with each additional OLUL drug
given (median daily number of OLUL drugs administered 1, IQR 0–2). Similarly, the hazard of an ADR
increased by 20% with each additional authorised drug (median daily number of authorised drugs
administered 2, IQR 1–3) (Table 20).TABLE 19 Prospective cohort study univariate analysis by categorical time invariant risk factor
Covariate Total patients
No. of patients
with ADR
Log-rank statistic
(p-value)
Gender Male 2602 382 0.900
Female 2122 312
Age Infant (< 1 year) 1369 78 < 0.001
Pre-school (1–5 years) 1259 155
School aged (5–11 years) 1105 231
Teenage (> 11 years) 991 230
Oncology Yes 106 45 < 0.001
No 4625 649
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FIGURE 6 Cumulative incidence curves by categorical time invariant risk factor. (a) Gender; (b) age (by category); and
(c) oncology status. (continued)
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FIGURE 6 Cumulative incidence curves by categorical time invariant risk factor. (a) Gender; (b) age (by category); and
(c) oncology status.
TABLE 20 Risk factors for ADRs assessed by multivariate analysis
Covariate
Prospective cohort study Nested case–control study
HR (95% CI) p-value HR (95% CI) p-value
Age on admission (in years) 1.06 (1.04 to 1.07) < 0.001 1.04 (1.02 to 1.05) < 0.001
Gender Female 1 0.301 1 0.152
Male 0.93 (0.80 to 1.08) 0.90 (0.77 to 1.04)
No. of drugs 1.25 (1.22 to 1.28) < 0.001 N/A
No. of authorised drugs N/A 1.22 (1.17 to 1.26) < 0.001
No. of OLUL drugs N/A 1.27 (1.20 to 1.34) < 0.001
Received a GA No 1 1
Yes 6.38 (5.30 to 7.68) < 0.001 5.30 (4.42 to 6.35) < 0.001
Oncology No 1 1
Yes 1.89 (1.36 to 2.63) < 0.001 0.93 (0.66 to 1.30) 0.655
N/A, not applicable.
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Our data show that 17.7% of all children who spent > 48 hours as an inpatient experienced at least one
ADR, 58% of which occurred after a GA. Opiate analgesic drugs and drugs used in GA were the most
commonly implicated drugs. The risk of experiencing an ADR in patients undergoing a procedure under
GA has not been assessed previously, including age, oncology treatment and the use of multiple drugs.
OLUL medicines were signiﬁcantly more likely to be implicated in an ADR than medicines used within the
terms of their MA (OR 2.25, 95% CI 1.95 to 2.59). Multivariate analysis in our case–control study
indicated that risk factors for ADRs were the administration of a GA and the number of medicines
administered per day, consistent with the ﬁndings of the cohort study.Strengths and weaknesses of the study
This is the largest paediatric in-hospital study investigating ADRs. Although this was a single-centre study,
the study population represents a wide range of paediatric medical and surgical specialties, as the hospital
serves as a paediatric centre for the local catchment area, and is the regional paediatric referral centre.
Our methodology included causality and severity assessments using validated tools. Denominator data are
available for all medication administered on the wards, whereas details on medication given during GA
were recorded only in patients if there was a suspected ADR to those drugs. As a result, the effect that
increasing the number of drugs given during GA has on the risk of an ADR remains unknown.
The observational approach depends on documentation by the clinical team regarding signs and
symptoms. Despite this intense surveillance, it is possible that some ADRs will be missed. Most symptoms
that are dependent on patient communication (e.g. nausea, pain, hallucinations) are under-represented in
younger or mentally disabled children. This could explain why the risk of developing an ADR increased
with age. In addition, some of the most common reaction types observed in our study, such as vomiting
and diarrhoea, are perhaps more likely to be manifestations of underlying illness among hospitalised
infants and toddlers. The possibility that an underlying illness is an alternative cause may mean that these
events are less likely to be assessed as probable or deﬁnite ADRs.
We recorded ADRs observed between 1 October 2009 and 30 September 2010. Patients who experienced
an ADR before 1 October 2009 or after 30 September 2010, respectively, were counted as admissions
without an ADR in the analysis. Consequently, there are 180 admissions that lie outside the observation
period where an ADR may have occurred that has not been recorded.
In terms of assigning drug courses an OLUL category, our nested case–control study also had its
limitations. First, we required a minimum amount of information to be available about the use of a drug
before it could be categorised as off-label. The absence of this information was a result of how drugs were
recorded on prescription charts; in general they were prescribed by the name of the active ingredient, and
details such as the exact preparation administered were not recorded. Hence the prescription chart records
were adequate for their primary purpose but not for our study. Second, there were assumptions outlined
in our methodology pertaining to the SmPC deﬁnitions of age, gestational age and the classiﬁcation of
cytotoxic drugs.Strengths and weaknesses in relation to other studies
Our study conﬁrmed risk factors previously identiﬁed: increasing age, oncology treatment and multiple
drug therapy. The risk of experiencing an ADR in patients undergoing a procedure under GA has not been
assessed previously. In our study it increased the risk by more than six times. Most previous paediatric
inpatient studies were carried out in general paediatric settings in which only a small number of patients
will have undergone GAs. Rashed et al.81 conducted a paediatric study on general medical wards and
reported that anaesthetic drugs, which accounted for only 1% of all prescriptions, were among the drugs
most commonly implicated in ADRs.81 In the two previous inpatient studies investigating paediatric surgical
patients and providing medication details, opiate analgesic drugs were among the two most commonly
implicated drugs. However, GAs were not included, perhaps because they were not speciﬁcally45
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46investigated.3,92 The differences of our study population are also reﬂected in the spectrum and severity
of common reaction types observed. Some reaction types, such as urinary retention and respiratory
depression/arrest, occurred almost exclusively in the postoperative period. In addition to the differences in
study populations, it is likely that reactions to drugs used in postoperative pain management were well
documented in our study population, as patients on these medications are speciﬁcally monitored for side
effects and are followed up by a specialist pain management team.
A recent review of preventability assessment (called avoidability assessment by some authors) of ADRs by
Ferner and Aronson25 concluded that no universal deﬁnition of preventability exists and that the reliability
of existing deﬁnitions is imperfect. The most frequently used avoidability assessment tools (AATs) were
Schumock and Thornton44 and Hallas,54 which are based on appropriateness of prescribing or treatment
choice. Although these tools might be used successfully to improve prescribing practice in speciﬁc clinical
circumstances, they become problematic wherever treatment is guided by tertiary paediatric specialist
advice, as it would be desirable to use the same expert input when assessing the prescribed treatment.
The same applies to areas outside paediatric specialties in which expert input would be required, for
example to assess the choice of GA drugs used. It is noticeable that studies that previously reported
avoidability of ADRs in hospitalised children had much smaller event numbers compared with 1446 ADRs
in our study (0–41 ADRs/study);19 one multicentre study detected only 408 ADRs between ﬁve centres,81
which would make literature searches and gathering expert advice more feasible.
The prevalence of OLUL prescriptions in paediatric inpatients ranges from 18% to 60%, and 3.4% to
36%, respectively.87 The corresponding ﬁgures in our case–control study were 23.7% and 7.5%,
respectively. These ﬁgures collectively are similar to a previous study from our centre3 in 1999, which
showed that 35% of prescriptions were OLUL. Our data show that OLUL were signiﬁcantly more likely to
be implicated in an ADR than drugs used within the terms of their MA (OR 2.25, 95% CI 1.95 to 2.59).
The risk estimate is higher than that found previously,3,75 which may be a reﬂection of the fact that the
previous studies were smaller (OR 1.5 and OR 1.08),3,75 looked at different ward types (e.g. included
paediatric intensive care)3 and used different deﬁnitions of OLUL drugs.75 We also categorised ADR risk
according to the type of OLUL use. By focusing on six categories that all had > 100 drug courses, we
found that (1) drugs licensed for use in children, but given at a dose greater than recommended, had a
lower risk of being implicated in an ADR than authorised drugs and (2) drugs licensed in children, but
given to a child below the minimum age or weight, had the greatest risk of being implicated in an ADR.
These two ﬁndings seem counterintuitive but can be explained by the fact that 69% of the drug courses
given at a higher dose than recommended were paracetamol. This reﬂects the widespread use of
15–20-mg/kg doses for ‘severe symptoms’, as recommended in the BNF-C.90 Paracetamol at these doses is
relatively safe particularly in inpatient settings, and indeed, paracetamol was rarely implicated in ADRs
throughout the entire study (see Table 17). We removed all paracetamol courses from our data set and
reanalysed; 15.4% of OLUL courses were implicated in at least one ADR and the OR of an OLUL medicine
being implicated in an ADR was 2.24 (95% CI 1.94 to 2.59). Category 5 (‘drugs licensed in children but
given to a child below the minimum age or weight’) had a diminished RR of being implicated in an ADR
(OR 2.97, 95% CI 2.36 to 3.73) but were still the most likely category to be implicated in an ADR.
Category 3 (‘drugs licensed for use in children, but given at a dose greater than recommended’) had an
increased (rather than a reduced) risk of being implicated in an ADR compared with category 1
(‘authorised medicines’) (OR 1.20, 95% CI 0.74 to 1.94).
Multivariate analysis of both the full cohort data and the nested case–control data indicates that risk
factors for ADRs are the administration of a GA and the number of drugs administered per day.
Furthermore, these ﬁndings are consistent with those of Santos et al.76 who found that off-label drug use
was signiﬁcantly associated with ADR risk (RR 2.44, 95% CI 2.12 to 2.89). However, in our study, we have
dissected drug use, and show that the number of OLUL drugs administered per day had a similar inﬂuence
on ADR risk to the number of authorised drugs administered per day. Most studies, including those in
adults, have shown that ADR risk increases with the number of drugs used by patients,3,59,75,93,94 which
reﬂects the complex interaction that occurs between drugs targeting different biological systems within theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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and the occurrence of drug–drug interactions.Implications of study findings
Our study used the same incidence calculations as a comparable prospective adult study by Davies et al.,59
who reported incidence ﬁgures of 14.7% on episode (admission) level and 15.8% on patient level. This
compares to our incidence ﬁgures of 15.9% and 17.7%, respectively. However, Davies et al.59 used the
Naranjo CAT and included deﬁnite, probable and possible ADRs, whereas we excluded ‘possible’ and
‘unlikely’ ADRs. It is therefore likely that our ﬁgures underestimate the true incidence of untoward events
that should be attributed to drugs. The assessment of symptoms due to the underlying condition and
differentiating these from those caused by drugs (e.g. tachycardia in patient treatment for acute asthma)
remains a challenge.
Although < 1% of reactions in our study were classiﬁed as severe, this does not take into account what
impact an ADR might have on the child and/or parent. The most common reaction in our study was
vomiting, which was mainly observed in postoperative patients. Vomiting is a common and non-speciﬁc
symptom in children. Such episodes are unlikely to be regarded as particularly signiﬁcant by clinicians.
However, parents and children often have very different views. For instance, Diez95 reported that parents
placed a very high value on the distress caused by PONV. A teenage patient is likely to feel very distressed
about having to be catheterised because of urinary retention or having to receive an enema to treat
constipation. Parents of children included in this study reported that suspected ADRs cause them concern,
irrespective of the ‘medical’ severity of the suspected reaction. Parents valued the proactive explanations of
ADRs given by oncologists and we suggest that a detailed discussion of ADRs should form part of the
preoperative assessment.96
In terms of OLUL drug use, our ﬁndings highlight the impact of the use of multiple drugs (whether OLUL
or authorised) and thus the need for good prescribing practice in reducing ADRs. The minimum number of
drugs should be given for the treatment of a disease process, at the lowest possible dose for the shortest
possible time. Our data implicate OLUL drugs as risk factors for ADRs in paediatric inpatients. Off-label use
is complicated and in some cases can be justiﬁed by the fact that evidence which may not necessarily have
led to a change in the SmPC is available in the scientiﬁc literature as a result of academic investigations.97
For instance, some of the most commonly implicated drugs in our study were frequently used off-label
(e.g. dexamethasone). However, we have no evidence that if these products were used in accordance with
a MA, they would be implicated in any fewer ADRs. An area of concern identiﬁed in our data is the use of
fentanyl, commonly OLUL, where 48% of courses were implicated in ADRs. A key issue with fentanyl may
be the dose used in children, suggesting a need for further evaluation of dosing strategies.
With all drugs, irrespective of their licensing status, the dose administered and thus the systemic exposure
to that drug, is an important determinant of the likelihood of an ADR. The importance of this is
highlighted by our ﬁnding that drugs licensed in children, but given to a child below the minimum age or
weight had the greatest risk of being implicated in an ADR, reﬂecting the lack of pharmacokinetic data in
children of different ages and/or weights. Advances in the development, and application, of paediatric
pharmacokinetic models will be important in the deﬁning, and implementation, of age- and weight
(or body surface area)-speciﬁc dosing regimens.98 Although such approaches are now being incorporated
in paediatric investigation plans for new drugs, the challenge for all stakeholders will be how to improve
this knowledge for drugs already on the market, most of which are not only generic off-patent
compounds but are also the most widely used.
In conclusion, our data show that ADRs in hospitalised children are as common as those observed in
hospitalised adults.59 The high proportion of ADRs occurring in the postoperative period and the indication
that OLUL drugs are more likely to be implicated in ADRs are of particular concern.47
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Background
Adverse drug reactions in children are an important public health problem. We have undertaken a
systematic review of observational studies in children in three settings: causing admission to hospital,
occurring during hospital stay, and occurring in the community. We were particularly interested in
understanding how ADRs might be better detected, assessed and avoided.Methods
We searched 19 electronic databases using a comprehensive search strategy. In total, 102 studies were
included. The primary outcome was any clinical event described as an ADR to one or more drugs.
Additional information relating to the ADR was collected: associated drug classiﬁcation; clinical
presentation; associated risk factors; and methods used for assessing causality, severity and avoidability.Results
Seventy-one per cent (72/102) of studies assessed causality and 33% (34/102) performed a severity
assessment. Only 19 studies (19%) assessed avoidability. Incidence rates for ADRs causing hospital
admission ranged from 0.4% to 10.3% of all children [pooled estimate of 2.9% (95% CI 2.6% to 3.1%)]
and from 0.6% to 16.8% of all children exposed to a drug during hospital stay. Anti-infective drugs and
antiepileptic drugs were the most frequently reported therapeutic class associated with ADRs in children
admitted to hospital (17 studies and 12 studies, respectively) and children in hospital (24 studies and
14 studies, respectively), whereas anti-infective drugs and NSAIDs were frequently reported as associated
with ADRs in outpatient children (13 studies and six studies, respectively). Fourteen studies reported rates
ranging from 7% to 98% of ADRs being either deﬁnitely or possibly avoidable.Conclusions
There is extensive literature that investigates ADRs in children. Although these studies provide estimates of
incidence in different settings and some indication of the therapeutic classes most frequently associated
with ADRs, further work is needed to address how such ADRs may be prevented.IntroductionAdverse drug reactions are a major health problem to the individual as well as for society.99 The WHO’s
deﬁnition of an ADR is ‘a response to a drug which is noxious, and unintended, and which occurs at doses
normally used in man for prophylaxis, diagnosis or therapy of disease, or for the modiﬁcation of
physiological function’.100 The high incidence of ADRs in children has been reported in three previous
systematic reviews of observational studies covering the period from 1966 to 2010.34,35,101 The reviews
provided estimates of ADR rates causing hospital admission, in hospitalised children and in outpatient
children, and demonstrated that ADRs in hospitalised children are a considerable problem. Two of the49
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50reviews35,101 provide data on the clinical presentation of the ADR and the drugs involved. In addition, the
more recent review101 provides information on the methods and persons involved in identifying ADRs.
However, there are a number of limitations to the previous reviews. Each review34,35,101 applied a search
strategy, using a limited number of keywords to just two electronic bibliographic databases – MEDLINE
and EMBASE. Importantly, as a consequence, relevant studies may have been excluded. In addition, the
reviews excluded studies that included adults as well as children, thus reducing the number of eligible
studies, and the more recent reviews excluded studies that evaluated adverse drug events (ADEs).
These reviews do not provide information about the drugs involved in ADRs or about which methods were
used for detecting, or assessing, the causality of an ADR.23 Establishing the relationship between the drug
and suspected reaction is fundamental to drug safety and being able to determine the avoidability44 of an
ADR in order to try to prevent its future occurrence is crucial to reducing the burden of ADRs.
We therefore undertook this systematic review to provide a more comprehensive assessment of all relevant
studies and to understanding how ADRs might be better detected, assessed and avoided.Methods
Study selection
Criteria for considering studies for this review
Included studies Observational studies that estimate the incidence of ADRs including retrospective and
prospective cohort studies of children.
Excluded studies Studies that focus on ADRs in relation to a speciﬁc drug (e.g. antibiotic drugs or
carbamazepine), clinical condition (e.g. epilepsy, asthma) or speciﬁc clinical presentations of ADRs
(anaphylaxis); case–control studies; those carried out exclusively on a neonatal intensive care unit; and
studies reporting medication errors, therapeutic failures, non-compliance, accidental and intentional
poisoning, and drug abuse.Participants
Children as deﬁned by the researchers. Studies included three deﬁned populations:
1. children admitted to hospital
2. children in hospital
3. children within the community.Interventions
Exposure to any systemic or topical medicinal product, including herbals and aromatherapy, as deﬁned
by researchers.Types of outcome measure
Any clinical event described as an ADR or non-avoidable ADE to an individual or group of drugs.Search methods for identification of studies
A range of electronic bibliographic databases were searched (see Appendix 1) using a search strategy of
text words and medical subject headings (MeSH) terms (see Appendix 2). In addition, we examined
references in relevant studies and those cited by previous systematic reviews. Contact with experts was
made to identify other potentially relevant published and unpublished studies. We did not apply language
restrictions to the search.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3Selection of studies
Screening on title, abstract and full publication stage
Duplicate citations were removed. A study eligibility screening pro forma based on prespeciﬁed inclusion
criteria was used. Two reviewers (RMDS, EG) independently screened each title and categorised as
‘include’, ‘exclude’ or ‘unsure’. The two independent categorisations for all titles were compared and the
title was categorised again following discussion if two reviewers disagreed. When there was agreement to
exclude, the citation was excluded at this stage. All other citations were reviewed at abstract level. This
process was repeated and when there was disagreement, discussion took place between reviewers and
citations were recategorised. Those with agreement to include or considered ‘unsure’ were reviewed at full
publication level. The process was repeated at full publication stage. Studies considered as unsure or
included at full publication stage were reviewed by a third reviewer (JJK). Reasons for exclusion were
documented at the abstract and full paper stage of the screening process.Checking for correct exclusion at each stage
Two reviewers (RMDS, EG) independently viewed the abstracts for a proportion (2%) of studies excluded
at title screening stage. Independent categorisations were compared (as above). This process was repeated
at abstract stage where a third reviewer (JJK) reviewed 10% of full papers for studies excluded based on
abstract. This was repeated at full publication stage, when the same reviewer (JJK) reviewed 20% of
excluded full papers. If any studies were excluded incorrectly at any stage then additional checking
was performed.Data extraction
We extracted the following data from each study:
1. Study characteristics Country; year completed; duration; number of sites; design (prospective or
retrospective); clinical setting; number of children.
2. Identification of ADR Deﬁnition of ADR, including deﬁnition of drug exposure; incidence deﬁnition and
calculation (numerator and denominator, either at patient or episode level); assessment of causal
relationship to drug; person who assessed and categorised ADRs; any method (e.g. case record review)
or reporting system used (e.g. Yellow Card scheme).
3. Information relating to the ADR Clinical presentation; associated drug(s)/drug classiﬁcation; associated
risk factors (including age, gender, polypharmacy); ADR considered avoidable.Assessment of methodological quality of included studies
As we were unable to ﬁnd a validated assessment tool for critically appraising observational studies of
ADRs, we developed a quality assessment form speciﬁcally for the review. The following aspects were
deemed important when assessing study quality: study design; methods for identifying ADRs; methods
used to establish the causal relationship between drug and effect; tools for assessing avoidability of the
ADR; and tools for assessing severity of the ADR. Criteria were graded as ‘yes’, ‘no’, ‘unclear’ or ‘not
reported’. Two reviewers (RMDS, EG) independently assessed methodological quality of each
study (Table 21).
Statistical analysis and data synthesis
For each of the three deﬁned populations; children admitted to hospital, children in hospital and children
within the community, a forest plot was produced to present the ADR incidence rate and 95% CI for each
relevant study. Studies were subgrouped according to whether the incidence rate was reported at the
patient and/or episode level, and whether or not all patients had been exposed to a drug. Further, for
rates reported at the patient level a distinction was made between studies that had included one
admission per patient and those that had included multiple admissions per patient. All results provided per
study were included. Pooled estimates were calculated if the variability in incidence rates was not
considered too large.51
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TABLE 21 Assessment of methodological quality
Aspect of study Criteria Grade
Study design Was the study design clear (prospective,
retrospective or combined)?
Yes/no/unclear/not reported
Methods for identifying ADRs Were the methods used to identify ADRs
described in sufﬁcient detail?
Yes/no/unclear/not reported
Were data collection methods (case
record review, drug chart review and
laboratory data) clearly described?
Yes/no/unclear/not reported
Were the individuals (clinicians,
self-reported, researchers) who
identiﬁed ADRs clearly described?
Yes/no/unclear/not reported
Methods for determining causality Was the process of establishing the
causal relationship described in detail?
Yes/no/unclear/not reported
Were standard methods (validated tool)
used in the assessment?
Yes/no/unclear/not reported
Methods for determining avoidability Was the assessment process of
establishing avoidability described in
detail?
Yes/no/unclear/not reported
Were standard methods (validated tool)
used in the assessment?
Yes/no/unclear/not reported
Methods for determining predictability Was the assessment process of
establishing predictability described
in detail?
Yes/no/unclear/not reported
Were standard methods (validated tool)
used in the assessment?
Yes/no/unclear/not reported
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52Univariate meta-regression was used to determine if study level characteristics (setting, gender, age,
oncology and number of drugs used) are associated with ADR incidence. Incidence rates for ADRs causing
admission and occurring in hospital, calculated at the patient level for a single episode were included.
Multivariate meta-regression was not undertaken owing to the paucity of covariate data. Risk factor
analyses reported by any study were collated.ResultsThe search was originally undertaken in November 2009 and retrieved 20,906 potentially relevant
citations. An update search was subsequently performed in October 2010 and retrieved an additional
3234 citations. Combining both searches we identiﬁed 24,140 potentially relevant citations, of which
5039 duplicate citations were removed. Screening at title and abstract stage excluded a further 18,592
and 251 citations, respectively. Full papers were reviewed and 95 citations met the inclusion criteria.
Agreement between reviewers at each stage of the review is described in Figure 7. Additional citations
were identiﬁed through checking for correct exclusion at each stage (n = 3), reference checking (n = 13)
and personal communication with authors (n = 5). In total, 116 citations relating to 101 studies were
included in the review (see Figure 7).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 7 Agreement of reviewers.
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A total of 101 studies (116 citations), were included in the review. Eighty (80/101) studies described the
clinical event as an ADR. In 10 of these studies, ADR was a category within ‘drug-related’ problems/
admissions; three studies described ADRs as drug-induced disease/illness. Sixteen studies described an
ADE, in which the non-preventable ADE was the same as our deﬁnition, and two studies used the term
‘iatrogenic disease’ to describe an ADR. Some studies included multiple settings: 42 studies investigated
ADRs as the cause of admission to hospital, 53 studies investigated ADRs in the hospital setting, and
35 studies investigated ADRs in the community setting. Characteristics for each individual study are
provided in Appendix 3.Assessment of methodological quality of included studies
All studies, including those that evaluated ADEs, explicitly stated that they had used either the WHO ADR
deﬁnition1 or a similar one, and that they excluded drug errors. Methodological features of each individual
study are provided in Tables 22–27.TABLE 22 Drug class and clinical presentation of ADRs: causing admission studies
Drug class Study
Population
of study
No. of
ADRs
No. of ADRs
due to drug
class (%) Clinical presentation
Anti-infective
drugs (n = 17)
Easton (1998)41 1682 admissions 10 1 (10) Colitis, ileus
Impicciatore (2002)48 116 children 12 4 (33.3) Urticaria, periorbital
oedema, neutropenia
Lamababusuriya
(2003)47
39,625
admissions
63 38 (60.3) Erythema multiforme,
Stevens–Johnson
syndrome, rash, raised
intracranial pressure
Oshikoya (2007)46 3821 children 17 7 (41.1) Provided for deaths
only × 1
Easton (2004)102 2933 admissions 29 Not reported Not reported
Mitchell (1988)33 7271 children 288 10 (3.5) Diarrhoea, fever,
erythema multiforme
death × 2
Major (1998)103 457 children 26 6 (23) Not reported
Santos (2000)104 624 children 14 6 (42.8) Not reported
Gallagher (2011)20 462 children 18 3 (16.6) Diarrhoea
Duczmal (2006)105 4996 admissions 58 Not reported Not reported
Ganeva (2007)106 73 children 6 4 (66.6) Not reported
Fattahi (2005)107 404 children 9 4 (44.4) Not reported
Martinez-Mir (1996)42 490 children 21 10 (47.6) Not reported
Yosselson-Superstine
(1982)43
906 children 29 Not reported Not reported
McKenzie (1976)32 3556 admissions 72 Not reported Provided for deaths
only × 2
ADRIC 1 6821 children 249 16 (6.4) Diarrhoea, rash,
vomiting, lip swelling,
deranged LFTs, thrush
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TABLE 22 Drug class and clinical presentation of ADRs: causing admission studies (continued )
Drug class Study
Population
of study
No. of
ADRs
No. of ADRs
due to drug
class (%) Clinical presentation
Antiepileptic
drugs (n = 12)
Easton (1998)41 1682 admissions 10 3 (30) Increased ﬁtting, rash,
aphasia/motor
regression
Impicciatore (2002)48 116 children 12 2 (16.6) Coma
Lamababusuriya
(2003)47
39,625
admissions
63 4 (6.3) Ataxia and cerebellar
signs, liver failure,
Stevens–Johnson
syndrome
Oshikoya (2007)46 3821 children 17 1 (5.8) Not reported
Mitchell (1988)33 7271 children 288 23 (7.9) Lethargy, ataxia, rash,
erythema
Le (2006)36 64,403
admissions
35 Not reported Not reported
Santos (2000)104 624 children 14 1 (7.1) Not reported
Yosselson-Superstine
(1982)43
906 children 29 Not reported Not reported
McKenzie (1976)32 3556 admissions 72 Not reported Not reported
Fattahi (2005)106 404 children 9 1 (11.1) Not reported
Jonville-Bera (2002)37 260 children 4 1 (25) Convulsion
ADRIC 1 6821 children 249 2 (0.8) Constipation, respiratory
depression
NSAIDS (n = 9) Duczmal (2006)105 4996 admissions 58 Not reported Not reported
Impicciatore (2002)48 116 children 12 1 (8.3) Coma
Lamababusuriya
(2003)47
39,625
admissions
63 3 (4.7) Rectal bleeding,
aspirin – Reye’s
syndrome
Major (1998)103 457 children 26 2 (7.6) Not reported
Gill (1995)108 909 admissions 10 1 (10) Not reported
ADRIC 1 6821 children 249 31 (12.4) Postoperative bleeding,
haematemesis,
constipation,
abdominal pain
Gallagher (2011)20 462 children 18 1 (5.5) Haematemesis
Mitchell (1988)33 7271 children 288 12 (4.1) Gastritis
Jonville-Bera (2002)37 260 children 4 1 (25%) Melaena
Cytotoxic
drugs (n = 8)
Mitchell (1988)33 7271 children 288 Not reported Deaths × 2
Major (1998)103 457 children 26 10 (38.4) Not reported
Santos (2000)104 624 children 14 2 (14.2) Not reported
Yosselson-Superstine
(1982)43
906 children 29 Not reported Death × 1
McKenzie (1976)32 3556 admissions 72 Not reported Provided for deaths
only × 3
continued
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TABLE 22 Drug class and clinical presentation of ADRs: causing admission studies (continued )
Drug class Study
Population
of study
No. of
ADRs
No. of ADRs
due to drug
class (%) Clinical presentation
Fattahi (2005)107 404 children 9 2 (22.2) Not reported
ADRIC 1 6821 children 249 110 (44.2) Thrombocytopenia,
anaemia, vomiting,
mucositis, deranged liver
function tests,
immunosuppression,
diarrhoea, nausea,
constipation, headache,
abdominal pain, back
pain, haematuria,
leukoencephalopathy,
deranged renal function
Gallagher (2011)20 462 children 18 9 (50%) Pyrexia, neutropenia,
lethargy, decreased
responsiveness, vomiting
Corticosteroids
(n = 7)
Easton (1998)41 1682 admissions 10 1 (10%) Unstable diabetes
Santos (2000)104 624 children 14 1 (7.1%) Upper gastrointestinal
bleed
Yosselson-Superstine
(1982)43
906 children 29 Not reported Not reported
McKenzie (1976)32 3556 admissions 72 Not reported Not reported
Ganeva (2007)106 73 children 6 2 (33.3%) Not reported
ADRIC 1 6821 children 249 102 (41.0%) Immunosuppression,
postoperative bleeding,
hyperglycaemia,
hypertension, gastritis,
increased appetite,
impaired healing,
adrenal suppression
Gallagher (2011)20 462 children 18 1 (5.5%) Vomiting
Vaccines
(n = 7)
Easton (1998)41 1682 admissions 10 1 (10%) Hypotonic–
hyporesponsive episode
Lamababusuriya
(2003)47
39,625
admissions
63 9 (14.2%) Rash, encephalopathy,
ﬁts, head lag
Easton (2004)102 2933 admissions 29 Not reported Not reported
Mitchell (1988)33 7271 children 288 5 (1.7%) Not reported
Santos (2000)104 624 children 14 1 (7.1%) Not reported
Gill (1995)108 909 admissions 10 2 (20%) Seizures, fever
ADRIC 1 6821 children 142 Fever, rash, irritability,
seizure, vomiting, pallor,
apnoea, limb swelling,
lethargy,
thrombocytopenia,
diarrhoea, abdominal
pain, respiratory distress,
Kawasaki’s disease
LFT, liver function test.
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TABLE 23 Drug class and clinical presentation of ADRs: in-hospital studies
Drug class Study
Population
of study
No. of
ADRs
No. of ADRs
due to drug
class (%) Clinical presentation
Anti-infective
drugs (n = 24)
Al-Tajir (2005)109 2351 episodes 2 2 (100) Not reported
Baniasadi (2008)110 693 children 27 Not reported Not reported
Choonara (1984)111 268 children 15 5 (33.3) Vomiting, oral monilia,
diarrhoea
Dharnidharka (1993)112 703 children 7 1 (14.2) Skin rash
dos Santos (2006)113 265 children 47 18 (38.2) Not reported
dos Santos (2009)114 3726 episodes 302 57 (18.8) Not reported
Easton-Carter (2003)115 17,432 episodes 41 Not reported Not reported
Farrokhi (2006)92 81 children 3 1(33.3) Not reported
Fattahi (2005)107 380 children 40 35 (87.5) Not reported
Gill (1995)108 899 episodes 76 15 (19.7) Not reported
Gonzalez-Martin
(1998)116
219 children 46 4 (8.6) Not reported
Jha (2007)117 943 children 13 12 (92.3) Macupapular rashes,
vomiting, diarrhoea,
drug fever
Jonville-Bera (2002)37 227 children 6 2 (33.3) Diarrhoea, rash
Impicciatore (2002)48 1619 children 29 9 (31.0) Urticaria, increased
transaminase levels,
vomiting, diarrhoea
Le (2006)36 64,403 admissions 1060 Not reported Not reported
Leach (1998)118 499 episodes 58 23 (39.6) Vomiting, rash,
diarrhoea, arthropathy,
neutropenia, nausea, ﬁts
Mitchell (1979)119 1669 children 280 Not reported Not reported
Maistrello (1999)120 1103 children 59 24 (40.6) Gastointestinal disorders
Martinez-Mir (1999)121 490 children 68 Not reported Not reported
Neubert (2004)75 156 children 31 Not reported Not reported
Oshikoya (2007)46 3821 children 27 12 (44.4) Red man syndrome,
pustular rash,
Stevens–Johnson
syndrome, erythema,
jaundice, anaphylaxis,
urticaria, fever
Shockrollah (2009)122 230 children 5 2 (40) Not reported
Turner (1999)3 936 episodes 157 34 (21.6) Not reported
Vazquez de la Villa
(1989)123
597 children 26 9 (34.6) Diarrhoea, vomiting,
rash
continued
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TABLE 23 Drug class and clinical presentation of ADRs: in-hospital studies (continued )
Drug class Study
Population
of study
No. of
ADRs
No. of ADRs
due to drug
class (%) Clinical presentation
Antiepileptic
drugs (n = 14)
Choonara (1984)111 268 children 15 7 (46.6) Drowsiness,
hyperactivity, ataxia
Dharnidharka (1993)112 703 children 7 1 (14.2) Skin rash
dos Santos (2009)114 3726 episodes 302 26 (8.6) Not reported
Easton-Carter (2003)115 17432 episodes 41 Not reported Not reported
Gill (1995)108 899 episodes 76 3 (3.9) Not reported
Gonzalez-Martin
(1998)116
219 children 46 5 (10.8) Not reported
Le (2006)36 64,403 admissions 1060 Not reported Not reported
Leach (1998)118 499 episodes 58 1 Apnoea
Mitchell (1979)119 1669 children 280 Not reported Not reported
Martinez-Mir (1999)121 490 children 68 Not reported Not reported
Neubert (2004)75 156 children 31 Not reported Not reported
Oshikoya (2007)46 3821 children 27 2 (7.4) Erythema
Telechea (2010)a 123 children 46 15 (32.6) Not reported
Vazquez de la Villa
(1989)123
597 children 26 4 (15.3) Sedation, paradoxical
reaction
Corticosteroids
(n = 10)
dos Santos (2006)113 265 children 47 11 (23.4) Not reported
Gill (1995)108 899 episodes 76 6 (7.8) Not reported
Gonzalez-Martin
(1998)116
219 children 46 3 (6.5) Not reported
Impicciatore (2002)48 1619 children 29 1 (3.4) Rash
Leach (1998)118 499 episodes 58 1 (1.7) Gastric irritation
Mitchell (1979)119 1669 children 280 Not reported Not reported
Neubert (2004)75 156 children 31 Not reported Not reported
Telechea (2010)a 123 children 46 4 (8.6) Not reported
Turner (1999)3 936 episodes 157 10 (6.3) Not reported
Vazquez de la Villa
(1989)123
597 children 26 1 (3.8) Cushing syndrome
Bronchodilators
(n = 9)
Choonara (1984)111 268 children 15 3 (20) Tachycardia
Easton-Carter (2003)115 17,432 episodes 41 Not reported Not reported
Gill (1995)108 899 episodes 76 8 (10.5) Not reported
Gonzalez-Martin
(1998)116
219 children 46 8 (17.3) Not reported
Impicciatore (2002)48 1619 children 29 5 (17.2) Tremor, tachycardia
Neubert (2004)75 156 children 31 Not reported Not reported
Telechea (2010)a 123 children 46 8 (17.3) Not reported
Turner (1999)3 936 episodes 157 8 (5.0) Not reported
Vazquez de la Villa
(1989)123
597 children 26 11 (42.3) Tachycardia,
nervousness, vomiting
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TABLE 23 Drug class and clinical presentation of ADRs: in-hospital studies (continued )
Drug class Study
Population
of study
No. of
ADRs
No. of ADRs
due to drug
class (%) Clinical presentation
Cytotoxic
drugs (n = 7)
dos Santos (2009)114 3726 episodes 302 10 (3.3) Not reported
Gonzalez-Martin
(1998)116
219 children 46 7 (15.2) Not reported
Jonville-Bera (2002)37 227 children 6 4 (66.6) Vomiting
Le (2006)36 64,403 admissions 1060 Not reported Not reported
Leach (1998)118 499 episodes 58 1 (1.7) Thrombocytopenia
Mitchell (1979)119 1669 children 280 Not reported Not reported
Telechea (2010)a 123 children 46 1 (2.1) Not reported
Diuretic drugs
(n = 6)
Easton-Carter (2003)115 17,432 episodes 41 Not reported Not reported
Leach (1998)118 499 episodes 58 1 (1.7) Overdiuresis
Mitchell (1979)119 1669 children 280 Not reported Not reported
Neubert (2004)75 156 children 31 Not reported Not reported
Telechea (2010)a 123 children 46 9 (19.5) Not reported
Turner (1999)3 936 episodes 157 31 (19.7) Not reported
a Telechea M, Lucas N, Giachetto L, Nanni G, Menchaca A. Importance of drug-induced pathology in an intensive care
unit of children. 2010, unpublished data.
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TABLE 24 Drug class and clinical presentation of ADRs: community
Drug class Study
Population
of study
No. of
ADRs
No. of
ADRs due
to drug
class (%)
Clinical
presentation
Anti-infective
drugs (n = 13)
Cirko-Begovic (1989)124 2459 children 63 49 (78) Not reported
Easton-Carter (2003)125 8601 consultations 118 Not reported Not reported
Horen (2002)77 1419 consultations 20 9 (45) Not reported
Juntti-Patinen (2006)126 Not reported for
children only
4 Not reported for
children only
Not reported for
children only
Kaushal (2007)127 1689 children 226 158 (70) Nausea, vomiting
and diarrhoea
Kramer (1985)78 4244 courses of
therapy
200 Not reported Diarrhoea, other
gastrointestinal
complaints and
skin rashes
Menniti-Ippolito
(2000)128
7890 children 119 79 (66) Cutaneous,
gastrointestinal,
eosinophilia,
neurological,
angioedema, fever
Planchamp (2009)129 12,995 consultations 43 Not reported Not reported
Sanz and Boada
(1987)130
1327 children 10 4 (40) Cutaneous
reaction and
diarrhoea
Munoz (1998)131 47,107 consultations 447 49.5% Included skin
reactions
Jonville-Bera (2002)37 A&E, 428 children;
private paediatricians,
1192 children
A&E, 4; private
paediatricians, 8
A&E, 2 (50);
private
paediatricians,
6 (75)
Diarrhoea, rash,
vomiting
Woods (1987)132 1590 children 235 40 (17) Diarrhoea,
drowsiness, rash,
headache,
hyperactivity,
anorexia,
abdominal pain,
vomiting, sleep
disturbance
Zahraoui (2010)133 Not reported 24 Not reported Not reported
NSAIDs (n = 6) Kaushal (2007)127 1689 children 226 2 (1) Not reported
Menniti-Ippolito
(2000)128
7890 children 119 3 (3) Cutaneous,
haematuria,
hypertranspiration
Munoz (1998)131 47107 consultations 447 Not reported Not reported
Planchamp (2009)129 12,995 consultations 43 Not reported Not reported
Sanz and Boada
(1987)130
1327 children 10 1 (10) Not reported
Woods (1987)132 1590 children 235 9 (4) Drowsiness,
abdominal pain,
aggressiveness,
vomiting
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TABLE 24 Drug class and clinical presentation of ADRs: community (continued )
Drug class Study
Population
of study
No. of
ADRs
No. of
ADRs due
to drug
class (%)
Clinical
presentation
Analgesic
drugs (n = 5)
Kaushal (2007)127 1689 children 226 1 (0.4) Not reported
Munoz (1998)131 47,107 consultations 447 Not reported Not reported
Planchamp (2009)129 12,995 consultations 43 Not reported Not reported
Woods (1987)132 1590 children 235 11 (5) Drowsiness,
irritability,
aggressiveness
Zahraoui (2010)133 Not reported 24 Not reported Not reported
Vaccines (n = 5) Horen (2002)77 1419 consultations 20 5 (25) Not reported
Jonville-Bera (2002)37 A&E, 428; private,
1192 (children)
A&E, 4;
private 8
A&E, 1 (25);
private, 2 (25)
A&E rash; private,
fever
Menniti-Ippolito
(2000)128
7890 children 119 14 (12) Not reported
Munoz (1998)131 47,107 consultations 447 ? 9.2% Not reported
Planchamp (2009)129 12,995 consultations 43 Not reported Not reported
Antihistamine
drugs (n = 4)
Cirko-Begovic (1989)124 2459 children 63 2 (3) Not reported
Kaushal (2007)127 1689 children 226 2 (1) Not reported
Menniti-Ippolito
(2000)128
7890 children 119 2 (2) Not reported
Woods (1987)132 1590 children 235 46 (20) Drowsiness,
aggressiveness, dry
mouth, headache,
irritability,
diarrhoea
Bronchodilators
(n = 3)
Kaushal (2007)127 1689 children 226 16 (7) Not reported
Kramer (1985)78 4244 courses of
therapy
200 Not reported Various
manifestations of
central nervous
stimulation
Woods (1987)132 1590 children 235 6 (3) Hyperactivity,
shakiness,
dizziness,
irritability, sleep
disturbance
Steroids (n = 3) Horen (2002)77 1419 consultations 20 1 (0.05) Not reported
Kaushal (2007)127 1689 children 226 12 (5) Not reported
Woods (1987)132 1590 children 235 5 (2) Abdominal pain,
diarrhoea
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TABLE 25 Drug class and clinical presentation of ADRs: combined settings (causing admission and in hospital)
Drug class Study
Population of
study
No. of
ADRs
No. of ADRs due to
drug class (%)
Clinical
presentation
Anti-infective drugs
(n = 2)
Haffner
(2005)134
703
admissions
101 Not reported Not reported
Speranza
(2008)135
173 children 24 10 (41.6) Not reported
Bronchodilators
(n = 1)
Haffner
(2005)134
703
admissions
101 Not reported Not reported
Antiepileptic drugs
(n = 2)
Haffner
(2005)134
703
admissions
101 Not reported Not reported
Speranza
(2008)135
173 children 24 4 (16.6) Not reported
Cardiovascular
drugs (n = 1)
Haffner
(2005)134
703
admissions
101 Not reported Not reported
Analgesic drugs
(n = 1)
Speranza
(2008)135
173 children 24 2 (8.3) Not reported
Antiulcer drugs
(n = 1)
Speranza
(2008)135
173 children 24 2 (8.3) Not reported
Psychotropic drugs
(n = 1)
Speranza
(2008)135
173 children 24 2 (8.3) Not reported
TABLE 26 Drug class and clinical presentation of ADRs: combined settings (in hospital and community)
Drug class Study
Population of
study
No. of
ADRs
No. of ADRs due to
drug class (%)
Clinical
presentation
Anti-infective drugs
(n = 1)
Kushwaha
(1994)136
20,310 admissions 267 Not reported Erythematous
maculopapular
rash,
thrombophlebitis,
erythema
multiforme, ﬁxed
drug reaction,
urticaria, jaundice,
aplastic anaemia,
thrombocytopenia
purpura
Vaccines (n = 1) Kushwaha
(1994)136
20,310 admissions 267 Not reported Nodular cyst in
gluteal region,
injection abscess
NSAIDs (n = 1) Kushwaha
(1994)136
20,310 admissions 267 Not reported Erythematous
maculopapular
rash
Analgesic drugs
(n = 1)
Kushwaha
(1994)136
20,310 admissions 267 Not reported Erythematous
maculopapular
rash, urticaria
Steroids (n = 1) Kushwaha
(1994)136
20,310 admissions 267 Not reported Injection abscess
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TABLE 27 Drug class and clinical presentation of ADRs: combined settings (admission, in hospital and community)
Drug class Study
Population of
study
No. of
ADRs
No. of ADRs due to
drug class (%) Clinical presentation
Steroid (n = 1) McKenzie
(1973)137
658 children 175 Not reported Psychotic reaction,
Cushing syndrome,
cataracts, hypertension
Anti-infective drugs
(n = 1)
McKenzie
(1973)137
658 children 175 Not reported Rash, diarrhoea, facial
ﬂush, monilia, pain in
injection site
Cytotoxics (n = 1) McKenzie
(1973)137
658 children 175 Not reported Alopecia, peripheral
neuritis, mouth ulcer,
injection site
inﬂammation,
leukopenia, secondary
infection
Notes
One patient in the Zahraoui (2010)133 study died (gastrointestinal bleeding and severe thrombocytopenia after prolonged
anticonvulsant treatment).
Mitchell (1988):33 ﬁve deaths (fever, vomiting, arrhythmia and cardiopulmonary arrest attributed to theophylline and
erythromycin; cardiac arrest and hypernatraemia attributed to halothane, and nitrous oxide pneumonia attributed to
chemotherapy-induced immunosuppression; cardiotoxicity attributed to doxorubicin; candida sepsis and meningitis
attributed to chemotherapy-induced immunosuppression).
Yosselson-Superstine (1982):43 one death (no details provided).
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Study design
The majority of studies were carried out prospectively (n = 84; 83%), which included 13 in those causing
admission, 26 studies with the ADR occurring in hospital, 23 in the community, 16 in hospital and
causing admission, and six in mixed hospital and community settings. Fourteen studies were carried out
retrospectively, which included six causing hospital admission, two in hospital studies, and four in the
community, one causing admission and in the hospital setting, and one the study that considered ADRs
that resulted in any medical care contact. Two studies (one in hospital and one in hospital and causing
admission) used both study designs. For the remaining study we were unable to determine the study
design (see Tables 22–27).Persons involved in identifying adverse drug reactions
Sixty-three studies reported that a clinician – medical doctor, nurse or pharmacist – was involved in the
identiﬁcation of ADRs. Thirty studies reported also involving either the child or parent. Eight studies did not
provide information about who identiﬁed the ADRs.Methods for identifying adverse drug reactions
Several methods were used to detect ADRs. Multiple ADR detection methods were used in 58/101 studies;
these consisted of a combination of case record review, drug chart review, laboratory data, computerised
ADR reporting system, attendance at ward rounds, and interviewing patients/parents or clinicians. In
31 studies, case record review alone was undertaken. The remaining 11 studies used parental interviews/
questionnaires (ﬁve studies), clinical assessments (three studies), clinician questionnaires (one study), ward
round (one study) and a nationwide computer database (one study). The remaining study report did not
refer to the methods used.63
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64Studies estimating the proportion of paediatric hospital admissions related
to adverse drug reactions
Description of studies
There were 42 studies in which ADRs had been investigated as the cause of admission to hospital. The
period under study varied widely, and ranged from 1 week to 11 years. The majority of studies were
described as being performed in a general paediatric unit or ward (n = 22).20,21,32,33,43,45,46,48,102,104,105,109,135,
137–145 Four studies41,47,103,117,146 included general medicine, one study147 in a hospital emergency
department. Two studies37,148 covered general medicine and a hospital emergency department, and one
study149 an integrated primary care information database. Two studies were performed in the PICU,108
one134 in combination with general paediatrics. Seven studies110,150–155 covered a combination of clinical
settings. The three remaining studies were performed in dermatology and venereology,106 infectious
diseases107 and an isolation ward.42Adverse drug reaction incidence
We do not have ADR incidence rates for 12 out of 42 of these studies, as the child-only data were not
available (n = 4), data were not split by clinical setting (n = 5), data were provided for ADRs in hospital but
not causing admission (n = 2), and data were provided for the total number of ADRs but not the ADR
frequency at the patient or episode level (n = 1). Figure 8 presents data from all of the studies that provide
incidence rates for ADRs causing admission to hospital (n = 30). These rates range from 0.4% to 10.3% of
children (single admission). One study was an extreme outlier48 and if this was excluded we found a
reduction in the upper limit of this range to 4%, and a pooled incidence estimate of 2.9% (95% CI 2.6%
to 3.1%).Studies estimating the proportion of children experiencing an adverse
drug reaction during their admission
Description of studies
We have included 51 studies in which ADRs have been investigated in the hospital setting. The period
under study varied widely and ranged from 1 day to 10 years. The majority of studies were described as
being performed in a general paediatric unit or ward (n = 24),32,37,45,46,48,109,111–117,123,135,137,142,144,145,156–160
two134,161 of which included intensive care also. Six studies108,122,124,162–164 were performed solely in the
intensive care setting, one118 of which included general medicine. Three studies75,165,166 included children
on an isolation ward. One study was performed using an integrated primary care information database.149
The remaining 13 studies covered a combination of clinical settings.3,92,107,110,119,120,150,152–155,167,168Adverse drug reaction incidence
We do not have ADR incidence rates for 18 out of 54 of these studies, as the child-only data were not
available (n = 3), the data were not split by clinical setting (n = 7), data were provided for the total number
of ADRs but not the ADR frequency at the patient or episode level (n = 5), data were provided for ADRs
and ADEs combined (n = 2), and data provided for ADRs causing admission but not in hospital (n = 1).
Figure 9 presents data from all of the studies that provide incidence rates for ADRs in hospital (n = 36).
These estimates range from 0.6% to 16.8% of patients (at a single episode and with prior drug exposure).
A pooled estimate has not been calculated, as the rates are considered too varied.Studies estimating the incidence of adverse drug reactions in
outpatient children
Description of studies
We have included 36 studies, where ADRs have been investigated in the community setting. The period
under study varied widely and ranged from 1 week to 11 years. The majority of studies were described as
being performed in a hospital outpatient or A&E department (n = 21).109,124–126,129,131,133,155,168–180 Nine
studies were performed in general practice.77,78,127,128,130,181–184 The remaining six studies were performed inNIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3an infant care and educational establishment,133 local community setting,185,186 general practice and
emergency department,37 outpatient population seeking medical care187 and after discharge
from hospital.45Adverse drug reaction incidence
We do not have ADR incidence rates for 18 (18/35) of these studies, as the child-only data were not
available (n = 10), the data were not split by clinical setting (n = 3), data were not available for the total
number of children/visits (n = 3), data were provided for the total number of ADRs but not the ADR
frequency at the patient or visit level (n = 1), and data were provided for errors only (n = 1). Figure 10
presents data from studies that provide incidence rates for ADRs in the community (n = 15). Two studies
were not included in this ﬁgure owing to their method of ADR ascertainment.
All settingsDrugs and clinical presentation associated with adverse drug reaction
We do not have information on the drugs involved in ADRs for 49 out of 101 studies, as the child-only
data were not available (37 studies), ADRs were a subset of events looked at and ADR-speciﬁc data were
not reported (10 studies), and drug data were not available in the publication (two studies). For studies
that provided data (52/101); anti-infective drugs were the drug class most commonly reported across the
three settings. Proportions ranged from 3.5% to 66.6% for causing admission studies (17 studies); 8.6%
to 100% for in-hospital studies (24 studies); and 17% to 78% for community studies (13 studies). The
most common associated clinical presentations reported were nausea, vomiting, diarrhoea and skin rash.
Antiepileptic drugs were the second most common reported drug class in both the causing admission and
in-hospital studies; proportions ranging from 0.8% to 30% (12 studies) and 3.9% to 46.6% (14 studies),
respectively. Reported clinical presentations were ataxia, skin rash, increased ﬁtting and drowsiness.
NSAIDs were frequently reported as being associated with ADRs in studies in children in outpatients, with
proportions ranging from 1% to 10% (six studies). Reported clinical presentations were cutaneous
reactions, haematuria, hypertranspiration, drowsiness, abdominal pain, aggressiveness and vomiting.
In addition, corticosteroids were commonly reported across the three settings. Proportions ranging from
5.5% to 41.0% for causing admission studies (seven studies); 1.7% to 23.4% for in-hospital studies
(10 studies); and 0.05% to 5% for community studies (three studies). The most common associated clinical
presentations reported were immunosuppression, postoperative bleeding, gastric irritation and diarrhoea.
The distribution of drugs implicated in ADRs reﬂect the prescribing practices for the individual settings. For
example, vaccines were commonly reported in causing admission studies (seven studies) and community
studies (ﬁve studies). Proportions ranged from 1.7% to 41.0% and 9.2% to 25% respectively, with rash
and fever being the most commonly associated clinical presentations. Cytotoxic drugs were reported in
both causing admission (eight studies) and in hospital studies (seven studies), and proportions ranged from
14.2% to 50% and 1.7% to 66.6%, respectively. The remaining studies reported a variety of drugs
implicated in ADRs, and for some more than one drug was the cause of a single ADR (see Tables 22–27).
Univariate meta-regression results (Table 28) suggest that the incidence rate for ADRs occurring in hospital
is higher than for ADRs causing admission (OR = 2.73, 95% CI 0.93 to 8.03). In addition, the results
suggest that the incidence rate is higher for studies with a relatively high mean/median number of drugs
per patient (OR = 1.49, 95% CI 1.14 to 1.94), a high percentage of females (OR = 1.13, 95% CI 0.91 to
1.40), a high percentage of oncology patients (OR = 1.15, 95% CI 0.89 to 1.50) and low mean age of
patients (OR = 0.71, 95% CI 0.39 to 1.27). However, only the variable representing the mean/median
number of drugs per patient achieves statistical signiﬁcance.67
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TABLE 28 Univariate meta-regression results for causing admission and in hospital incidence rates
Covariate OR (95% CI) p-value
Setting Admission 1 (0.93 to 8.03) 0.07
Hospital 2.73 (0.93 to 8.03)
% female patients 1.13 (0.91 to 1.40) 0.23
Mean age (years) 0.71 (0.39 to 1.27) 0.21
Mean/median number of drugs 1.49 (1.14 to 1.94) 0.01
% oncology patients 1.15 (0.89 to 1.50) 0.25
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3Risk factors
Risk factor analyses reported by all studies were collated. Consistent with the meta-regression results,
evidence is provided – from 10 out of 19 studies that consider gender as a risk factor – that boys are less
likely to have an ADR and, from 16/17 studies, that risk increases with the number of drugs taken. In
addition, three out of three studies suggest that the risk of ADRs is greater with off-label use. Only two
studies considered oncology as a risk factor. The results for the age analyses do not follow a clear pattern
and are difﬁcult to interpret owing to the variety of age categorisations used.Tools for assessing causality
Nearly three-quarters of the studies (71/101) mentioned a causality assessment, of which the Naranjo
algorithm was the most frequently used tool (29/71). Of the 71 studies, six used a self-assessment method
rather than a published CAT. Despite the majority of studies mentioning a causality assessment, only half
of these studies (36/71) reported causality data that were complete for all identiﬁed ADRs, speciﬁc to the
paediatric population and did not include errors as part of the assessment.Tools for assessing severity
Thirty-four (34/101) studies performed an ADR severity assessment. Rates ranged from 0% to 66.7% of
reported ADRs considered to be severe. By setting, the proportion of ADRs occurring in hospital assessed
as severe ranged from 0% to 66.7%, compared with 0–45.5% of ADRs causing admission, and 0–32.6%
of ADRs occurring in the community. Twenty studies provided a reference to indicate the severity tools
used; however, tools differed widely. Examples of ADRs assessed as severe were those that caused death
or were directly life-threatening, caused hospital admission, prolonged hospitalisation or caused transfer to
higher level of clinical care.Assessment of avoidability
Nineteen (19/101) studies performed an avoidability assessment; however, data were available for only
14 out of 19 studies, as child-only data were not available in 4 out of 19 and ADR-speciﬁc data were not
provided in 1 out of 19 studies. For these 14 studies, 7–98% of ADRs were designated as either deﬁnitely
or possibly avoidable. Three studies provided the rationale for 62 avoidable ADRS: inappropriate selection
or indication for use of drug (n = 14), inadequate patient education (n = 14), prescribing not rational
(n = 11), lack of appropriate prophylaxis for known ADR (n = 9), lack of appropriate monitoring of drugs
(n = 5), previous known ADR to medication (n = 3), dose prescribed was too high (n = 3), inappropriate
duration of treatment (n = 1), drug was not prescribed per treatment protocol (n = 1), inappropriate
duration of drug and monitoring of treatment (n = 1). Ten studies used a recognised AAT, of which half
used that of Schumock and Thornton.4469
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70DiscussionThis is the largest systematic review of ADRs in children to date and shows clearly that ADRs are an
important clinical problem for children and have been the subject of a large number of studies. Unlike
other systematic reviews,34,35,101 our review searched for studies using a comprehensive search strategy of a
large number of databases, including those speciﬁc to toxicology and pharmacology. We included studies
in which ADEs had been evaluated, and that included both adults and children. When compared with the
previous reviews this resulted in an additional 69 studies being included in our review, of which we
were able to extract data from 24. In addition, we contacted authors of studies to obtain unpublished
information. As a result, we were able to obtain unreported ADR incidence data for an additional 24 out
of 101 studies. This allowed us to make a more informed judgement regarding ADR incidence estimates.
In agreement with previous studies, this review found that ADR incidence rates were generally higher in
hospitalised children than ADR rates causing hospital admission or in an outpatient setting. One of the
main difﬁculties with comparing ADR incidence rates, particularly from observational studies, is the
different numbers and denominators used, leading to high levels of variability between studies in the
calculation and reporting of incidence rates. Owing to this, a pooled estimate has been provided for ADRs
causing admission only.
Concerning risk factors associated with ADRs, we found evidence – from both univariate meta-regression
and the collation of risk factor analyses from individual studies – that the use of multiple drugs is an
important predictor of ADRs. This may be due to the additive risk of an ADR when receiving several drugs
or drug–drug interactions.
We examined the methods used for detecting, and assessing, the causality, severity and avoidability of an
ADR. The assessment of causality in individual cases of ADRs is required to establish whether or not there
is an association between the untoward clinical event and the suspected drug.23 The detection of ADRs
depends on the validity and reliability of the tests used and if sensitive methods are performed, in theory,
all ADRs should be detected. We found that one-third (30/101) of studies did not report which CAT they
used, with an additional six not using a recognised algorithm. As a consequence there may be either an
underestimation or overestimation of ADRs in these studies. Over one-third of studies (34/101) assessed
ADRs for the severity of the reactions, just eight of which did not report any severe ADRs. The ability to
classify ADRs by severity provides a mechanism for clinicians to identify problem areas and implement
interventions to inform paediatric pharmacovigilance practice.
The absence of avoidability data was most noticeable in this review, with only 14 studies (14/101; 14%)
providing avoidability data. Therefore, it is not possible to consider this important aspect of drug safety in
order to prevent future ADRs.44 Further studies are clearly required to determine which ADRs are
potentially avoidable. These studies could provide the necessary data in order to enable clinicians to
administer medications in the safest and appropriate way.
The reporting quality of some of the included studies was poor, which may have affected the results. Not
all provided a clear deﬁnition of the term ‘ADR’, and often insufﬁcient information was given in the
publication in order to determine whether ADRs included medication or prescribing errors. ADR incidence
data were not always clearly described in the publications; in many studies (n = 48/101) reporting was
unclear regarding whether the incidence rate was reported at the patient and/or episode level, and
whether or not all children had been exposed to a drug.
It is disappointing, given the large number of studies that we identiﬁed that addressed this problem, that
most did not include these important methodological aspects, which means that few lessons have been
learnt about how to prevent ADRs in children.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3ConclusionsThis review conﬁrms previous studies that have shown ADRs to be an important problem in children and
has highlighted therapeutic classes of drugs most commonly associated with them. Further work to
address prescribing practices in different settings and avoidability of ADRs is needed to indicate how such
ADRs may be prevented.71
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drug reactions
This chapter contains information reproduced from Gallagher RM, Kirkham JJ, Mason JR, Bird KA,Williamson PR, Nunn AJ, et al. Development and Inter-Rater Reliability of the Liverpool Adverse Drug
Reaction Causality Assessment Tool. PLOS ONE 2011;6:e28096,51 © 2011 Gallagher et al., an open-access
article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution and reproduction in any medium, provided that the original author and
source are credited.Abstract
Aim
To develop and test a new ADR CAT.Methods
A comparison between seven assessors of a new CAT (formulated by an expert focus group) with the
Naranjo CAT in 80 cases from a prospective observational study and 37 published ADR case reports
(819 causality assessments in total).Main outcome measures
Utilisation of causality categories, measure of disagreements, inter-rater reliability (IRR).Results
The LCAT, using 40 cases from an observational study, showed causality categories of one unlikely,
62 possible, 92 probable and 125 deﬁnite (1, 62, 92, 125) and ‘moderate’ IRR [kappa (κ) = 0.48] compared
with Naranjo (0, 100, 172, 8) with ‘moderate’ IRR (κ = 0.45). In a further 40 cases, the LCAT (0, 66,
81, 133) showed ‘good’ IRR (κ = 0.6), whereas Naranjo (1, 90, 185, 4) remained ‘moderate’.Conclusions
The LCAT assigns the full range of causality categories and shows good IRR. Further assessment by
different investigators in different settings is needed to fully assess the utility of this tool.IntroductionCausality assessment of ADRs is a method used for estimating the strength of relationship between drug(s)
exposure and occurrence of adverse reaction(s). Causality assessment of ADRs may be undertaken by
clinicians, academics, the pharmaceutical industry and regulators, and in different settings, including
clinical trials.188–191 At an individual level, health-care providers assess causality informally when dealing
with ADRs in patients to make decisions regarding future therapy. Many regulatory authorities assess
spontaneous ADR reports,189,191 where causality assessment can help in signal detection and risk–beneﬁt
decisions regarding medicines,192,193 using formal CATs to aid in this process.
An early paper by Sir Austin Bradford Hill194 describing minimum criteria for establishing causality of AEs,
pre-dates the earliest attempts to formulate ADR CATs. Bradford Hill set out criteria for establishing
causality, which included assessment of strength of the association, consistency of the association,
speciﬁcity, temporal relationship, biological gradient (dose response), biological plausibility, coherence,
experimental evidence and reasoning by analogy. These elements of assessing strength of relationship73
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74between exposure (drugs) and outcome (adverse reaction) are used widely in ADR CATs. Attempts to
formalise causality assessment of ADRs into structured CATs have been ongoing for > 30 years.23,195
It is known that assessing ADR likelihood without structure can lead to wide disagreements between
assessors.196 Disagreements may mean that opportunities to avoid or ameliorate harm are missed during
clinical care or that cases are misclassiﬁed in epidemiological studies. These disagreements may be the
result of differing clinical backgrounds, specialties and experience between assessors. A large number of
CATs have been developed ranging from the simple to the complex. These tools aim to limit disagreement
between assessors of ADR cases as to the likelihood that a reaction is related to a particular medication
taken by the patient. None has gained universal acceptance.197
One of the most widely used CATs is the Naranjo ADR probability scale.23 This is a simple 10-item
questionnaire that classiﬁes the likelihood that a reaction is related to a drug using concepts such as
timing, plausibility/evidence, de-challenge and rechallenge/previous exposure. Each element of the
questionnaire is weighted and the total score is used to categorise the event into unlikely, possible,
probable and deﬁnite. The tool was developed 30 years ago by adult pharmacologists/physicians and
psychiatrists. Published case reports were used to validate the reliability of the tool in assessing causality.
It has been widely used, including recently by investigators in two large prospective observational studies
of ADRs causing hospital admission and occurring in hospital inpatients.59,198 However, the reliability and
validity of the Naranjo scale has been questioned by a number of investigators.24,188,193,199,200
While undertaking a prospective observational pilot study of ADRs in children, we found several difﬁculties
with using the Naranjo scale, and aimed to address those difﬁculties. Our original aim was to use the
Naranjo ADR Probability Scale for the larger observational study; we planned to assess the causality
of the ADRs prospectively rather than at the end of the study period. When beginning to assess this
heterogeneous mix of potential ADR cases during the pilot study with the Naranjo scale, the investigators
found that some questions were not appropriate in this clinical context. This led to many elements of the
Naranjo scale being categorised as ‘unknown’. In particular, question six (‘Did the reaction reappear when
a placebo was given?’) and question seven [‘Was the drug detected in the blood (or other ﬂuids) in
concentrations known to be toxic?’] were very often answered as ‘unknown’. Administration of a placebo
and assessment of drug concentrations are not part of practice when assessing potential causality of ADRs
in this clinical setting. An answer assigned as ‘unknown’ gives a zero score for that element in the Naranjo
scale. This will lower the total achievable score on an individual case basis. This meant that the thresholds
for recognising ADRs were not achieved, which, in turn, underestimated the likelihood of an ADR. This led
to a lack of sensitivity for many of the early cases assessed in our study, as the overall score obtained for
each causality assessment was artiﬁcially lowered. The investigators encountered several cases that were
unanimously thought to be deﬁnite ADRs (e.g. repeated episodes of febrile neutropenia during oncological
chemotherapy) but which did not reach the threshold for ‘deﬁnite’ causality using the published Naranjo
scale. Accordingly, the Naranjo score did not have face validity when applied to our patient population.
Moreover, the weighting for each question and the ADR classiﬁcation scoring boundaries used in the
Naranjo scale were not justiﬁed in the original publication, or subsequently. Therefore, we developed a
CAT that would overcome some of these issues, while at the same time (1) making it as easy, or easier,
to use than the Naranjo scale (a feature that holds a distinct advantage for large observational studies of
ADRs among other situations) and (2) ensuring that the basic principles of assessing causality were
maintained. The speciﬁc aim of this study was to develop a CAT with good face validity and acceptable
inter-rater reproducibility.MethodsThe pilot study team (RG, JB, KB) noted concerns with using the Naranjo scale. This triggered a process
in which each of seven investigators (RG, JB, KB, MPir, TN, RS, MT) independently assessed the ﬁrst
40 consecutive case reports from an observational study of suspected ADRs causing hospital admission
using the Naranjo scale. In summary, there were eight cases in which problems with assessments wereNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3found. There was one case in which major discrepancies occurred between at least two out of seven
raters, i.e. where the range of causality probability differed by more than one category (e.g. possible and
deﬁnite), and seven cases in which close to half of the raters differed from the others by one causality
category. The questions (within the Naranjo scale) that caused the discrepancies in these cases were
identiﬁed and reviewed. This exercise led to the recognition that a new CAT was required.
The team made several choices at the start of the development of the new CAT. In order to relate to the
existing literature, it was agreed that the output of the new tool would take the same form as the Naranjo
scale. That is, categorical scores from both the Naranjo scale and the new tool would take the same
four-point ordinal scale (unlikely, possible, probable and deﬁnite). In order to ﬁt with clinicians’
experiences, the format of the new tool was an algorithm, with dichotomous responses to each decision
followed by routing to further, speciﬁc questions, rather than the weighted responses used in the Naranjo
scale. The study team decided to develop the new tool in two stages: ﬁrst, use the extensive clinical and
pharmacovigilance expertise in the group to develop a tool that had face validity to the team, and, second,
iteratively assess the tool to optimise interobserver agreement within the study team. In the ﬁrst step of
the process, each question in the Naranjo scale was reviewed by the investigators at a consensus meeting
to assess whether it was appropriate to (1) retain it (with or without modiﬁcation); (2) reject it; or
(3) combine it with another question(s). The aim was to create a new, more appropriate CAT (Table 29).
The new LCAT was then used to assess 20 new suspected ADR case reports from our observational study.
The collated causality categories for all seven assessors showed 1 (0.7%) unlikely, 18 (12.9%) possible,
2 (1.4%) probable and 119 (85%) deﬁnite. The assessors achieved moderate agreement with a kappa
score of 0.51 (95% CI 0.19 to 0.82). The team considered that there was an inappropriate bias towards
the category of deﬁnite. Accordingly, the CAT was reviewed. Major discrepancies between scorers were
identiﬁed and each question within the algorithm was reviewed to assess face validity and likelihood of
inter-rater disagreement. Questions that caused the major discrepancies were then modiﬁed. The new CAT
was then tested on a further 20 case reports: 10 from the ADRIC study and 10 from an observational
study of inpatient ADRs in an adult hospital. Collated causality categories for the 10 ADRIC 1 cases
showed 0 (0%) unlikely, 24 (34%) possible, 39 (56%) probable and 7 (10%) deﬁnite with a kappa score
of 0.27 (95% CI 0.11 to 0.44). Collated causality categories for the 10 adult cases showed 0 (0%)
unlikely, 13 (19%) possible, 48 (69%) probable and 9 (13%) deﬁnite, with a kappa score of 0.13
(95% CI –0.14 to 0.38). The results of these assessments prompted another review of the appropriateness
of the tool and questions. A third iteration was used so that the development and evaluation of tool
prototypes was based on discussions in which 80 cases were used (Figure 11).
After the third iteration, the investigators were satisﬁed with the ﬁnal version of the new tool (Figure 12)
in terms of ease of use, lack of ambiguity and appropriateness of the causality assignment. This was
judged by expert opinion and consensus within the group.
The assessment of IRR within the study team for the LCAT followed a stepwise procedure:
l The original 40 case reports (case reports of raw clinical data from an observational study) initially
assessed using the Naranjo scale were assessed by each of the seven investigators using the new CAT
to compare the outcomes of the methods and the IRR between the two tools.
l In order to examine the tool using cases other than those collected in our observational study, 37 cases
of ADRs were randomly selected from the Annals of Pharmacotherapy and independently evaluated by
the seven assessors using only the new tool.
l As the original 40 cases from our observational study had been used in the design of the new tool,
a further new set of 40 ADR case reports from our study was then used to assess IRR using both the
Naranjo scale and the LCAT.75
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TABLE 29 Decisions made about questions within the Naranjo scale
No. Naranjo scale questions Yes No Do not know Outcome for LCAT
Q1 Are there previous conclusive
reports on this reaction?
+1 0 0 Retained Knowledge of previous reports
can be important when assessing if an
AE is due to drug or disease
Q2 Did the AE appear after the
suspected drug was administered?
+2 –1 0 Modified Timing of event in relation to
drug exposure is important when
determining causality
Q3 Did the adverse reaction improve
when the drug was discontinued or
a specific antagonist was
administered?
+1 0 0 Modified Knowledge of de-challenge, if
available, may provide further evidence
as to causality of an event. However, an
event may have long-lasting sequelae.
A new question was added to the
Liverpool tool to cover this possibility
Q4 Did the adverse reaction reappear
after the drug was re-
administered?
+2 –1 0 Combined Knowledge of rechallenge, if
available, may add to the level of
certainty regarding causality assessment.
This question is combined with Naranjo
Q8 regarding dose–response relationship
to increasing dose. This can also provide
evidence to support or refute causality
Q5 Are there alternative causes (other
than the drug) that could on their
own have caused the reaction?
–1 +2 0 Modified This question is replaced
within the Liverpool tool by a question
involving likelihood of alternative cause,
with an option to answer ‘unsure’
(which prompts the user to seek further
evidence of the reaction). Naranjo Q5 is
worded such that it is difﬁcult to
answer ‘no’
Q6 Did the reaction reappear when a
placebo was given?
–1 +1 0 Rejected With the exception of clinical
trials, placebo use is not common
practice and this question is no longer
relevant
Q7 Was the drug detected in the
blood (or other ﬂuids) in
concentrations known to be toxic?
+1 0 0 Modified Objective evidence of the ADR
occurrence will already be taken in to
account when the user is deciding
whether the event is likely to be drug or
disease related. A question in the
Liverpool tool asks for objective evidence
of likely ADR mechanism. If apparent,
this may provide evidence of causality to
an assessor
Q8 Was the reaction more severe
when the dose was increased, or
less severe when the dose was
decreased?
+1 0 0 Combined This question is combined
with one addressing de-challenge in the
Liverpool tool. The answer to this
question may be important in
establishing if there is a dose–response
relationship between drug and AE
Q9 Did the patient have a similar
reaction to the same or similar
drugs in any previous exposure?
+1 0 0 Modified This is included in the
Liverpool algorithm, in relation to the
same drug(s) only, and given the same
weighting as a positive rechallenge. This
may provide evidence of susceptibility,
and likelihood, of the event being
related to a drug
Q10 Was the AE conﬁrmed by any
objective evidence?
+1 0 0 Modified See Q7
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•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Assess 40 ADRIC study 1 cases (Naranjo)
Develop new tool
Assess 20 new ADRIC 1 cases (new tool v1)
Modify tool
Assess 10 new ADRIC 1 cases and 10 adult cases 
(new tool v2)
Modify tool
Retest tool on original 40 ADRIC 1 cases 
(new tool v3)
Validation of Liverpool Causality Assessment 
Tool on new cases
Moderate agreement
Inappropriate bias to possible and probable
Questions within Naranjo reviewed
Consensus opinion to use flow chart
Moderate agreement
Inappropriate skew to definite causality
Consensus meeting to determine changes to be made
Fair agreement for ADRIC cases
Poor agreement for adult cases
Consensus meeting to determine changes to be made
Investigators satisfied with version 3 to retest against Naranjo
Moderate kappa
Appropriate spread of causality categories
Assess 40 new ADRIC 1 cases using Liverpool and Naranjo tools
Assess published case reports
FIGURE 11 Flow chart of the development of the Liverpool ADR Causality Assessment Tool.
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Do you suspect
an adverse
drug reaction?
Yes
No
Yes
No
No
No
Yes
No
No
Did the event appear
after the drug was
administered
or dose increased?
Did the event improve
(± treatment) when
the drug was stopped
or dose reduced?
What is the probability
that the event was
due to an underlying
disease?
Was there a positive
rechallenge?
Definite Probable
Possible
Unlikely
Is there a past history
of the same event
with this drug in
this patient?
Is there any objective 
evidence supportive of 
the causal ADR
mechanism?b
Was the event
associated with
long-lasting disability
or impairment? 
Were pre-existing
symptoms exacerbated
by the drug?
Has the event previously
been reported with
this drug?
No
Yes
Yes
Yes
Yes or
unassessablea
Low
Yes
No
Yes
No
High or
unsure
FIGURE 12 Liverpool Causality Assessment Tool (LCAT). a, unassessable refers to situations where the medicine is
administered on one occasion (e.g. vaccine), the patient receives intermittent therapy (e.g. chemotherapy), or is on
medication which cannot be stopped (e.g. immunosuppressant drugs); and b, examples of objective evidence:
positive laboratory investigations of the causal ADR mechanism (not those merely confirming the adverse reaction),
supratherapeutic drug levels and good evidence of a dose-dependent relationship with toxicity in the patient. An
independent panel with extensive expertise in pharmacovigilance and statistics (the ADRIC Steering Group) was
asked to review the tool upon completion of the internal evaluation.
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78Analysis
The inter-rater agreements at each stage of the assessment process were assessed using a linear weighted
kappa with 95% CI for ordered categories. Exact agreement percentages (%EA) were computed to
measure the absolute concordances between assessor scores. Percentage of extreme disagreement (%ED),
where the causality scores between two raters of the same case are wider than one causality interval apart
(e.g. deﬁnite for one rater and possible for the other), were also computed to measure extreme
disagreements between pairwise rater assessments. To supplement the pairwise kappa scores, a global
kappa score measuring nominal scale agreement across multiple assessors was calculated with 95% CI.201
The global kappa score provides a single statistic to quantify assessor agreement for each set of cases.
Kappa values were interpreted according to the guidance from Altman:202 poor agreement < 0.2;
fair 0.21–0.40; moderate 0.41–0.60; good 0.61–0.80; and very good 0.81–1.00.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3ResultsAssessment of the original 40 consecutive ADR cases by the seven investigators using the Naranjo scale
showed collated categorisation of causality scores for all assessors (n = 280 assessments) of 0 (0%)
unlikely, 100 (36%) possible, 172 (61%) probable and 8 (3%) deﬁnite (Table 30). %EA for the pairwise
comparisons between raters ranged from 43% to 93%. The %ED was 2.5% for four of the 21 pairwise
comparisons. There were no extreme disagreements in 17 out of 21 pairwise comparisons. Pairwise kappa
scores ranged from 0.27 to 0.86 and the assessors achieved moderate IRR with a global kappa score of
0.45 (95% CI 0.35 to 0.54) (Table 31). The same cases assessed using the new LCAT showed collated
causality categories of 1 (0.4%) unlikely, 62 (22%) possible, 92 (33%) probable and 125 (45%) deﬁnite.
%EA ranged from 43% to 93%. All 21 pairwise comparisons displayed with %ED ranging from 5–20%.
Pairwise kappa scores ranged from 0.27 to 0.84, and the assessors achieved moderate IRR with a global
kappa score of 0.48 (95% CI 0.42 to 0.54) (see Table 31).TABLE 30 Causality category assignments of investigators for the original 40 cases assessed using the Naranjo tool
and the LCAT
Assessor Tool
ADRIC original (N = 40)
Unlikely: n (%) Possible: n (%) Probable: n (%) Deﬁnite: n (%)
RG Naranjo 0 (0.0) 18 (45.0) 22 (55.0) 0 (0.0)
Liverpool 0 (0.0) 7 (17.5) 23 (57.5) 10 (25.0)
JB Naranjo 0 (0.0) 17 (42.5) 22 (55.0) 1 (2.5)
Liverpool 0 (0.0) 15 (37.5) 8 (20.0) 17 (42.5)
KB Naranjo 0 (0.0) 18 (45.0) 21 (52.5) 1 (2.5)
Liverpool 0 (0.0) 18 (45.0) 4 (10.0) 18 (45.0)
MT Naranjo 0 (0.0) 14 (35.0) 24 (60.0) 2 (5.0)
Liverpool 1 (2.5) 5 (12.5) 17 (42.5) 17 (42.5)
TN Naranjo 0 (0.0) 10 (25.0) 29 (72.5) 1 (2.5)
Liverpool 0 (0.0) 3 (7.5) 15 (37.5) 22 (55.0)
MPir Naranjo 0 (0.0) 12 (30.0) 27 (67.5) 1 (2.5)
Liverpool 0 (0.0) 7 (17.5) 12 (30.0) 21 (52.5)
RS Naranjo 0 (0.0) 11 (27.5) 27 (67.5) 2 (5.0)
Liverpool 0 (0.0) 7 (17.5) 13 (32.5) 20 (50.0)
Totals Naranjo 0 (0.0) 100 (35.7) 172 (61.4) 8 (2.9)
Liverpool 1 (0.36) 62 (22.1) 92 (32.9) 125 (44.6)
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DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3The 37 randomly selected ADR case reports from the Annals of Pharmacotherapy assessed by the seven
investigators using the LCAT showed collated categorisation of causality scores (n = 259 assessments) of
1 (0.4%) unlikely, 67 (26%) possible, 136 (53%) probable and 55 (21%) deﬁnite (Table 32). %EA ranged
from 57% to 97%. Pairwise comparisons between raters showed some extreme disagreement (18/21),
with the %ED ranging from 5% to 11%, whereas three showed no extreme disagreements. Pairwise
kappa scores ranged from 0.31 to 0.96 and the assessors achieved moderate IRR with a global kappa of
0.43 (95% CI 0.34 to 0.51) (Table 33).
These case reports were not assessed by the investigators using the Naranjo scale. The Annals of
Pharmacotherapy require authors to apply a Naranjo assessment prior to publication of each case report in
the journal. The collated categorisation of the case report author assessments for the 37 cases showed 0
unlikely, 5 (14%) possible, 29 (78%) probable and 3 (8%) deﬁnite (see Table 32).
The 40 newly selected ADR cases assessed by the seven investigators using the Naranjo scale showed
collated categorisation of causality scores (n = 280 assessments) of 1 (0.4%) unlikely, 90 (32%) possible,
185 (66%) probable and 4 (1%) deﬁnite (Table 34). %EA ranged from 63% to 90%. %ED was 2.5% for
four pairwise comparisons. There were no extreme disagreements in 17 out of 21 comparisons. The
pairwise kappa scores ranged from 0.19 to 0.81, with moderate IRR and a global kappa score of 0.44
(95% CI 0.33 to 0.55) (Table 35). The same cases assessed using the LCAT showed collated causality
categories of 0 (0%) unlikely, 66 (24%) possible, 81 (29%) probable and 133 (48%) deﬁnite. %EA ranged
from 65% to 88%. %ED ranged from 2.5% to 7.5% for 14 pairwise comparisons. There were no
extreme disagreements in 7 out of 21 comparisons. Pairwise kappa scores ranged from 0.51 to 0.85 and
the assessors achieved good IRR with a global kappa of 0.60 (95% CI 0.54 to 0.67) (see Table 35).TABLE 32 Causality category assignments of investigators for the 37 case reports published by the Annals of
Pharmacotherapy
Assessor Tool
Annals of Pharmacotherapy (N = 37)
Unlikely: n (%) Possible: n (%) Probable: n (%) Deﬁnite: n (%)
RG Liverpool 0 (0.0) 11 (29.7) 18 (48.7) 8 (21.6)
JB Liverpool 0 (0.0) 11 (29.7) 20 (54.1) 6 (16.2)
KB Liverpool 0 (0.0) 12 (32.4) 19 (51.4) 6 (16.2)
MT Liverpool 0 (0.0) 10 (27.0) 18 (48.7) 9 (24.3)
TN Liverpool 1 (2.7) 10 (27.0) 20 (54.1) 6 (16.2)
MPir Liverpool 0 (0.0) 10 (27.0) 17 (46.0) 10 (27.0)
RS Liverpool 0 (0.0) 3 (8.1) 24 (64.9) 10 (27.0)
Totals Naranjo 0a (0) 5a (13.5) 29a (78.4) 3a (8.1)
Liverpool 1 (0.39) 67 (25.9) 136 (52.5) 55 (21.2)
a Authors of case reports in Annals of Pharmacotherapy completed a Naranjo causality assessment.81
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TABLE 34 Causality category assignments of investigators for the 40 new ADR cases assessed using the Naranjo tool
and the LCAT
Assessor Tool
ADRIC new (N = 40)
Unlikely: n (%) Possible: n (%) Probable: n (%) Deﬁnite: n (%)
RG Naranjo 0 (0.0) 18 (45.0) 21 (52.5) 1 (2.5)
Liverpool 0 (0.0) 11 (27.5) 12 (30.0) 17 (42.5)
JB Naranjo 0 (0.0) 19 (47.5) 21 (52.5) 0 (0.0)
Liverpool 0 (0.0) 14 (35.0) 8 (20.0) 18 (45.0)
KB Naranjo 0 (0.0) 15 (37.5) 25 (62.5) 0 (0.0)
Liverpool 0 (0.0) 13 (32.5) 10 (25.0) 17 (42.5)
MT Naranjo 1 (2.5) 9 (22.5) 27 (67.5) 3 (7.5)
Liverpool 0 (0.0) 8 (20.0) 9 (22.5) 23 (57.5)
TN Naranjo 0 (0.0) 13 (32.5) 27 (67.5) 0 (0.0)
Liverpool 0 (0.0) 8 (20.0) 12 (30.0) 20 (50.0)
MPir Naranjo 0 (0.0) 12 (30.0) 28 (70.0) 0 (0.0)
Liverpool 0 (0.0) 9 (22.5) 13 (32.5) 18 (45.0)
RS Naranjo 0 (0.0) 4 (10.0) 36 (90.0) 0 (0.0)
Liverpool 0 (0.0) 3 (7.5) 17 (42.5) 20 (50.0)
Totals Naranjo 1 (0.36) 90 (32.1) 185 (66.1) 4 (1.4)
Liverpool 0 (0.0) 66 (23.6) 81 (28.9) 133 (47.5)
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3
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DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3DiscussionA recent systematic review of studies assessing the reliability of causality assessments concluded that ‘no
causality assessment method has shown consistent and reproducible measure of causality’.188 In order to
do this, we planned to have assessments conducted independently by seven assessors. Initial assessments
revealed some signiﬁcant issues with the Naranjo scale, which led us to develop the LCAT.
In assessing the original 40 possible ADR cases with the Naranjo tool, several difﬁculties were found with
some of the questions in the tool. Some of the questions were frequently, or always, answered as
‘unknown’. There were two questions that caused discrepancies between raters in eight cases when
scoring with the Naranjo tool. The ﬁrst question that caused difﬁculty was question 5 (see Table 30) [‘Are
there alternative causes (other than the drug) that could on their own have caused the reaction?’].
Individual raters interpreted this question in two different ways: some raters took a literal approach and
interpreted the question to mean any ‘alternative cause’, almost always answering with a ‘yes’, whereas
other raters took a more practical approach and interpreted the question as ‘Was there an alternative
plausible cause?’, and, in doing so, these raters gave variable answers to the question. Question 10 (‘Was
the AE conﬁrmed by any objective evidence?’) was the second that caused discrepancies in Naranjo
scoring. This caused problems for assessors in two very different ways: ﬁrst, assessors had difﬁculty in
deciding, on an individual case basis, what constitutes objective evidence and, second, assessors had
difﬁculty deﬁning whether the objective evidence related to evidence that the ADR had occurred or
evidence of the mechanism. For example, a patient taking an opioid for analgesia might develop
abdominal pain secondary to constipation and need admission to hospital for treatment and symptom
control. In this case, raters may differ in their interpretation regarding question 5 and whether or not there
may be alternative causes to explain the constipation (some of this may have to with the level of detail in
the case report). Raters may also have difﬁculty in answering question 10. Some raters may suggest that a
physical examination of a palpable faecal mass constitutes objective evidence, whereas others may suggest
that it is not objective and might argue that an abdominal radiograph showing faecal loading is more
objective. Others might use either of these two ﬁndings to aid in their assessment of ‘alternative causes’.
If so, these raters might score question 5 in a positive manner because of the available evidence and then
score question 10 positively because of the evidence, in effect scoring positively for the same information
twice. It seems counterintuitive to take account of positive evidence and score it twice when assessing a
possible ADR report. Even so, there were still very few discrepancies between the scores overall with most
assessments resulting in a ‘possible’ or ‘probable’ causality being assigned.
We designed a new method, the LCAT, using an algorithm in the form of a ﬂow chart. This new tool was
assessed to have face validity by a multidisciplinary investigating group. Seven assessors used both the
LCAT and Naranjo tool to initially assess 40 possible ADR cases from the large observational study. The
LCAT performed just as well as Naranjo in terms of IRR but gave a broader range of causality outcomes,
which was deemed more appropriate by the investigating group. When the seven investigators assessed a
second different set of 40 cases the LCAT outperformed Naranjo, showing a ‘good’ IRR.
We believe that the LCAT has several advantages over the Naranjo scale. First, it performed as well as the
Naranjo scale with the ﬁrst set of cases that were assessed. More importantly, the IRR improved over time
with the new tool, whereas the IRR when using Naranjo remained similar, despite the fact that there was
as much exposure to this tool within the assessing group. The improved IRR with the new tool may be
explained by increasing experience of its use. The proportion of exact agreements between assessors was
similar between the two tools for both sets of cases despite the improvement in the global kappa score for
the new tool. This is because it is difﬁcult to achieve a ‘deﬁnite’ category using the Naranjo scale, and
assessors mainly scored cases as ‘possible’ or ‘probable’. Therefore, the chances of exact agreement
between two assessors of the same case using the Naranjo scale are likely to be falsely elevated compared
with the kappa scores that adjust for chance agreement. This paradox has been discussed previously in the
literature.203–205 The percentage of extreme disagreement between raters was higher for the LCAT than the
Naranjo tool. Owing to the difﬁculty in achieving a ‘deﬁnite’ score with the Naranjo tool, the chances of85
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86ﬁnding extreme disagreement, when comparing pairwise assessments, is likely to be falsely low. The
observed %ED decreased when using the LCAT, from the ﬁrst set of 40 cases to the last set. This may also
be explained by increasing experience of its use. The implication of this explanation would be that there is
a learning curve associated with using the LCAT. An e-learning package is under evaluation.
Second, the IRR on assessing published case reports with the new tool was similar to that when we
assessed our observational study cases with the Naranjo scale. Five of the seven assessors work in
paediatric practice and the published case reports were adult cases. This perhaps provides an indication,
albeit indirectly, of the robustness of the tool, even when used for cases from unfamiliar clinical settings.
Third, in the Naranjo scale, almost all cases were categorised as possible or probable. With the new tool,
the range of categorisations was broader with some cases judged as being deﬁnite. A novel aspect of the
tool which makes this possible is that prior exposure that led to the same ADR, for example during a
previous course of chemotherapy, was judged as being equivalent to a prospective rechallenge. It is also
important to note that the cases were extracted from an observational study of suspected ADRs in
children, and thus some case selection had occurred, making it improbable to record a score of ‘unlikely’
when assessing with either tool.
Fourth, a ﬂow diagram rather than scoring system was used in the new CAT and was felt by assessors to
be easy to follow and quick to complete. We used a classiﬁcation approach based on binary decisions
(taking account of ‘don’t know’ responses). In this case we need to ensure that the binary decisions are
robust. Once this has been done then the instrument should be relatively context independent. A
weighted scoring system, such as the Naranjo scale, will give more inﬂuence to some variables than others.
A weighting scheme involves the validation of the items in the tool and the weightings. Ideally, the
weightings need to be developed and validated in a context that is similar to the context in which it is
applied. Thus a weighting scheme is more likely to be sensitive and speciﬁc within a deﬁned context (as
long as you have a gold standard) but is more likely to be context dependent. We feel it is more important
to develop a tool that is context independent, as we need to compare different settings when assessing
causality of ADRs.
In summary, we present a new CAT, developed by a MDT, which we believe to be at least equivalent to, if
not better than, the Naranjo scale. We believe the new tool to be practicable and likely to be acceptable
for use by health-care staff in assessing ADRs. We have undertaken an extensive validation of the tool,
with a total of 819 causality assessments by seven investigators, using investigators within ADRIC.
Although this validation is equivalent to, if not better than, that undertaken for many other tools,23,206,207
one limitation is that the increase in IRR for the second set of 40 case reports using the new tool remains
unexplained. A second limitation is that the study has been undertaken internally and not yet assessed
independently by other investigators.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3Chapter 6 Development of the Liverpool Adverse
Drug Reaction Avoidability ToolAbstract
Background
A recent systematic review of ADRs in children19 highlighted that few studies performed an avoidability
assessment (19/102). There was wide variation in the results with rates ranging from 7% to 98% of ADRs
being classed as either possibly or deﬁnitely avoidable.19 There is currently no standardised method for
determining avoidability and many of the established tools are not suitable for use in paediatrics. We have
used an adapted version of the Hallas scale54 as a basis for the development of a new AAT.Objectives1. To develop and test a new AAT that is more suitable for use in paediatrics but which is also
generalisable and applicable to a variety of other settings.
2. To compare individual to group assessments of avoidability.Setting
A large children’s hospital providing a local and also specialist regional and national services: Alder Hey.Main outcome measures
Inter-rater reliability, measure of disagreement, utilisation of avoidability categories.Methods
The study involved multiple phases. Phase 1 consisted of three parts (deﬁning the tool, modifying the tool
and reﬁning the tool), all of which involved a MDT approach. Phase 2 involved the independent
assessment of 50 ADR cases from the ADRIC inpatient study by six reviewers and a comparison of the
results. Phase 3 will involve consensus meetings and group testing.Results
Phase 1 The assessment of 20 ADR cases was undertaken by two different MDT groups. Group members
commented that a mixture of professions was needed to give a full assessment of avoidability. Changes to
the tool were made as a result of the ﬁndings with two of the questions being amended to include
‘known preventative strategies’.
Phase 2 The assessment of 50 ADR case reports by six individual reviewers, where pairwise kappa scores
ranged from poor to good. Stronger agreement was found within professions than between professions.Discussion
To date, the ADRIC avoidability work stream has deﬁned a tool to assess avoidability of suspected ADRs.
We have conducted preliminary testing. Following the completion of phase 2, further discussion of the
tool and methodology suggested that additional testing was needed and that this should be carried out in
a group setting using consensus methods.Conclusion
Avoidability assessment is feasible but needs careful attention to methods. Further testing in a group
setting is required to develop and validate the tool. The next step in the development process will be to
investigate how to optimise group assessment.87
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88IntroductionPreventability, or avoidability as it is sometimes referred to, is an important concept in the study of ADRs.25
Preventing avoidable harm due to ADRs is a prime clinical motivation for studying drug safety. According
to the WHO, ADRs rank among the top 10 leading causes of mortality in some countries. ADRs are
common yet often preventable.208 Patient and medication safety is high on the agenda of the EMA,209 the
Council of Europe210 and the WHO.208 The WHO has identiﬁed some key areas including measuring harm,
understanding causes, identifying solutions, evaluating impact and translating evidence into safer care.
Hakkarainen et al.211 conducted a meta-analysis of preventable ADR studies and they concluded that
preventable ADRs are a signiﬁcant burden to the health-care system and a cause of morbidity among
outpatients, and that roughly half of all ADRs in adults both inpatients (45%) and outpatients (52%) may
be preventable.
The importance of examining avoidability of ADRs became clear from two sources: the ADRIC systematic
review indicated the few previous studies that had examined avoidability and those that had used
inconsistent methods;19 difﬁculties were encountered during the assessment of avoidability using existing
tools (see Chapter 3).
The study of avoidability is complex. A key factor causing this complexity is that there is no universally
accepted deﬁnition for preventability.25 Ferner and Aronson25 stated that there are two aspects to
preventability: whether or not in principle an event is preventable, in the absence of error and, if it is,
whether or not we can, in fact, prevent it. They gave the example of penicillin hypersensitivity reactions,
which, in principle, can be avoided in patients who are known to be susceptible, by not giving the drug;
however, in practice these reactions can still occur owing to lack of information available to the prescriber.25
They also stated that harm is never absolutely preventable, but any intervention that reduces the probability
of harm can be said to have made a contribution to prevention.25 Ferner and Aronson25 concluded in their
systematic review that several deﬁnitions exist and none ﬁts all circumstances. In a follow-up paper, they
outlined a novel method for determining preventability.212 This novel method involves classifying ADRs by
mechanism and clinical manifestation to inform judgement about theoretical preventability.212 According to
Ferner and Aronson,25 complete analysis requires consideration of pharmacodynamic and pharmacokinetic
mechanisms of the ADR, its time course, its dose-responsiveness and individual susceptibility factors.212
Despite the importance of avoiding ADRs, this area remains under-researched. This may be attributable to
the methodological problems in the area, which Hakkarainen et al.26 have summarised in a systematic
review on methods for assessing the preventability of ADEs.26 They listed inconsistent terminology as one
of the problems; there is wide variation in the terms and deﬁnitions used (ADRs, ADEs, etc.) and this
hinders the interpretation and comparison of studies.26 In their review they used the term ADE, which
included ADRs and other AEs related to medications. The deﬁnition of an ADR used in this study is that of
Edwards and Aronson:49 ‘an appreciably harmful or unpleasant reaction, resulting from an intervention
related to the use of a medicinal product, which predicts hazard from future administration and warrants
prevention or speciﬁc treatment, or alteration of the dosage regimen or withdrawal of the product’.
The need for developing a new AAT arose during the ADRIC inpatient study when we tried to use the
Hallas scale54 to determine avoidability but had difﬁculties with some of the language used particularly
‘present-day knowledge of good medical practice’ and that the event could have been avoided by ‘an
effort exceeding obligatory demands’. In the ADRIC admissions study Gallagher et al.21 used the Hallas
scale54 to determine avoidability and found that 78% of ADRs were unavoidable, and 22% were either
possibly or deﬁnitely avoidable. Gallagher et al.21 suggested some potential prevention strategies for ADRs
based on their assessment of the ADRs they classed as ‘deﬁnitely avoidable’ – that more careful attention
to practical aspects of care, such as improved monitoring, following prescribing guidelines and improved
patient education, could lead to a reduction in the frequency of ADRs causing admission.21 The Hallas
scale54 was used for the ADRIC admissions study but appeared unsuitable for the ADRIC inpatient study
owing to difﬁculties mentioned before around the terminology used. As a result of this it was decided byNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3the study group that we would design a new AAT that would be more suitable for use in paediatrics but
could also be used in other settings. Ideally, the newly developed AAT should be generalisable to a variety
of different patient groups, reproducible and easy to use.Aim and objectives of this work
The aim of the ADRIC avoidability work stream was to assess the avoidability of ADRs reported in ADRIC
and to identify strategies for clinical practice that might reduce the incidence of ADRs. A preliminary step
was to develop a new avoidability tool that met all of the criteria of a good tool as described by
Hakkarainen et al.26 and was also generalisable. The objectives were to develop an algorithm with
dichotomous responses based on Hallas et al.54 and to conduct reliability/validity testing on the new tool as
per Hakkarainen et al.26 recommendations.Methods
Preliminary work
A modiﬁed version of the Hallas scale54 was used as the starting point for the development of a new AAT
but the focus was on the available information sources. We wanted to ascertain if the relevant information
was available in sources that prescribers would be expected to use, and, if so, whether the recommended
advice was followed. The intention was to keep the tool as generalisable as possible by asking if accessible
management or treatment plans were available. These could be local, national or international. We
recommended that only high-quality guidelines were considered, for example Scottish Intercollegiate
Guidelines Network (SIGN), the National Institute for Health and Care Excellence (NICE), Royal College of
Paediatrics and Child Health (RCPCH) or other peer-reviewed guidelines.213 Because guidelines are not
always available, or contain no information on prevention of ADRs, we added other information sources,
for example BNF-C, SmPC (see Appendix 4).
A pilot study was carried out in November 2011, when three reviewers independently assessed 50 cases
using a modiﬁed version of the Hallas scale and 50 cases using the original Hallas scale.54 The results
were compared and IRR testing was carried out on both groups. The kappa scores for both groups were
low – the modiﬁed Hallas54 group scores were poor and it was decided that the AAT should be converted
to a ﬂow diagram in an attempt to make it easier and more consistent to use. It was also decided that
some questions needed reviewing and that this should be done by a consensus approach.25 We achieved
consensus by agreement among peers without pre-set criteria and the consensus group was a MDT
(research nurse, doctor and pharmacist).Phase 1a: define the tool
It was agreed that the best way to develop a new tool was to take a consensus approach in reviewing
cases. The format of the new tool was a ﬂow diagram, with dichotomous responses to each question
followed by a routing to the next relevant question; it was decided this would differ from the speciﬁc
criteria Hallas54 has for each avoidability category. Initially, 20 cases were reviewed to deﬁne the tool. This
was carried out by a MDT [MAT, AJN and HLM (LEB as an observer)] working together to discuss clinical
practice and avoidability outcome. Each question in the newly modiﬁed avoidability ﬂow diagram was
reviewed by the investigators during the consensus meetings and any necessary changes were made. Any
cases that were classiﬁed as ‘unassessable’ had the rationale recorded as either lack of information about
the case or of available guidance. The MDT initially looked at 20 cases (randomly selected) from the ADRIC
inpatient study and carried out an avoidability assessment. It was felt that it was not appropriate to
distinguish between guidelines, and, for the purpose of ADRIC inpatient study cases, we accepted
any available guidance based on an acceptable body of opinion, for example SIGN, Alder Hey guidance
or NICE guidance. A glossary was prepared to further explain this and other terms. Any areas of
disagreement or discrepancies were reviewed by MPir, who also reviewed the iterations as they
moved through the various stages of development.89
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90Phase 1b: modify the tool
The ﬂow diagram was modiﬁed using 20 randomly selected cases from the ADRIC inpatient study, with
rephrasing of questions and adding information. Consensus of opinion was reached and this version of the
tool (Figure 13) was carried forward to the next phase.Phase 1c: refine the tool
Two MDT groups (the original plus a new group: nurse, pharmacist and paediatrician) reached consensus
about a second set of 20 cases from the ADRIC inpatient study, which were a randomly selected stratiﬁed
sample (probable and deﬁnite cases: 11 surgical, 4 oncology, 2 medical and 3 cardiology). Both groups
reviewed the same 20 cases. The results were compared, kappa scores were calculated and the
concordance of routes and the ﬁnal avoidability categories were assigned. Both MDT meetings were
observed with assumptions and approaches of the teams recorded. Changes to the tool were made as a
result of the ﬁndings with two of the questions being amended to include ‘known preventative strategies’.Were other information
sources or information
in the history available
for prevention of the
ADR which could have
been  followed?
Was there a known history
of allergy or previous similar
reaction to the drug?
Is there sufficient
information available
about the case and the
treatment to allow 
assessment?
Was the reaction
predictable on the basis of
the known pharmacology
of the drug(s)?
Was there an appropriate
treatment or management
plan, with information
about the ADR and its
avoidance, available?
Was the drug(s) used in
accordance with the 
treatment or
management plan?
Was
appropriate
action taken to
avoid the ADR?
Unassessable
Not
avoidable
Possibly
avoidable
Definitely
avoidable
Yes
Yes
Yes
No
No
Yes
No
No
No
No
Yes
NoYes
Yes
FIGURE 13 Version of the AAT used in phase 1c.
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The reﬁned tool (Figure 14) was then tested on a further set of ADRIC inpatient study cases with the aim
being to improve IRR. This phase involved the assessment of a further 50 cases by six individual reviewers
using the newly reﬁned tool. See the accompanying glossary and guide (see Appendix 4) to the questions
in the tool for further details on completing an avoidability assessment. These 50 cases were a stratiﬁed
sample (possible, probable and deﬁnite cases: 26 surgical, nine oncology, nine medical and six cardiology).
The reviewers included two nurses, two pharmacists and two doctors. These cases were assessed in terms
of pairwise agreements between the investigators. Cases where extreme disagreement occurred, i.e.
where the avoidability assessment differed by more than one category, for example ‘not avoidable’ and
‘deﬁnitely avoidable’, and any cases for which half of the raters differed in assigning a category were
identiﬁed and the questions that caused the discrepancies were reviewed.
The results were presented as categorical scores from the newly developed tool and inter-rater agreements
were calculated using kappa scores with 95% CI, and pairwise kappa scores were compared with global
kappa scores. The %ED where the avoidability scores between two raters of the same case are wider than
one interval apart were calculated to measure extreme disagreement between pairwise kappa scores.
Pairwise kappa scores were also calculated by specialty to investigate the differences between surgical,
medical, oncology and cardiology cases.Phase 3: consensus meetings and individual testing
The next step in the development process (Figure 15) will be to investigate if group avoidability
assessments are superior to individual avoidability assessments.
Following the completion of phase 2, it was decided that further testing was needed and that perhaps the
best way to assess avoidability is in a group setting. Agreement in phase 2 ranged from poor to good;
possible reasons for this may be due to lack of experience in certain specialty areas or a possible training
effect. The next step in the development process will be to carry out group assessments of additional cases
and compare these with assessments made by individual reviewers. This further testing in a group setting
is required to develop and validate the tool.Were other information
sources or information
in the history available
for prevention of the
ADR which could have
been  followed?
Was there a known history
of allergy or previous similar
reaction to the drug?
Is there sufficient
information available
about the case and the
treatment to allow 
assessment?
Was the reaction
predictable on the basis of
the known pharmacology
of the drug(s)?
Was there known
preventive strategies
and/or appropriate
management plan(s),
with information about
ADR avoidance available?
Were the strategies
and/or management
plan(s) followed?
Was
appropriate
action taken to
avoid the ADR?
Unassessable
Not
avoidable
Possibly
avoidable
Definitely
avoidable
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Yes
No
No
No
No
Yes
NoYes
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FIGURE 14 The Liverpool ADR Avoidability Assessment Tool.
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IGURE 15 The development process.
DEVELOPMENT OF THE LIVERPOOL ADVERSE DRUG REACTION AVOIDABILITY TOOLF92ResultsPhase 1 The assessment of 20 ADR cases was undertaken by two different MDT groups. Group members
commented that a mixture of professions was needed to give a full assessment of avoidability. Changes to
the tool were made as a result of the ﬁndings, with two of the questions being amended to include
‘known preventative strategies’.
Phase 2 The assessment of 50 ADR case reports by six individual reviewers, where pairwise kappa scores
ranged from poor to good. Stronger agreement was found within professions than between professions.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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We have conducted preliminary testing. The tool has face validity and is easy to use. However, a number
of issues were raised. These include the dependence on guidelines and variations in clinical practice. It may
not be possible to deﬁne a generalisable tool. It may be possible to deﬁne a tool that individuals can use
consistently. However, the tool in itself may not be sufﬁcient to develop consistent results between
individuals or across settings. Consistent results may require a standard body of guidelines, or gold
standards for acceptable care. Consistent results may require clinical experience relevant to the suspected
ADR. Nevertheless, the tool may provide useful insights within an individual setting. The next step in the
development process will be to investigate if group assessment improves agreement and reliability.
There have been many attempts to devise tools or scales to help determine avoidability. Commonly used
scales include Hallas et al.,54 Schumock and Thornton,44 Dormann et al.,214 Ducharme et al.215 and
Olivier et al.216 The Ferner and Aronson25 systematic review identiﬁed eight different approaches to
assessing avoidability. They suggested an approach to preventability based on analysis of the mechanisms
of ADRs and their clinical manifestations.25,212 Hakkarainen et al.26 identiﬁed 18 unique instruments for
assessing preventability of ADEs, which ranged from implicit instruments to explicit algorithms in which
criteria for preventability were clearly expressed.26 They also reported that although there was wide
variation in the methods used they all shared a common theme; the basis for deﬁning preventability was
whether an error or substandard care had resulted in an ADE.26
Hakkarainen et al.26 have made some useful suggestions for future research. They recommend that future
studies include reliability and validity testing; take action to standardise the measurement process; provide
information on the assessors in terms of training and experience in assessing preventability; and describe
how the assessments took place (i.e. whether cases were assessed independently or via consensus and
how any disagreement is dealt with). They also stated that owing to the limitations and diversity of
assessments it remains unknown if variation in preventability rates in different settings and populations is
due to the methodology used or actual differences in preventability rates.26 They suggested that there is a
need for modifying previous instruments or developing new ones for use in different settings, and that a
starting point for developing a new instrument could be to begin with a clear deﬁnition for the
preventability of different types of ADEs.26 They also recommended that any newly developed instruments
should be compared with existing ones and that if one or more instrument gained rigorous evidence and
became a gold standard it would facilitate comparisons of different studies.Future work in adverse drug reactions in childrenl The assessment of ADRIC admissions study cases using the newly developed avoidability tool,
comparing the results with the Hallas (14) assessments carried out in Chapter 2.
l Identifying reasons for avoidable ADRs.
l Using suggestions about possible strategies to avoid ADRs from ADRIC to see if there are generalisable
steps to take that will promote avoidability.ConclusionsAvoidability assessment is feasible but needs careful attention to methods. The Liverpool ADR AAT showed
mixed IRR in the individual assessment phase; therefore, further testing in a group setting is required to
develop and validate the tool.93
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adverse drug reactions: implications for
communication and pharmacovigilance
This chapter contains information reproduced from Arnott J, Hesselgreaves H, Nunn AJ, Peak M,Pirmohamed M, Smyth RL, et al. Enhancing communication about paediatric medicines: lessons from a
qualitative study of parents’ experiences of their child’s suspected adverse drug reaction. PLOS ONE
2012;7:e46022,29 © Arnott et al., an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution and reproduction in any
medium, provided that the original author and source are credited; and information reproduced with
permission from Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M, Smyth RL, et al. What can
we learn from parents about enhancing participation in pharmacovigilance? Br J Clin Pharmacol
2012;75:1109–17,96 with permission from the British Pharmacological Society and Blackwell Publishing.Abstract
Background
There is little research on families’ experiences of suspected ADRs in children and little evidence to guide
clinicians when communicating with families about problems with medicines.Aims
To identify any unmet information and communication needs described by families following a suspected
ADR in a child.Methods
Semistructured qualitative interviews with 20 children and young people and the parents of 44 children
and young people who had experienced a suspected ADR. Interviews were conducted face to face or by
telephone; most were audio recorded and transcribed. Analysis was informed by the principles of the
constant comparative method.Results
Many parents described being dissatisﬁed with clinicians’ communication about ADRs. In contrast, the
accounts of parents of children with cancer emphasised conﬁdence in clinicians’ management of ADRs and
the way clinicians communicated about medicines. The accounts of children and young people largely
reﬂected parents’ accounts. Families were positive about the Yellow Card Scheme and felt that recording
and reporting ADRs was important. Parents, children and young people linked symptoms to medicines
using a similar reasoning as clinicians use to evaluate the possibility of an ADR.Conclusions
Most parents felt that clinicians’ communication about ADRs was poor, suggesting that improvements are
needed. The accounts of parents of children with cancer indicate that prospective explanation about ADRs
can be effective. Convergence between parents and clinicians in their reasoning for linking children’s
symptoms to medicines could be a starting point for improved communication.95
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FAMILIES’ EXPERIENCES OF SUSPECTED ADVERSE DRUG REACTIONSIntroductionTo inform communication with families about ADRs and to guide strategies for actively involving families in
pharmacovigilance, we conducted qualitative interviews with children who had experienced a suspected
ADR and their parents – the ADRIC-QUAL study.Clinical communication with families about adverse drug reactions
The literature on communicating about medicines indicates the advantages of involving patients in
open discussions about the beneﬁts and risks of medicines in order to support informed consent and
decision-making. However, patients have generally been found to be poorly informed about medicines.12,27
A great deal of work on communication about medicines has been motivated by a concern to promote
treatment adherence, rather than on enhancing communication about medicines as an important goal in
its own right.217 Although optimising adherence is an important objective, concern with promoting
treatment adherence has, arguably, meant that little attention has been given to examining the
experiences of patients following a suspected ADR.28
Even less attention has been given to investigating the particular experiences and needs of child patients
and their parents following a suspected ADR. Their situation is likely to be complicated by the frequent
prescribing of OLUL drugs in paediatrics218–220 and by parents’ distinctive role in caring for their children.221
Evidence that members of the public are particularly concerned about the risks of medicines to children
comes from a study comparing laypeople’s responses to hypothetical scenarios involving medicines for
child or adult patients. Respondents perceived the risks of ADRs to be more severe and reported that they
would be less likely to take (or give) a medicine when the recipient was a child rather than an adult.222Families’ involvement in pharmacovigilance
The MHRA is responsible for monitoring medicines in the UK. One way they do this is by collecting
spontaneous reports of suspected ADRs submitted via the Yellow Card Scheme.223 Given the frequent use
of OLUL medicines in paediatrics,218 health practitioners are strongly recommended to submit Yellow Cards
for suspected ADRs in children.17 However, there is considerable concern about under-reporting of
ADRs,40,224,225 and partly in response to such concerns, the Yellow Card Scheme was extended to patients
and their families in 2005.223
Adult patients who use the Yellow Card Scheme or its international equivalents have been found to
provide more detailed reports of ADRs than clinical practitioners and to value the opportunity to contribute
to pharmacovigilance.12,226–232 These patients have spoken of having altruistic motives for reporting ADRs,
as do clinicians,226,233 and being motivated by the severity of the ADR and a concern that certain ADRs
were not listed on the medicine patient information leaﬂet.233 However, public awareness and participation
in the Yellow Card Scheme is low12,27,28 and studies of patients who have managed to access the Yellow
Card Scheme are, therefore, likely to be of limited use in identifying strategies to promote wider
participation. Research with patients who have experienced an ADR but have not used the Yellow Card
Scheme is limited. A recent study of adult patients who had been hospitalised because of a suspected ADR
but had not used the Yellow Card Scheme indicated that they considered the scheme to be remote and
impersonal, and they felt that it was not a patient’s responsibility to report ADRs to the MHRA.28
Exploring the particular motives of parents for using the Yellow Card Scheme and the barriers they
encounter is important for several reasons. Previous research has focused primarily on adult patients, yet
the need for parental conﬁdence in pharmacovigilance is particularly pressing owing to the widespread use
of OLUL medicines in children218,234 and public concern about the safety of children’s medicines.219,235–240
Also, the perspectives of parents may differ from those of other lay users of spontaneous reporting
pharmacovigilance schemes because of parents’ distinctive caring and protective role.221,241 Moreover,
previous research has largely focused on the experiences of people who have used the Yellow Card
Scheme, which as we note above, is likely to be of limited use in enhancing participation. It is important to
test those assumptions by examining the views of parents who have witnessed ADRs in their children butNIHR Journals Library www.journalslibrary.nihr.ac.uk
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Card Scheme.Aims
We designed our qualitative study to explore all aspects of participants’ experiences and views, from their
accounts of communication at the point at which medicines were prescribed to their views about the
implications of ADRs for future health, and their views and experiences of reporting ADRs using the Yellow
Card Scheme.Methods
Sampling, setting and recruitment
The methods used have been detailed elsewhere,29,96 so only a brief outline is provided here. As
recommended in qualitative research when there has been little previous research on a topic, we sampled
for maximum variation242,243 using three sampling routes to ensure participant diversity, particularly in
terms of clinical specialty and the nature of the suspected ADRs. Route 1 comprised the two cohort studies
(see Chapters 2 and 3) that were part of the ADRIC programme. ‘ADRIC families’ were eligible for the
study if they could be approached before discharge. Treating clinicians initially introduced the study to
families. The interviewers subsequently provided the parents, children and young people who expressed an
interest in participating with more detailed information and then arranged the interview. We used route 2,
the Yellow Card Scheme,223 to access parents with experience of reporting ADRs to the MHRA.242,243
The MHRA sent invitation letters to all parents who had submitted a Yellow Card on behalf of a child of
< 17 years of age, outlining the study and inviting parents to return a reply slip to the study team if they
wished to participate. Qualitative interviewers telephoned parents to further explain the study and arrange
an interview.
As we recruited few children via route 1 and none via route 2, we used a third sampling route to extend
the sample of children in the study. For this extended sample, clinical teams identiﬁed children who had
experienced a suspected ADR while receiving inpatient care at Alder Hey. ADRIC researchers facilitated this
process by publicising the study, regularly visiting wards and clinics to prompt staff to identify eligible
participants, and checking nursing notes via the hospital computerised records system.
Sampling to all routes ran in parallel with data analysis and was discontinued when saturation on the
main analytical categories was reached.244 A UK NHS research ethics committee approved the study
(Northwest 3 Research Ethics Committee 08/H1002/7). All participants gave written informed consent
or assent.Interviews
Interviewers (JA, HH and ES) explained their independence from clinical teams and the MHRA before all
interviews. Face-to-face interviews were conducted with participants, with the exception of Yellow Card
parents, who we interviewed by telephone as they resided across all parts of the UK. Interviews were
semistructured and informed by a topic guide that contained prompts about families’ experiences of
children’s signs and symptoms and how they linked these to a medicine; awareness of suspected ADRs;
written and verbal communication with clinicians and views about the implications of ADRs for children,
and views and experiences of the Yellow Card Scheme. Interviewers tailored their approach and questions
to ensure that interviews were conversational and suited to the needs of both parent and child
participants. Interviews were audio-recorded and transcribed. Transcripts were checked by the interviewer,
who removed all identifying details before analysis.Analysis
The analysis drew on the constant comparative approach244–250 and was broadly interpretive. JA led the
analysis reading transcripts several times to develop analytic categories. BY and MT supported this process97
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FAMILIES’ EXPERIENCES OF SUSPECTED ADVERSE DRUG REACTIONSby reading a sample of the transcripts and by ‘testing’ and developing the analysis through periodic
discussion with JA. All three analysts compared within and between transcripts, and iterated between
developing analytical categories and new data.245,247–253 We used a number of methods that are
recommended to help ensure rigour in the analysis of qualitative data including respondent
validation,245,252 attending to exceptional or ‘outlier’ cases247–250,252,253 and scrutinising the quality of the
developing analysis for its coherence and potential to inﬂuence practice. The latter was also assisted by
discussion among the wider ADRIC team252,254 to support multidisciplinary investigator triangulation.255,256
Excerpts from interviews are presented to evidence the analysis; in these omitted speech is indicated by
[. . .], explanatory text by [text] and excerpts are coded ‘AP’ (ADRIC parents), ‘AC’ (ADRIC children) ‘YCP’
(Yellow Card parents) or ‘EC’ (extended child sample).Results
Participants
We conducted audio-recorded interviews with a total of 45 parents (41 mothers, 4 fathers) and 19
children. Of these, 27 parents and 11 children were recruited via the ADRIC cohort studies (route 1),
17 parents were recruited via the Yellow Card Scheme (route 2) and eight children were recruited via
route 3 (the extended children’s sample).
Interviews lasted approximately 60 minutes (range 17 to 138 minutes) and were conducted between
1 and 56 weeks after the suspected ADR. Four participants were interviewed in a private setting in the
hospital. The remainder were interviewed in their homes. Appendix 5 shows the characteristics of
participants, including child age range, gender, ranked Index of Multiple Deprivation (IMD), type of drug
associated with the suspected ADR and the body system affected by the ADR.
The ﬁndings from the interviews are presented in two parts: Part 1 focuses on participants’ perspectives
on communication about ADRs; Part 2 focuses on participants’ perspectives on contributing to
pharmacovigilance through the UK’s spontaneous reporting scheme.Part 1: participants’ perspectives on communication about
adverse drug reactions
Little explanation of the risks of medicines at the time they were prescribed
Although some of the children reported receiving general advice about potential ADRs before a medicine
was given, most children and parents indicated that clinicians did not explain the risks of medicines when
the medicines were prescribed: ‘No side-effects were made known to me’ (YCP5); ‘I didn’t know codeine
would make me constipated’ (AC07); ‘They didn’t really tell me about anything about being sick or being
itchy. They never really said anything about that’ (EC13). Parents explained how clinicians focused on other
issues, such as explaining their child’s condition and the importance of medicines or surgery in treating the
condition: ‘They [the surgeons] don’t discuss the drugs; they discuss the surgery itself’ (AP23). If the risks
of medicines were discussed, it was often at a time when parents struggled to absorb information, such as
shortly before a child was due to be anaesthetised: ‘On the day your child is being operated on or when
the anaesthetist comes up you are not thinking of anything other than [. . .] what’s going to happen in the
operation’ (AP16). Participants also reported difﬁculties with written information about medicines and
potential ADRs. They either did not receive these documents or found them hard to engage with: ‘I did a
carefree glance [at the patient information leaﬂet] and chucked it’ (YCP13).
A key exception to these accounts was the parents of children with cancer, who described how clinicians
provided comprehensive information about the types of reactions that medicines could cause and
emphasised how clinicians carefully timed and paced their explanations so that parents could absorb theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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neutropenic’ (AP6).How participants become aware of adverse drug reactions
Parents usually described an initial period in which they began to suspect something was wrong based on
a wide collection of physical symptoms and changes in their child’s behaviour that were ‘out of the
ordinary’. With the exception of patients whose suspected ADR had ﬁrst been identiﬁed by clinicians or
those who had cancer, participants initially tended to attribute symptoms to trivial causes, such as minor
illness, injury, or changes in lifestyle or environment. It was only when symptoms worsened that
participants became concerned: ‘His colour dropped and his breathing went a bit funny and he started to
panic, that worried me’ (AP25) and they started to consider possible links to medicines.
Participants reported how they started to link symptoms to a medicine when they noticed patterns, such as
temporal associations between a medicine being given and the onset of symptoms: ‘It just seems strange
to me that she had it [the medicine] and then straight away like she got that temperature’ (AP10); ‘When I
went on the ketamine I wasn’t being sick at all. Then when I went on the morphine I was being sick. So, it
was quite obvious that it was the morphine that was making me sick’ (AC09). Some also noticed how
symptoms receded between doses and then returned following another dose: ‘I noticed a difference [. . .]
when she was having it [the medicine] and when she wasn’t having it [. . .] she started on it again and
then we noticed the symptoms within a few days again of having it’ (YCP7). The absence of an alternative
explanation for the symptoms also inﬂuenced participants’ attributions: ‘[The medicine] is the only thing
she’s had and she hadn’t had a cold or been ill before it’ (YCP10); ‘I was like, well, the only reason this
would have happened would probably have been the medication’ (AC08).With few exceptions, parents were critical about adverse drug reaction
management and communication
Parents indicated that clinicians’ communication about suspected ADRs was often poorly matched to their
needs. They described receiving contradictory information and a lack of communication that might help
them understand what was happening to their child while his/her symptoms were being assessed: ‘No-one
actually ever said why it [the hallucination] was happening, the nurses thought it was a bit funny, they all
kept coming over to see him and laughing with him sort of thing’ (AP14). The way in which clinicians
managed and communicated uncertainty surrounding an ADR’s identiﬁcation did little to reassure parents
‘I was saying “well, when she goes home, can I give her paracetamol? Can she never have paracetamol or
can she never have a drug that might affect her liver?” And they were going “well [. . .] it should be ﬁne”
but no-one was saying “well you can, I’ll write it down and you can have it” ’ (AP12). Parents also
described receiving detailed information at times when they were anxious (e.g. when a child was critically
unwell or immediately prior to surgery). At these times parents found it hard to absorb information. They
reported receiving little or no information at times when they were less anxious and better able to absorb
information. Children voiced fewer concerns in communicating with practitioners than parents, perhaps
because most children relied on their parents for information about medicines ‘Sometimes I can’t
understand them [the doctors] so I just ask my dad’ (AC01); ‘My mum deals, is the information box and if I
have any questions I just ask her’ (AC10).
Some parents were intensely critical of how practitioners communicated about ADRs. One parent was
frustrated during a visit to outpatients when clinicians could not explain what was happening to his/her
child and spoke of feeling that he/she was being lied to by clinicians: ‘They were fobbing me off [. . .] I felt
like they were lying to us’ (AP5). More commonly, parents emphasized how their concerns had been
ignored or dismissed by clinicians: ‘Dismissive and wasn’t taking me very seriously’ (AP10). Yellow Card
and ADRIC parents both voiced criticisms of clinicians’ communication, although Yellow Card parents were
particularly emphatic in their criticisms. This was prominent when they felt clinicians had ruled out the
possibility that a child’s symptoms could be related to a medicine with seemingly little exploration of
parents’ concerns or explanation of the reasons for ruling out an ADR: ‘She [general practitioner] literally
said word for word “what would you like me to do?” And I just felt that was really dismissive’ (YCP14).99
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FAMILIES’ EXPERIENCES OF SUSPECTED ADVERSE DRUG REACTIONSParents who felt clinicians had ignored or dismissed their concerns described a sense of abandonment: ‘I
just, just felt like nobody cared, nobody was interested and they just wanted me to go away’ (YCP5).
A striking exception to the highly critical accounts of these parents came from the parents of children with
cancer. These parents were almost uniformly highly positive in their accounts of how clinicians
communicated about ADRs.Parents of children with cancer were positive about adverse drug
reaction communication
Despite the life-threatening nature of the illness and the risks of cancer treatment, parents of children with
cancer felt well supported by how clinicians communicated with them about medicines. There was a sense
from these parents that clinicians took ADRs seriously, were adept in communicating about them and had
well-developed systems in place for the management of ADRs: ‘It’s quite scary when you ﬁrst go home
with this big bag of drugs [. . .] they said [. . .] you can ring any time, and I rang nearly every day’ (AP7).
Parents pointed to how clinicians discussed possible ADR symptoms and how to respond before an ADR
happened, so that parents were clear about what to look out for and what action to take in the event of a
suspected ADR. Consequently, parents felt that clinicians communicated about medicines and ADRs in a
way that was ordered, timely and reassuring.Implications of poor communication about suspected adverse
drug reactions
Parents who were dissatisﬁed with how practitioners had communicated reﬂected on the implications.
They commented on how a lack of information about potential ADRs at the time of prescription had
prevented them from being involved in decisions about their child’s care. In one case, a lack of information
at the time of prescription had resulted in a parent continuing to give morphine to alleviate their child’s
agitation, only to subsequently discover that agitation could be a result of itchiness caused by morphine:
‘As she kept getting more and more agitated we kept boosting it [the morphine] [. . .] and the more we
pressed the booster [. . .] the itchier she got’ (AP16). A few parents remarked on how they blamed
themselves for what had happened because they felt ‘responsible for what goes into’ their child
(YCP10) and pointed to the distress this had caused: ‘I was devastated [. . .] I just felt like crying all the
time’ (AP8). Parents also spoke of fearing a repetition of the ADR: ‘Will it happen again? [. . .] could it
happen to him, to the baby?’ (AP8) and of their uncertainty about the implications of ADRs for their child’s
future health and use of medicines. Parents were also confused about whose responsibility it was to
prevent a recurrence of the ADR: ‘I don’t know if it would be down to me to turn round and say
something or whether they have actually put something in their notes’ (AP14). Some assumed that the
responsibility was theirs alone: ‘It’s something that I [. . .] have to ask to make sure he never gets given
that again’ (AP18). By contrast, children tended to focus on their experience of the symptoms of the
suspected ADR. One child emphasised how he had not been perturbed because the hallucinations that he
experienced had ‘distracted’ (AC04) him from the pain that he was feeling. However, most children
described the experience as unpleasant or frightening: ‘It was really scary. I wasn’t bothered about pain
[. . .] I just felt so scared’ (AC10).
In the context of poor communication, the experience of a suspected ADR sometimes coloured parents’
views about medicines and some expressed reluctance to give certain medicines to their child in the future.
For example, one parent became convinced that her child’s ADR was a reaction to morphine and that her
child could never have morphine again: ‘She’s due for this big operation and she can’t have morphine’
(AP11). However, clinical review of this particular case suggested that the suspected ADR was linked to an
avoidable over-dosage and that, rather than avoiding morphine altogether in future, it might be in the
child’s best interests to personalise the dose. Another parent refused to allow her child to have the ﬁnal
course of her vaccine: ‘I will categorically say that [. . .] I will deﬁnitely not let her have the third [human
papilloma virus] vaccine’ (YCP3). One child said he would refuse a medicine again: ‘I don’t want to have
that medicine ever again because [. . .] it just makes you go all angry’ (AC09), although most children
reported they would take the medicine again if it was likely to help them.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3How participants thought communication about suspected adverse drug
reactions should be handled
Reﬂecting their accounts of poor communication about ADRs and the resulting implications as described
above, parents wanted clinicians to help them to understand what had happened to their child. Children
similarly described a need to understand their experience ‘I would have liked to have known that the
ﬂoppiness wasn’t just me and I would have liked to have known that I would have felt sick after’ [. . .] all I
want to know is what is going to happen, when is it going to happen, how is it going to happen and am I
going to be in pain’ (EC17). As one parent explained, the need to understand the ADR seemed to be
intrinsic rather than motivated by ulterior considerations: ‘[It’s] not necessarily the case that everyone’s
going to jump and say, “Right, I’m going to sue the drug company” and all of these sorts of things. I think
parents genuinely, who are concerned about their child’s health, want to know what it was’ (YCP8).
Participants wanted discussions about ADRs to be paced and timed in a way that would help them to
absorb the information: ‘You just don’t think straight when you’re there [. . .] doctors have got to
understand that [. . .] and maybe spend a little more time to try and explain a little bit more than they
do’ (AP11); ‘Because when you are in hospital and they ask have you got any questions, you can’t
really think of it because you are drugged up [. . .] and your mind goes blank. And when you get home
and then you do a bit of revising and stuff like you think “oh, I should have asked that question” and stuff
like that’ (EC12).
Parents particularly wanted to understand what the suspected ADR meant for their child’s future health
care, to know what steps would be taken to help prevent their child suffering further ADRs and to ensure
he/she would receive appropriate medicines in the future. Without exception, parents accepted that a
certain level of risk came with medicines and most appreciated that clinicians faced uncertainty in
identifying ADRs: ‘I think it was the antibiotics. The doctors think it is that but they can never say it is that,
because there is a possibility that it’s not that’ (AP1); ‘It’s just something that, you know, just happens [. . .]
I’m sort of accepting about it’ (YCP13). Many parents were critical of how clinicians communicated about
ADRs and some of them got the impression that clinicians were unwilling to discuss ADRs. However, none
of the parents blamed clinicians for their child’s ADR or said they intended to formally complain. Only one
parent expressed a slight ‘loss of trust’ (YCP8) in clinicians. However, as we note above, a few participants
explained that their trust in medicines had diminished. Alongside their wish for dialogue with clinicians
about ADRs, several participants also wanted accessible and reliable written information about ADRs: ‘They
should give you a little pamphlet or something to say [. . .] look this is what she’s got’ (AP12).Part 2: participants’ perspectives on pharmacovigilance
Awareness of the Yellow Card Scheme
Most Yellow Card parents remarked that they had found out about the Yellow Card Scheme through their
training or work as a health practitioner: ‘The only reason I knew about it was because of the course that
I’d done’ (YCP7), or through friends or relatives who were health practitioners. In contrast, only two ADRIC
parents had heard of the Yellow Card Scheme before we interviewed them and both were nurses. None
of the children had previously heard of the Yellow Card Scheme. None of the ADRIC or Yellow Card
participants knew for certain whether or not the practitioners had submitted a Yellow Card reporting the
suspected ADR: ‘I don’t know if one was ﬁlled in or not’ (AP20), but some remarked that they would
appreciate being informed if a practitioner had done so: ‘Yeah, I think they should tell you’ (AC02).Motivations, views and experiences of parents who submitted Yellow Cards
Most Yellow Card parents emphasised how they had submitted a Yellow Card because they wanted to
help prevent other children experiencing the sorts of ADRs that their child had suffered. They also hoped
that their report would contribute to the review of certain medicines ‘if they look into things, and [. . .] if
there is too many incidents, they might have to relook at the tablet or relabel the information leaﬂet’
(YCP7). Parents did not usually think their reports would directly help their own child: ‘I didn’t think it
would help me at all. I didn’t have any expectation for us’ (YCP10) and none of them wanted a medicine101
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FAMILIES’ EXPERIENCES OF SUSPECTED ADVERSE DRUG REACTIONSto be withdrawn from the market solely because of the difﬁculties their child had experienced. Linked to
their altruistic motivations, Yellow Card parents also described a sense, albeit nebulous, of ‘achieving
something positive from that experience rather than just sort of happening’ (YCP14). Those Yellow Card
parents who had professional knowledge of the Yellow Card Scheme added that they were motivated to
submit a report by a sense of professional obligation. Those who were not health practitioners expressed a
preference for reports about suspected ADRs to come from health practitioners rather than themselves:
‘I wished it [Yellow Card] had come from the doctor ﬁrst’ (YCP10).
Some Yellow Card parents seemed to understand that a certain number of reports would be needed in
order to trigger action by the MHRA: ‘if enough people say something about this then something should
and probably will get done’ (YCP16). Others were unsure about what happened to the data after they had
submitted it. Most parents did not report expecting to receive feedback from the MHRA in response to
their Yellow Card but those that had received a response were pleased: ‘What I’m delighted about is the
response it makes you feel very pleased, glad that I followed it up’ (YCP3). As noted in Part 1, many
Yellow Card parents emphasised how the health practitioners they consulted had not taken their concerns
about their child’s ADRs seriously. In this context, the opportunity the Yellow Card Scheme offered a
welcome opportunity for parents to voice their concerns about medicines in a way that was not ﬁltered or
inﬂuenced by practitioners: ‘I felt very pleased that I could [. . .] take control of it really and let someone
know regardless of whether the doctor thought’ (YCP8). Other parents spoke of how submitting a Yellow
Card provided a form of redress: ‘It’s kind of restorative justice in a way’ (YCP6) or helped to resolve their
feelings of guilt about what had happened to their child: ‘It felt that I might have failed [my child] so that’s
what I am doing it all for, really, to try and ofﬂoad that information’ (YCP10).Views and experiences of participants who had not submitted Yellow Cards
As we note above, the children we interviewed and most ADRIC parents knew nothing of the Yellow Card
Scheme prior to participating in this study. When we explained the Yellow Card Scheme to them during
the interviews, like the Yellow Card parents, most of the children and ADRIC parents were generally
positive about the Scheme ‘I think that is a good idea as patients might think [an ADR] is important and
doctors don’t’ (EC16) or spoke of the need for more to be done to publicise the Yellow Card Scheme: ‘We
should be told about things like this [the Yellow Card Scheme] [. . .] if anyone has a reaction to a drug
then they need to know that something is going to happen about it. It should be recorded’ (AC10). All but
one parent said they would consider using the Yellow Card Scheme in future: ‘Now that I know about it,
yeah, I would do. I’ll tell my friends about this actually’ (AP23). Despite this positivity, none of the ADRIC
parents said that they would like to complete a Yellow Card for the particular ADR that we had discussed
during the interview. Parents’ reluctance may be linked to their experiences of their child’s ADR. As
described above, both ADRIC and Yellow Card parents had been dissatisﬁed with how health practitioners
had communicated about ADRs, but ADRIC parents also described confusion and uncertainty about roles
and responsibilities for recording and reporting a suspected ADR. Some assumed this was a practitioner’s
role: ‘[I] just assume the doctor would sort it out’ (AP14), or expected that practitioners would submit
Yellow Cards as a matter of course: ‘I would more than likely think that the doctors would do it [. . .] if the
child has had a reaction they would automatically’ (AP13). Others implied that practitioners might
disapprove of parents who submitted Yellow Cards and regard such parents as stepping beyond their role:
‘they might think that you are trying to do their job for them’ (AP20).
Some ADRIC parents were also reluctant to submit a Yellow Card on this occasion because they were
uncertain about whether an ADR had occurred: ‘I don’t think they linked it to an adverse reaction at the
time’ (AP25) or they felt that they or other members of the public were not equipped to decide if an ADR
had occurred: ‘I’m not medical so I wouldn’t know what a reaction would be’ (AP18); it [the side effect]
may not be from the drug, and [a parent] might think it is and go onto the internet and say that on a
Yellow Card’ (AP22).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Perspectives on communication about adverse drug reactions
Parents were generally disappointed with how clinicians communicated about suspected ADRs. Although
children focused on the concern or distress the ADR had caused them, they voiced fewer problems with
clinicians’ communication. Children pointed to how their parents acted as intermediaries or conduits for
communication about medicines and ADRs and this parental role may explain why children voiced fewer
problems in communication compared with parents. The majority of parents reported receiving little or no
advance explanation about the problems that might be associated with medicines. When information was
provided, it was in ways that parents found hard to absorb. As a result, parents were taken by surprise
when their child experienced a suspected ADR. This turned into frustration and confusion when clinicians
were unresponsive to parents’ concerns and some parents felt dismissed or abandoned as a result. In the
absence of explanation about what steps could be taken to prevent further ADRs, a few parents were
reluctant to give their children medicines in the future. The key exception to these negative parental
accounts was parents of children with cancer, who, despite their intense fears about the illness and
treatment, were generally highly satisﬁed with how clinicians communicated about ADRs.
As well as being a source of avoidable distress, poor clinician–parent communication about suspected
ADRs will impact on what parents communicate to their children about the ADR, challenge parents’ and
children’s conﬁdence in medicine, and contribute to negative perceptions and misunderstandings of
medicines.257,258 This could lead to poor adherence in the future. We found considerable convergence
among participants about the nature of helpful communication. Their suggestions, which are similar to
those reported elsewhere, included the importance of the timing and pacing of information, as well as the
need for clinicians to explicitly acknowledge what had happened and help families to understand events
that they perceived to be signiﬁcant, even if the event is not signiﬁcant from the perspective of
clinicians.258–260 The accounts of parents of children being treated for cancer indicated that, despite the
complexities involved in prospectively explaining about ADRs while not raising undue alarm about
medicines, communication about ADRs can be conducted in ways that parents ﬁnd informative,
understandable and reassuring.
One important challenge facing clinicians who communicate about ADRs is the uncertainty involved in
attributing symptoms to medicines. We found that families’ accounts of how they linked symptoms to a
medicine resembled the logic that underpins tools for assessing ADRs53,188 in research and clinical practice.
Participants noted temporal associations between a medicine’s administration and the onset of symptoms,
the receding of symptoms between doses and the absence of alternative explanations for symptoms. This
common ground could be a starting point for improving communication about ADRs. Alongside our other
ﬁndings – parents accepted that all medicines come with risks, appreciated the uncertainty in attributing
symptoms to medicines and did not blame clinicians for suspected ADRs – we think there is reason to be
optimistic about the potential to improve clinician–family communication about medicines. However, this
needs to be conﬁrmed by investigating clinicians’ perspectives on communicating with parents about
suspected ADRs.Perspectives on spontaneous reporting of suspected adverse drug reactions
To our knowledge, this is the ﬁrst study to speciﬁcally investigate how parents and children view the
opportunity to report suspected ADRs directly to the MHRA. All participants saw value in direct reporting
and those who had submitted Yellow Cards were satisﬁed with the Yellow Card Scheme. However, our
key ﬁndings come from the ADRIC parents, none of whom had previously submitted a Yellow Card. These
parents were generally supportive of the aims of the Yellow Card Scheme after it had been explained.
Although they were positive about using the Scheme in the future, they were reluctant to use the Scheme
to report the ADR discussed in their interviews. Comparing the settings, roles and perceptions of the
Yellow Card and ADRIC parents helps to shed light on these ﬁndings. The Yellow Card parents generally
reported events that had happened in the community, and linked to their professional roles, many were
conﬁdent about using the Yellow Card Scheme. In contrast, the children of ADRIC parents had received103
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FAMILIES’ EXPERIENCES OF SUSPECTED ADVERSE DRUG REACTIONShospital care for their ADR or were hospital inpatients at the time the ADR occurred. As such, these
parents either expected that it was the responsibility of the practitioners looking after their child to submit
a Yellow Card, or they were uncertain about whether it was legitimate for parents to report the ADR.
Moreover, only a few ADRIC parents had personal links to health practitioners or were themselves
health practitioners.
Parents who submitted a Yellow Card reported multiple motivations. Altruistic motivations, such as a
desire to contribute to the improving the safety of medicines at a population level, were particularly
prominent in their accounts. This is similar to ﬁndings on other patient groups who have reported ADRs, to
clinicians’ motivations for submitting Yellow Cards12,261,262 and it is also consistent with the goals of the
MHRA.223 Linked to their dissatisfaction with practitioners for not taking their concerns about suspected
ADRs seriously, some parents experienced reporting as providing a form of redress or felt reassured, as
others have also described,12,261,262 by the availability of an independent vehicle for ‘ofﬁcially’ recording
ADRs. A few parents pointed to how submitting a Yellow Card had helped to resolve feelings of guilt
(about the medicines they had given or allowed their child to take), a motivation that has not been
previously described and may be unique to parents and others who care for vulnerable patients. In this
way, the Yellow Card Scheme seemed to enable parents to take action that seemed psychologically
important following their child’s ADR, even if it would not directly beneﬁt their child.
Consistent with previous research on adult patient reporters,12,27,28 our ﬁndings indicate that awareness of
the Yellow Card Scheme is limited and that further work is needed to promote the Yellow Card Scheme.
Our study provides insight into the perspectives of parents and children who had not used the Yellow Card
Scheme but were ‘eligible’ to do so. As we note above, participants supported the aims of the Yellow
Card Scheme but they were reluctant to use it to report the ADR that we interviewed them about. The
reasons for their reluctance may help inform strategies to widen participation in pharmacovigilance. The
parents we interviewed were concerned that, because they lacked medical knowledge, their reports would
be inaccurate or of little value. Emphasising that reports from members of the public can make a valuable
contribution to drug safety would help to overcome such barriers, as would emphasising that people do
not need to be certain that a medicine deﬁnitely caused a reaction in order to submit a report. Some
parents expected that their child’s practitioners would report the ADR, yet practitioner participation in
spontaneous reporting and other forms of pharmacovigilance is poor.40 Informing the public that their
reports are an adjunct to practitioner reporting may help to motivate them to participate in
pharmacovigilance. Parents also worried that their reports might be perceived as undermining
practitioners. These concerns could be addressed by emphasising that the Yellow Card Scheme is
conﬁdential and that information will not be shared with practitioners without a reporter’s consent.Limitations
Our study had some limitations. First, we relied on clinical teams for access to children and ADRIC families.
Clinical teams may have ﬁltered out participants with whom their relationships were strained. To address
this we sampled Yellow Card parents, as we could access them without consulting with clinicians.
However, many Yellow Card parents were health professionals themselves, or had contacts who were, and
their views on communication about ADRs and pharmacovigilance may be distinctive. Previous studies of
patients’ perspectives on spontaneous reporting pharmacovigilance schemes share similar limitations. This
arises from the limited public awareness of the Yellow Card Scheme. In this context, our sampling of
participants with experience of a suspected ADR but who had not used the Yellow Card Scheme is
particularly important. The views of such groups have rarely been investigated, yet they are crucial in
identifying how public participation in pharmacovigilance may be promoted. Moreover, the accounts of
both ADRIC and Yellow Card parents triangulate in pointing to the difﬁculties parents experience in
communication about ADRs. Finally, the interviews were conducted sometime after the suspected ADR,
which may have shaped participants’ accounts in certain ways. However, understanding the meanings that
parents and children take away from their experiences of ADRs is crucial in learning how to enhance their
experiences and it is these meanings that were the focus of our study.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3ConclusionsPoor communication about children’s ADRs was a source of signiﬁcant difﬁculty for parents and our
ﬁndings will help to guide clinicians regarding what topics to cover in their discussions about medicines
and ADRs. At the time of prescription, parents wanted to know the potential risks associated with
medicines. In the aftermath of a suspected ADR, both parents and children wanted to understand what
had happened and in some cases this might include explicit acknowledgement that an ADR had possibly
occurred. Parents also wanted know the potential future implications of the suspected ADR for their child.
Parents and children linked symptoms to medicines in ways that resembled the reasoning used clinically for
identifying ADRs. Clinicians could possibly use this common ground as a starting point for communicating
with families when an ADR is suspected. However, our study’s most important contributions may lie in
providing insight for clinicians into how valuable discussions of ADRs can be for parents and the important
role that parents have as a conduit for communicating with children about medicines and ADRs.
Parents who had used the Yellow Card Scheme found it straightforward and were satisﬁed with its aims.
Participants who had not used the Yellow Card Scheme were also satisﬁed with its aims but parents were
uncertain about their role in reporting ADRs and many assumed that submitting a Yellow Card was the
responsibility of practitioners. Therefore, although raising public awareness of reporting schemes is
important, our ﬁndings indicate that this will not improve public participation by itself and that
pharmacovigilance agencies will need to present their schemes in ways that empower and support lay
reporters. Based on our ﬁndings, we recommend that agencies emphasise the following points when
publicising their schemes: (1) the value of laypeople’s reports in promoting drug safety; (2) that reports will
not be shared with practitioners without the reporter’s permission; and (3) that reports can be submitted
even when there is uncertainty about whether or not a medicine caused a reaction.105
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strategy about suspected adverse drug reactions
affecting childrenAbstract
Background
Families have unmet information needs following a suspected ADR in a child or young person.Aims
To develop a strategy to support communication about suspected ADRs between families and clinicians by:
1. identifying any barriers to effective communication with families from the perspective of clinicians
following a suspected ADR
2. developing information leaﬂets about ADRs for parents, children and young people to support their
communication with clinicians.Methods
Semistructured qualitative interviews with 42 clinicians about their experiences of ADRs in children.
Face-to-face interviews were audio-recorded and transcribed. Analysis was informed by the principles of
the constant comparative method. A parental leaﬂet on ADRs was developed, based on feedback from a
range of stakeholders, including parents and clinicians. The usefulness of the leaﬂet was examined by
conducting structured interviews with 17 clinicians after they had used the leaﬂet during routine
parent–clinician discussions about suspected ADRs.Results
Clinicians described using all the features of communication that parents wanted to see. However,
clinicians made active decisions about when and what to communicate to families about suspected ADRs.
These decisions mean that communication may not always match families’ needs and expectations.
Clinicians describe a number of complexities with effective communication, some of which are unique to
paediatric settings. The complexities perceived by clinicians may explain, at least in part, the discordance
between clinician and family perspectives. Clinicians found the leaﬂet useful in supporting discussions with
parents about a suspected ADR in their child.Conclusions
The parent leaﬂet was useful in supporting discussions between parents and clinicians about suspected
ADRs. Further strategies to improve communication between families and clinicians should focus on
aligning clinicians’ decision-making about what and when to communicate with families following a
suspected ADR rather than focusing on developing clinicians’ communication skills.IntroductionThe ADRIC-QUAL interviews (see Chapter 7) elucidated the communication difﬁculties that many families
experienced following a suspected ADR. In their interviews parents also indicated that written information
about ADRs in the form of a leaﬂet may help to address their communication needs by supporting
discussions between families and clinicians about suspected ADRs. In response to these ﬁndings, we
developed information leaﬂets that could be given to parents and children following a suspected ADR and107
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108used to support them in communicating with clinicians about ADRs. As well as being the catalyst for
developing the leaﬂets, the ﬁndings from the families’ interviews also informed the content of the leaﬂets.
The ﬁndings described in Chapter 7 suggest that from the perspective of parents, there is a need to
enhance communication about ADRs between clinicians and parents. However, as communication is a
two-way process, it is important to also examine communication about ADRs from clinicians’ perspectives,
particularly to identify which strategies are likely to be feasible for use in everyday practice to enhance
communication with families. Accordingly, this study aimed to describe clinicians’ views of communicating
with families about ADRs and to relate the ﬁndings to the accounts given by parents.Methods: development of a leaﬂet for parents
Process
The parent leaﬂet was developed iteratively through numerous cycles of drafting, comment and redrafting,
culminating in a pilot study to test the suitability of the leaﬂet for supporting communication about ADRs
in clinical practice.External review
The text and format of the parents’ leaﬂet was reviewed externally through three routes:
1. During interviews with clinicians about their experiences of ADRs, clinicians were shown a copy of the
leaﬂet and asked to comment on the content and the potential usability of the leaﬂet.
2. The leaﬂet was reviewed by parent members of the MCRN at Alder Hey and by parents from the
Research User Group at Liverpool Women’s Hospital.
3. The leaﬂet was reviewed by the Paediatric Medicines Expert Advisory Group at the MHRA.
Two prototype text-only versions of information leaﬂets for children were reviewed internally and revised
within the ADRIC team. The children’s leaﬂets were further reviewed and revised as follows:
1. Children’s views of the leaﬂets were sought during some of the qualitative interviews that we
conducted (see Chapter 7 ). In response to comments during these interviews we developed a third
leaﬂet aimed at young people aged ≥ 16 years. This leaﬂet matched the level of information provided
on the parents’ leaﬂet.
2. We engaged a professional designer to enhance the age-appropriateness of the design of the leaﬂets
to ensure their suitability for the target age groups.
3. Children and young people from the MCRN Young Person’s Advisory Group at Alder Hey reviewed and
commented upon the leaﬂets.
4. The revised children’s and young people’s leaﬂets were then reviewed by the ADRIC steering committee.
5. Following this review the leaﬂets were forwarded to the Paediatric Medicines Expert Advisory Group at
the MHRA to mirror the review process that we had conducted for the parents’ leaﬂets.
We approached the Royal College of Paediatricians and Child Health to ask if it would consider hosting the
parents’ leaﬂet on the publicly available Medicines for Children website (www.medicinesforchildren.org.uk).
Including the leaﬂet on this website offers the advantage of making the leaﬂet available widely for parents
and clinicians, as all hosted leaﬂets are freely available for download by anyone accessing the website. The
leaﬂet was reviewed by the Patient Information Leaﬂet Committee, which requested that it be piloted to
assess the suitability of the leaﬂet for use in clinical practice before its inclusion on the website.Piloting the parent leaflet
The pilot study took place in Alder Hey. We conducted brief structured interviews with doctors and nurses
after they had actually used the leaﬂet in the routine interactions that they had with families when they
usually explained about any suspected ADRs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The leaﬂet was used on 17 occasions. There were three further occasions when doctors declined to use
the leaﬂet: either because they did not feel an ADR had occurred or they did not feel it was appropriate to
introduce the concept of an ADR to a family at that particular time. Excerpts from interviews are presented
to evidence our conclusions; in these excerpts omitted speech is indicated by [. . .] and explanatory text by
[text], and excerpts are coded ‘N’ (nurse) or ‘D’ (doctor).Pilot study results: development of a leaﬂet for parentsThe pilot study indicated that from the perspective of clinicians, the leaﬂet was well designed and useful in
supporting communication between parents and clinicians following a suspected ADR in a child. Clinicians
commented that the leaﬂet was ‘very well laid out and [. . .] jargon free’ (P06:N) and ‘simple to read’
(P09:N). They also reported that the leaﬂet supported conversations with families by prompting clinicians
to include information that they would not normally have covered when discussing ADRs with parents. In
this way, clinicians indicated that the leaﬂet helped them to offer additional reassurance to parents. Some
clinicians also felt the leaﬂet empowered parents to ask questions that they might not have otherwise
voiced or felt able to ask: ‘Some of our other families [who had not seen the leaﬂet] [. . .] mightn’t have
thought of those things or they are thinking “oh [. . .] it is all right to ask this and ask that” ’ (P06:N). All
clinicians said they would use the leaﬂet again: ‘Oh yeah, I would be quite happy to do it again’ (P02:N);
‘Yeah I would use it again’ (P12:D).Pilot study feedback and leaflet validation
The results of the pilot study were fed back to:
l the Patient Information Committee at the Royal College of Paediatricians and Child Health
l the Medicines Management Committee at Alder Hey
l the ADRIC Steering Group (including members of the MHRA).
The leaﬂet for parents is now available at www.medicinesforchildren.org.uk/search-for-a-leaﬂet/side-
effects-from-childrens-medicines/.Methods: clinicians’ perspectives on communicating with
families about suspected adverse drug reactions in childrenThe methods were similar to those used in Chapter 7, with the key elements noted below.
We purposively sampled clinicians across three sites for maximum variation241 in terms of professional role
(nurse, doctor or pharmacist), length of practice, seniority and specialty. Site 1 was a specialist regional
paediatric hospital that had been actively involved in the ADRIC studies of the prevalence and
characteristics of paediatric ADRs.20,22 We were aware that clinicians at this hospital may have a
heightened awareness of the subject because of the ADRIC studies. Therefore, to enhance the
transferability of our ﬁndings we included two additional sites (sites 2 and 3), which were paediatric units
in local district general hospitals.Procedure
The researcher (JA) made initial contact with a senior research lead at each site, who helped the researcher
to access a list of eligible clinicians. JA then contacted clinicians by e-mail with a brief outline of the study
and an invitation to take part. Where a clinician did not reply they were sent one reminder e-mail.
Clinicians who expressed an interest in the study were provided with a participant information sheet and
their written consent was sought. One of two experienced qualitative researchers (JA and AR) conducted
the interviews with each clinician at the hospitals where the clinicians worked.109
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110A topic guide was developed to steer the interviews and this was adapted to reﬂect the different roles
of each professional group in the sample. The topic guide included prompts to elicit clinicians’ deﬁnitions
and experiences of ADRs; their perceptions of how families’ experienced ADRs; their accounts of
communicating about potential ADRs with families, both at the time a medicine was prescribed and
following a suspected ADR; and their accounts of recording and reporting ADRs. Interviews were
audio-recorded and transcribed. The researchers also kept ﬁeld notes of each interview detailing the
interview context, including the setting and observations and reﬂections on the interview process.Results: clinicians’ perspectives on communicating with
families about suspected adverse drug reactions in childrenWe invited 90 clinicians to participate; 46 did not respond to an initial and reminder invitation and one
doctor agreed to take part but we were unable to arrange an interview. Non-respondents included doctors
(n = 28), nurses (n = 15) and pharmacists (n = 3). We audio-recorded interviews with 42 clinicians, which
included doctors (n = 26), nurses (n = 12) and pharmacists (n = 4). The mean length since registration to
practice of our sample was 18.5 years (range 3–36 years). Table 36 shows other sample demographics
(interviews lasted approximately 70 minutes). We found no difference in participant characteristics or study
ﬁndings between sites. In the following sections we present preliminary ﬁndings from our analysis.
Why communicate about adverse drug reactions?
Clinicians indicated that they viewed providing both prospective and retrospective information to families
about ADRs as an important part of their clinical practice. They also talked of the need to optimise
adherence to medicines and pointed to how prospective communication about ADRs helped to guard
against the possibility that parents may refuse a medicine in the future because their child had experienced
an ADR about which that they had not been warned. Only a few clinicians described how discussing ADRs
prospectively was important in order to actively involve parents in their child’s clinical care.
In their accounts of retrospective communication following a suspected ADR, clinicians more commonly
pointed to the importance of the active involvement of parents. For example, a few clinicians mentioned
how discussing ADRs retrospectively was important in order to overcome the circumstances of the ADR.
Clinicians also spoke of how important it was to ensure that parents were adequately briefed about the
ADR and the medicine implicated in its causation so that parents could pass on this information in future
interactions with health teams.Definitions of adverse drug reactions
In some cases, clinicians indicated that although they recognised and responded clinically to possible side
effects to a medicine, they did not necessarily consciously ‘label’ these symptoms as an ADR. The
descriptions of ADRs used by clinicians reﬂect the clinicians’ thresholds for communication with parents.
However, they did not mirror formal deﬁnitions of ADRs used in pharmacovigilance, such as in the MHRA
Yellow Card system for reporting suspected reactions. We also noticed that some clinicians used the
terms allergic and side effect interchangeably, and that this informed how and what clinicians
communicated to families.How much information to communicate about adverse drug reactions?
Clinicians’ accounts pointed to factors that led them to constrain or ﬁlter the information that they
communicated to families about ADRs. These constraints reﬂected commonly accepted practice and ‘rules
of thumb’ in communicating about medicines, as well as their judgements about the characteristics of the
drug reaction, such as how severe, common or expected clinicians perceived an ADR to be. Clinicians also
indicated that they constrained their prospective communication about ADRs in order to promote
adherence to medicines: ‘If we read out the list of all potential reactions to parents, paracetamol for
example, no-one would take paracetamol’ (23:D). A common theme reported by clinicians was the needNIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 36 Sample demographics
Professional role Level/grade Specialty
Length of time
since registration
Doctor Non-consultant General paediatrics 5–10 years
Doctor Non-consultant General paediatrics < 5 years
Pharmacist Consultant General paediatrics Missing
Nurse Missing General paediatrics Missing
Nurse Staff nurse Paediatric A&E Missing
Nurse Specialist nurse practitioner Paediatric oncology > 10 years
Pharmacist Senior General paediatrics > 10 years
Doctor Consultant Paediatric neurology > 10 years
Doctor Non-consultant Community paediatrics 5–10 years
Pharmacist Senior General paediatrics and research > 10 years
Pharmacist Senior General paediatrics 5–10 years
Nurse Sister Missing > 10 years
Nurse Specialist nurse practitioner Pain and sedation > 10 years
Nurse Student General medicine N/A
Doctor Missing Missing Missing
Doctor Consultant Paediatric allergies > 10 years
Doctor Consultant Paediatric nephrology > 10 years
Doctor Consultant Paediatric neurology > 10 years
Doctor Consultant Paediatric general surgeon > 10 years
Doctor Consultant General paediatrics > 10 years
Doctor Consultant Paediatric nephrology > 10 years
Doctor Consultant Paediatric respiratory/cystic ﬁbrosis/
allergy/asthma
> 10 years
Doctor Consultant Neonatal > 10 years
Nurse RSCN Paediatric A&E 5–10 years
Nurse Sister Paediatric > 10 years
Doctor Missing Paediatric A&E > 10 years
Nurse Sister Paediatric > 10 years
Doctor Non-consultant Paediatric A&E < 5 years
Doctor Consultant Paediatric cardiology > 10 years
Nurse Staff nurse General paediatrics < 5 years
Doctor Consultant Paediatric anaesthetist > 10 years
Nurse Sister Paediatric diabetes > 10 years
Doctor Consultant Paediatric respiratory > 10 years
Nurse Missing General paediatrics > 10 years
Doctor Consultant General paediatrics > 10 years
Doctor Consultant Paediatric anaesthetist > 10 years
continued
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TABLE 36 Sample demographics (continued )
Professional role Level/grade Specialty
Length of time
since registration
Doctor Consultant Missing Missing
Doctor Consultant Paediatric rheumatology > 10 years
Doctor Consultant General paediatrics > 10 years
Doctor Consultant Paediatric rheumatology > 10 years
Doctor Consultant Oncology Missing
Doctor Consultant Paediatric rheumatology > 10 years
N/A, not applicable; RSCN, Registered Sick Children’s Nurse.
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112to balance the information they gave to parents about ADRs with the need to avoid causing parents any
unnecessary anxiety at the time a medicine was prescribed.Who should discuss suspected adverse drug reactions with families
Clinicians’ views about who should discuss ADRs with parents were varied, although most emphasised that
the member of staff who was ‘seeing the child’ (09:D) or responsible for the child’s care should also be the
one who takes responsibility for communicating about ADRs. The clinical severity of a suspected ADR also
inﬂuenced clinicians’ views about who should discuss a suspected ADR with a family retrospectively.
Clinicians thought that nurses were well placed to discuss relatively minor, expected and transient ADRs
with families, whereas ADRs that were more serious required a discussion between doctors and parents.DiscussionThis is the ﬁrst study to report clinicians’ perceptions of discussing ADRs with parents. Similar to the
ﬁndings from studies about other populations,263–267 the clinicians in this study reported that
communication about ADRs was generally important in clinical practice. However, in speciﬁc cases they
described ﬁltering the information that they discussed with families. Clinicians’ views about what
constituted an ADR also inﬂuenced their communication. When clinicians felt ADRs were mild, transient
and expected they reported either not discussing these with families or constraining the information that
they gave families. Evidence from our study of parents’ experiences of ADRs reported in Chapter 7
suggests that the level of parental anxiety and concern may relate more to suboptimal communication
than to the perceived severity of an ADR. For example, parents of children with cancer were reassured and
conﬁdent managing in suspected ADRs, even although the ADRs such children experienced could be
severe. In contrast, parents of children who experienced relatively minor ADRs reported feeling confused,
dismissed and abandoned.29Limitations of the study
This study explored clinicians’ accounts of discussing ADRs with families and may be subject to recall bias.
In addition, during interviews, we found clinicians tended to drift into normative or idealised descriptions
rather that giving speciﬁc accounts of what they did in practice when discussing ADRs with families.
Because of this, it is difﬁcult to establish to what extent clinicians’ accounts reﬂect day-to-day practice.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/pgfar02030 PROGRAMME GRANTS FOR APPLIED RESEARCH 2014 VOL. 2 NO. 3Strengths of the studyl Wide range of participants, including doctors, pharmacists and nurses.267
l Multicentred (specialist and non-specialist).
l Everyday interactions on busy wards in which the relationship with doctors was mainly episodic discrete
rather than long term.ConclusionTaken together, the ﬁndings of this chapter and Chapter 7 point to a mismatch between clinicians’ and
parents’ accounts of communication about ADRs. Although the clinicians spoke of the importance of
communicating with parents about ADRs, parents pointed to deﬁciencies in clinicians’ approaches to
communication. Our initial analyses suggest that this mismatch may relate, at least in part, to decisions
made by clinicians about what and when to discuss ADRs with parents. Some of the difﬁculties
experienced by parents may also have their roots in the different ways in which ADR terminology is used
by clinicians. Our preliminary results suggest that clinicians use terms that describe ADRs in ways that
reﬂect whether they need to tell parents about the incident, or whether they need to modify clinical
management. The same terms are used by pharmacovigilance specialists with a broader drug safety
agenda. This variation in the use of terminology may be one explanation for the low rates of reports to
spontaneous pharmacovigilance systems. Further analysis is needed to clarify the results of these ﬁndings.Conclusion and future research directions
Adverse Drug Reactions In Children was conceived and developed in 2006, which was the ﬁrst year of
operation of the NIHR MCRN and shortly before the European Regulation on Better Medicines for Children
became law in January 2007.268 The programme was an ambitious one and aimed, for the ﬁrst time, to
investigate the whole spectrum from when and where ADRs in children occurred to the development of
solutions to reduce the burden of ADRs. As originally conceived, the key component parts were:
l Identification To identify the nature of ADRs in children and the drugs causing these ADRs in
hospitalised patients.
l Quantification To determine the proportion of hospital admissions related to ADRs, and those
occurring in hospital; to estimate the whole burden associated with local, specialist regional and
national paediatric care.
l Evaluation To evaluate the risk factors for ADRs, including OLUL use of medicines.
l Intervention To develop tools and guidelines for improving the recognition and ultimately reducing the
burden of ADRs through enhanced prevention.
At the time of submission, two important studies had been conducted by Pirmohamed et al.198 in the adult
population. First, a prospective study of 18,820 admissions to two adult hospitals showed that 6.5%
of the admissions were due to ADRs, which led to death in 0.15% of adult patients (equivalent to
5700 deaths per year in the UK) at a cost to the NHS of £500M.198 A further study, examining ADRs
occurring in 3728 patients in hospital, showed that 15.8% of adult patients experienced an ADR after
admission to hospital.59 Importantly, > 70% of ADRs, in both the hospital admission study and the
inpatient study, were potentially avoidable. Although the burden of disease and use of drugs in children is
considerably lower than in adults, the majority of drugs are not evaluated in children, leading to a much
higher proportion of drugs being used OLUL, with the consequent safety concerns.3,269 Previous studies
addressing ADRs in children had considerable limitations. The populations studied were poorly described,
heterogeneous and the methodologies used to determine ADRs were unsatisfactory or inadequately
reported, making incidence estimates highly unreliable. Assessment of causality, severity and avoidability
was generally absent or inadequate and there was no assessment of risk factors for ADRs in children.
There was a clear rationale for the ﬁrst two studies proposed in ADRIC, which would be conducted at the113
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114largest children’s hospital in Europe with 12,600 children admitted per year and long term, each study
conducted over 1 year.
Similarly, although systematic reviews of studies to identify ADRs in children had been conducted
previously, there was a need for a systematic review, which was fully comprehensive and went beyond
attempting to describe the aggregate incidence of ADRs, to examine the nature of ADRs in children
and the drugs associated with them, and the quality of the methods used to detect, assess and avoid
these ADRs.
We anticipated detecting a proportion of ADRs, which had not been previously described and which were
unknown or unpredictable, from the known pharmacology of the drug and thus, originally planned to
develop screening tools to improve recognition of such ADRs and of known ADRs. However, during the
course of the ﬁrst two studies, such unknown ADRs were not detected and we did not feel that
development of such a screening tool was appropriate. However, a number of other problems were
identiﬁed by the early studies, which required the development of tools for the beneﬁt of patients in the
NHS. These included the need to develop entirely new, validated tools to assess causality and avoidability,
which became a focus of the later studies in ADRIC. In addition, the interviews with families whose
children had experienced an ADR highlighted a disturbing degree of distress associated with this and some
concern from them about the ways in which this diagnosis had been communicated by their health
professionals. An additional focus of the later parts of the programme was to understand this better by
conducting interviews with clinicians about how they communicate ADRs to families and to develop
information leaﬂets for clinicians and families to help guide these discussions.
The prevalence of ADRs associated with admission to hospital was around 2.9%, lower than reported in a
similar study in adults (6.5%).198 When we assessed the origin of the prescriptions for the drugs
responsible, the majority originated either directly from hospital or from protocols led by hospital
practitioners. This also differed from experience in adults. Although many of the ADRs were predicted and
the families were expecting them, for example in the children being treated with immunosuppressive
therapy, other signals were more disturbing. These included the cases of respiratory depression associated
with drugs used to treat status epilepticus and bleeding post tonsillectomy in children treated
perioperatively with corticosteroids to prevent vomiting.
The most surprising ﬁndings were from the study of ADRs in hospital. First, we found that the incidence of
ADRs in children is much greater than in adults. We included probable and deﬁnite ADRs, which gave an
incidence of 17.7%; a comparable study, published by our group in adults,59 reported an incidence of
14.7% but this included ADRs classiﬁed as deﬁnite, probable or possible. If we included possible ADRs in
our numerator, the comparable ﬁgure is that > 25% children in hospital experience an ADR. We also
observed that the risk of experiencing an ADR was increased over six times in children who had a general
anaesthetic during their admission and over half of the drugs implicated in all ADRs were used either
perianaesthetic or post anaesthetic. These drug groups have been under-represented in previous studies
and our ﬁndings have important implications for all clinicians concerned with the perioperative and
postoperative management of children, in particular in view of the recent moves to ambulatory surgery in
the UK and elsewhere.
The signals in studies 1 and 2 (see Chapters 2 and 3) of ADRs associated with drugs used during and after
surgery are the most novel and concerning ﬁndings of this programme. In study 2, we were able to
include only children who had been in hospital for > 48 hours. Most children who have surgery are in
hospital for shorter periods than this and a very high proportion are discharged on the day of surgery.
The anaesthetic care of children receiving their surgery as ‘day cases’ is adapted to ensure adequate
control of pain and vomiting in the home environment. One example of this is use of a single dose of a
corticosteroid to control vomiting over the ensuing 24 hours period, which in turn may contribute to
postoperative bleeding following procedures such as tonsillectomy. Our study has highlighted a need to
understand better the morbidities associated with anaesthesia and surgery in children.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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than authorised medicines. This again highlights the implications for how drugs are used in children.
Furthermore, we observed that drugs licensed for use in children but given to a child below the minimum
age or weight had the greatest risk of being implicated in an ADR, emphasising the importance of studies
to provide pharmacokinetic data in children of different ages.
The LCAT is now available and is being used in research and clinical practice. Further work is being
conducted to assess, by a randomised controlled trial, whether or not a short training package in the use
of the tool – available online – enhances this assessment. We believe that the LCAT is the best tool
currently available for assessment of ADR causality. Importantly, it has been developed, not only for
children, but also for assessment of ADRs in adults. The Liverpool AAT is at an earlier stage of
development, but we have learnt much from the development of the LCAT, in particular the visual
algorithm is user friendly and allows a more rapid assessment. By providing a simple tool that can be used
by all clinicians, the ADRIC programme has made an important contribution to the future assessment of
ADRs. Like LCAT, the Liverpool AAT has been developed to provide this assessment of ADRs in both
children and adults.
We have learnt much during the course of this programme, about the problems in communicating ADRs
to children and families. The materials produced to aid these discussions have either undergone full
assessment and user testing (the information leaﬂet to inform clinicians’ discussions) or will shortly do so,
and we will make these leaﬂets available via the internet. More could be done to provide information to
young people, for example via smartphone apps.
The ADRIC programme of research has highlighted a number of important implications for future research.
The end of the ADRIC programme symposium included a workshop on the research implications of the
burden of ADRs in paediatrics, and the key research questions from this are highlighted in Appendix 7.
Following discussion within the ADRIC Steering Group, the recommendations for future research are
prioritised below:
1. Risk–benefit evaluation There is a need to explore the balance of drug safety compared with drug
efﬁcacy and, potentially, there has been too much focus on safety and monitoring at the expense of
potential beneﬁt. More research is necessary to assess the values that parents and children place on the
use of different medicines and the risks that they will ﬁnd acceptable within these contexts. Indeed, the
conceptual framework within which the balance between safety and efﬁcacy of medicines and
individual drugs presents is an important area for further research, and poses the question whether the
weighting between efﬁcacious outcomes and safety of patients is appropriately calibrated. This subject
is currently less understood in children than adults. There is a clear need for innovative means to
interrogate and evaluate the risk and beneﬁt associated with use of drugs in children. Methodological
developments mean that this theme could be rigorously addressed, for example through the use of
discrete choice experiments incorporating the views of parents, adolescents and younger children,
regulators and industry. Important questions also include how do the decision-making differences
between children and parents for particular drugs differ, and how the individual’s perspective may vary
between the younger child and adolescent.
2. Evaluation of ADRIC outputs Two key ADRIC outputs are the LCAT and the Liverpool AAT. Although
these tools are at different stages of development there is potential for further research with both.
Following validation, the Liverpool AAT will be used to assess the avoidability of the ADRIC admissions
study cases and the results will be compared with the Hallas54 assessments carried out in Chapter 2.
Similarly, for the inpatient study cases we will aim to assess a proportion of the cases using the new
Liverpool AAT. This will help us to identify potentially avoidable ADRs. There is the potential to evaluate
the use of both tools in a variety of settings including other paediatric and adult hospitals and clinical
trial AE reporting. The applications of these tools in clinical practice and education could be explored.
For example, a learning package which incorporates the LCAT has been developed in order to explore
whether or not it can be used in this context to improve the causality assessment skills of clinicians.115
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1163. Dose optimisation There is a clear need to reduce the burden of ADRs in children, and one component
strategy is to optimise dosing in children and young people. A clear ﬁrst step will be a comprehensive
review of the literature to identify how extrapolations from adults to children are achieved, which
methods have or have not been used, and an evaluation of the utility of those methods that have been
used. The ﬁndings will help to inform a gold standard practice for extrapolation, which can be targeted
towards drugs identiﬁed as high risk within ADRIC and other relevant studies, and in combination
with alongside pharmacokinetic/pharmacodynamic (PK/PD) evaluation studies. Alongside studies of
risk–beneﬁt evaluation, enhanced methodologies for extrapolation would make a signiﬁcant contribution
to the potential of adaptive licensing within the regulatory framework for drugs in children.
4. Enhanced ADR monitoring associated with surgery and anaesthesia in children The signals in studies 1
and 2 (see Chapters 2 and 3) of ADRs associated with drugs used during and after surgery are the most
novel and concerning ﬁndings of this programme, and have important implications for further research.
Our study has highlighted a need to understand better the morbidities associated with anaesthesia and
surgery in children. This will require a study that can follow up children in the community and in the
home setting to assess the incidence of ADRs following surgery, and compare these according to the
anaesthetic and postoperative drugs, surgical procedures and their comorbidities. Such an observational
study could lead to an assessment of which children should be discharged on the day of surgery and,
for those who are, randomised controlled trials will be able to assess the most appropriate treatment
regimens to prevent pain, vomiting and other postoperative complications.
5. Evaluation of strategies for communication about ADRs We identiﬁed that families have unmet
information needs following a suspected ADR in a child or young person and responded to this through
the development of a series of leaﬂets. Further research should focus on the development of
communication strategies, supported by the use of leaﬂets and other media. The reasons for the
mismatch in the perceptions of families and clinicians about how ADRs are communicated should be
investigated, inclusive of the uncertainties around terminology. The evaluation of any strategies
developed should take into consideration how improvements in communication have a direct impact on
the individuals involved (e.g. improved health outcomes for the patient) as well as their indirect impacts,
for example, improve rates of ADR reporting by families and clinicians.
6. Quantification of ADRs in children in other settings The ADRIC programme generated rich data in a
number of settings relevant to paediatric practice, but there remain signiﬁcant gaps in the knowledge
of the quantiﬁcation of ADRs in children in a variety of settings. In addition to understanding the
burden of ADRs in particular settings, such as theatres and critical care, and populations (most notably
neonates), there is also a need to undertake comprehensive studies of the burden and impact of
long-term side effects, which was not an objective within the ADRIC programme.
Finally, ADRIC has provided an important focus on this important and neglected area of paediatric
medicine. It has provided the most comprehensive assessment to date of the size and nature of this
problem in children presenting to, and cared for in, hospital, and the outputs that have resulted will
improve the management and understanding of ADRs in children and adults within the NHS.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Tool glossary
Appropriate management plan(s) This could include any local, national or international guidelineavailable, for example hospital guidelines, NICE, Scottish Intercollegiate Guidelines Network (SIGN),
British Thoracic Society (BTS), the British Society for Paediatric and Adolescent Rheumatology (BSPAR),
World Health Organization (WHO) or the National Guideline Clearinghouse (NGC). For example, in the
case of postoperative nausea and vomiting, appropriate management plans could include Alder Hey
Children’s NHS Trust guideline on postoperative nausea and vomiting, or the Association of Paediatric
Anaesthetists of Great Britain and Ireland (APA) guideline on the prevention of postoperative vomiting
in children.
Known preventative strategies Prophylactic or concomitant medicines or any necessary monitoring.
Information about the ADR and its avoidance: does the management plan mention any preventative
measures to be taken to avoid the ADR, including medicines to be given prophylactically or concomitantly
or any necessary monitoring, etc. (electrolytes, full blood count or blood pressure)? A management plan
may or may not contain information regarding prevention of ADRs but more often than not they contain
no information regarding the prevention of ADRs.
Other information sources Examples include the British National Formulary for Children (BNFC), SmPC,
advice from colleagues, history from the parents/patients or information from a journal article, etc.
Unassessable The case could not be assessed owing to lack of information about the case and/or
treatment or conﬂicting information.
Not avoidable The ADR was unavoidable based on the information available at the time of the reaction.
There are four scenarios that lead to an ADR being categorised as ‘not avoidable’:
l If the reaction was unpredictable and there was no known history of previous similar reaction or allergy
to the drug.
l If there was an appropriate management plan with information about the ADR and its avoidance and
it was followed.
l If there was no appropriate management plan, with information about the ADR and its avoidance
available, there were no other information sources available to consult and there was no information in
the history available for prevention of the ADR.
l If there was no appropriate management plan, with information about the ADR and its avoidance
available but there were other information sources available to consult or information in the history
available for prevention of the ADR and appropriate action was taken to avoid the ADR.
Possibly avoidable There was no appropriate management plan available to follow but there were
other information sources or information in the history available to prevent the ADR and these were
not followed.
Deﬁnitely avoidable There were known preventative strategies or an appropriate management plan was
available with information about the avoidance of the ADR but the strategies and or management plan
were not followed.157
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Is there sufficient information available about the case and the treatment
to allow assessment?
If the answer is ‘yes’ then there is sufﬁcient information available about the case and the treatment, and
the assessor can proceed to the next question; if the answer is ‘no’, either due to lack of information or
conﬂicting information, the case becomes ‘unassessable’.Was the reaction predictable on the basis of the known pharmacology
of the drug(s)?
This question relates to whether the ADR is predictable on the basis of known pharmacology, as there is
lots of unknown pharmacology. If the answer is ‘no’ then you proceed to the question asking if there was
a known history of a previous similar reaction. If the answer is ‘yes’ then you proceed down the left-hand
side of the ﬂow diagram, which asks questions regarding availability of appropriate management plans
and if they were followed.Was there a known history of allergy or previous similar reaction to
the drug?
The purpose of this question is to establish if the patient has experienced a similar reaction in the past,
and answering ‘no’ to the question takes you to ‘not avoidable’, as an unpredictable reaction where the
patient had no previous history of occurrence means that the reaction could not have been prevented on
this occasion. In theory this reaction could be avoided in the future.Were other information sources, or information in the history available for
prevention of the adverse drug reaction that could have been followed?
This is an important question to establish if there was something else that could have been done to avoid
the ADR either by consulting a more senior clinician for advice or looking in other reference source
examples including (but not limited to) BNFC, SmPC, consulting the parents or conducting a quick search
for journal article, etc. If the answer is ‘no’ to this question then the reaction is categorised as ‘not
avoidable’; if the answer is ‘yes’ then you proceed to the next question.Was appropriate action taken to avoid the adverse drug reaction?
This question allows the reaction to be categorised as ‘not avoidable’ if appropriate action was taken to
avoid the ADR but it occurred anyway, and in cases for which other information sources were available but
the appropriate action was not taken, i.e. answering ‘no’ to the question, the ADR is categorised as
‘possibly avoidable’.Were there known preventative strategies and/or appropriate management
plan(s) available with information about the adverse drug reaction and
its avoidance?
This question is designed to establish if there was an appropriate treatment guideline available. This could
include any local, national or international guideline available: for example hospital guidelines, NICE, SIGN,
BTS, WHO, NGC. If there was information available regarding the management of the condition but the
guidance made no reference to the ADR or its prevention then by answering ‘no’ to the question you are
directed to answer the question about whether other information sources were available. This allows for
the application of other measures. If the answer is ‘yes’ to this question then you proceed to the next
question below.Were the strategies and/or management plan(s) followed?
If there was an appropriate management plan available and it contained information about the avoidance
of the ADR but it was not followed then this would mean that answering ‘no’ to this question would
categorise the ADR as ‘deﬁnitely avoidable’; if the answer is ‘yes’ that the drug(s) was used in accordance
with the management plan then the ADR is categorised as ‘not avoidable’.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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(years)bwww.journalslibChild
genderrary.nihr.ac.ukIMD
scorescassociated with
suspected ADRBody system affected by
suspected ADRYCP2 12+ Male 17,251 Drugs used for
attention deﬁcit
disorderNeurologicalYCP3 12+ Female 20,387 Immunological
products and vaccinesHaematologicalYCP4 12+ Male 31,691 Non-opioid analgesia RenalYCP5 12+ Female 20,737 Immunological
products and vaccinesNeurological, musculoskeletal,
gastrointestinal, skin and mucous
membranes, mental healthYCP6 12+ Female 31,439 Immunological
products and vaccinesNeurological, immune, musculoskeletalYCP7 6–11 Female NA Respiratory Mental healthYCP8 12+ Female 29,831 Immunological
products and vaccinesMusculoskeletal, neurologicalYCP9 6–11 Male 22,922 Immunological
products and vaccinesGastrointestinalYCP10 12+ Female 30,656 Immunological
products and vaccinesNeurological, musculoskeletal, immuneYCP11 0–2 Male 31,508 Immunological
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paracetamolCollapsed/fainted? Need to review
notesAC, ADRIC children; AP, ADRIC parents; EC, extended child sample; NA, not available; YCP, Yellow Card parents.
a Where a parent and child from the same family were interviewed we include both participants’ identiﬁers in the
same row.
b Age reported in year groups: 0–2; 3–5; 6–11; ≥ 12 years.
c Calculated using Lower Super Output Area 2007 ranked score data, whereby lower scores indicate greater deprivation
(data for families outside England are not reported and marked NA owing to incompatibility between IMD scoring
systems within UK).
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Drug Reactions In ChildrenOutputs from a discussion group: what are the research
implications of the burden of adverse drug reactions
in paediatrics?
Symposium: Drug Safety in Children – Adverse Drug Reactions In Children
Atlantic Tower by Thistle Hotel, Liverpool
Friday 26 April 2013
14.00–15.00Participants
Professor Munir Pirmohamed (Moderator), Professor Matthew Peak, Professor Sir Alasdair Breckenridge,
Professor Deborah Ashby, Professor Michael W Beresford, Dr Andrew Rose, Dr Jamie Kirkham,
Dr Sudeep Pushpakom, Dr Amitabh Shankar, Dr Petr Jirasek, Dr Virginia Ramos-Martin, Charlie Orton,
Norkasihan Ibrahim, Mohammed Amali, Dave Delaney, Catherine Birch, Beth Conroy.©
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NS, UK.Next steps summaryDosing Work with industry to develop adaptive licensing.
In literature how do researchers extrapolate from
adults to children? Explore what has been used,
what has not been used and utility of
methodologies. Use ﬁndings to develop a gold
standard practice for extrapolation and apply to
drugs identiﬁed as high risk within ADRIC
Take forward drugs highlighted by ADRIC as a
focus for further study, monitor the PK/PD of
these drugs and aim to develop risk models – they
may not differ across agel What extrapolation methods have/have not
been used in literature, of those used which
are successful?ADRIC
outputsLCAT and avoidability tools
The discussion focused primarily on the LCAT as
this tool is fully completed:
1. Develop an ‘app’ for assessment tools
2. Use tools in RCTs to improve ADR reporting
3. Use tools in real world sense to improve
practice – would give a consistent approach
to assessments
4. Test outputs elsewhere, e.g. other hospitals
and settings
LCAT e-learning tool
1. Test elsewhere
2. Conduct a larger RCT of LCAT e-learning tool
to determine effect of clinician assessment of
ADR causality
3. Use in real world and medical training could
improve how the LCAT is used in practicel Use outputs in randomised controlled trials to
improve reporting
l Use outputs in real world scenarios to
improve practice
l Hypothesis testing RCT of effect of LCAT
e-learning tool on clinician assessment of
ADR causality179
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NKey
implicationIHR Journals Library wKey discussion pointsww.journalslibrary.nihr.ac.ukNext steps summaryQuantiﬁcation There are knowledge gaps in the quantiﬁcation of
ADRs in a variety of settings not included in the
ADRIC study:
1. Other sites outside specialist tertiary care
(e.g. District General Hospitals) – explore
variation across settings, variation across age
at other sites
2. Neonates
3. Theatres and critical care
4. A&E
5. Long-term side effects
6. Post discharge and in the home setting
7. Other settings: primary and community care
There are also benefits of evaluating long-term side
effects, which was not looked at in ADRIC.
What lessons from the adult studies can be
extrapolated to children?l Explore ADRs in settings where data are not
yet described, e.g. neonates, critical care,
community settings and primary care and
long term/longitudinallyRisk–beneﬁt
evaluationThere is a need to explore the balance of safety
vs. efﬁcacy. Is there too much focus on safety in
monitoring at the expense of potential beneﬁt?
Is the weight between efﬁcacious outcomes and
safety of patients always sensible?
This subject is currently less understood in children
than adults. For further work, one paediatric area
could be focused on, e.g. paediatric oncology
What are parental views of risk–beneﬁt
evaluation? What are the children’s views? How
do the decision making differences between
children and parents for particular drugs differ?
Does the beneﬁt/risk comprehension and decision
differ with age, e.g. from pre-school to
adolescence?l What are parents’ views on risk–beneﬁt
evaluation? What are children’s views on
risk–beneﬁt evaluation? How do these differ
and vary across the child and young person’s
age spectrum?Interventions Development of interventions that could reduce
harm to be given alongside high-risk drugs
identiﬁed by ADRICl Development of targeted interventions for
identiﬁed high-risk drugsMonitoring ADRIC has highlighted a need to understand
better the morbidities associated with anaesthesia
and surgery in children. This requires a study that
can follow-up and monitor children in the
community and home setting to assess the
incidence of ADRs following surgery, compare
these according to the anaesthetic and
postoperative drugs, surgical procedures and their
comorbidities. An observational study could lead
to an assessment of which children should be
discharged on the day of surgery and for those
who are, RCTs will be able to assess the most
appropriate treatment regimens to prevent pain,
vomiting and other postoperative complications
Explore active reporting, passive reporting and the
difference between them
Communicate and collaborate with industry in the
development and reﬁnement of monitoring
systems within paediatric pharmacovigilancel Observational study of ADRs in children
following discharge after surgery
l RCT of treatment regimens designed to
minimise pain, vomiting and postoperative
complications in early discharged childrenRCT, randomised controlled trial.
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